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The complement system is a major component of innate immunity and an effector of 
antibody-mediated immune responses. Unlike the other two activation pathways of 
the complement system, the alternative pathway is permanently switched on. 
Discrimination by complement between self and foreign is therefore achieved by 
selective protection of healthy host tissue and cells.  
This study investigated the alternative pathway regulator factor H (FH), 
which is crucial for protection of self surfaces from complement. FH engages via its 
N- and C- terminal ends with activation-specific fragments of C3, C3b and C3d. The 
middle region of FH has no binding sites for complement components. It presumably 
ensures that the binding sites at either end of the extended and flexible FH molecule 
cooperate in recognizing C3b in fluid phase or on self surfaces, but not on foreign 
targets.  
This study was aimed at achieving an atomic level understanding of the 
structure of the middle portion of FH, thereby testing hypotheses as to how it 
promotes the overall biological efficacy of the intact protein. High-resolution NMR-
derived structures of two module pairs FH-10-11 and FH-11-12 were solved and 
combined with SAXS data to produce a model of FH-10-12. This was combined, in 
silico, with the previously solved FH-12-13 structure, then the model of FH-10-13 
was used to revisit SAXS data for FH-10-15 and FH-8-15. A unique structure 
emerged, unlike any other encountered previously in the family of complement 
regulators, in which CCPs 13, 14 and 15 have a highly compacted organization that 
has repercussions for function. 
While devoid of binding affinity for host ligands, this central region is a 
binding site for PspC, a virulence factor of S. pneumoniae. It has been speculated that 
the bacteria use this interaction to sequester FH in a conformation that resembles the 
one adopted by FH on self cells and makes it particularly good at regulating 
complement. Structural and functional investigations of this interaction were 
performed to establish the molecular basis of the use of FH by this pathogen in order 
to avoid complement-mediated elimination. It was found that PspC and FH form a 
near-irreversible complex, while FH-8-15 binds PspC almost as tightly as intact 
protein. When bound to PspC, FH has a higher affinity for some of its targets, 
supporting the theory that this bacterial protein stabiles a particularly active 
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1.1 The innate immune system 
 
The immune system is a complex organization consisting of a network of 
molecules and cells that serves to protect the host against numerous infectious agents 
as well as other hazards. Historically, it has been divided into two major components: 
the innate (or non-specific) immune system and the acquired (or specific) immune 
system. While these components to some extent operate independently it is now 
recognized that there is extensive crosstalk between them, ultimately resulting in 
cooperative elimination of invading microorganisms and other dangerous entities.  
In the presence of danger signals, the innate immune system is capable of a 
very rapid antibody-independent response. An important molecular component of 
innate immunity is the complement system of proteins. Following activation 
complement stimulates inflammation, coats or opsonises cells and particles for 
clearance, and undertakes direct cell killing via pore formation and cytolysis. The 
complement system, which first appeared in a primitive form in simple organisms 
more than 1000 million years ago (1), thus acts as a powerful first line of defense. It 
is activated by groups of pathogen- or danger-associated molecular patterns (2) (or a 
lack of host markers) and has no immunological memory, i.e. the extent of response 
is the same towards an infectious agent however many times it invades. In addition to 
acting independently of antibodies, the complement system is activated by antibody-
antigen complexes whereupon it becomes an important effector arm of adaptive 
immunity. Moreover, following activation, complement can signal to B and T-cells 
leading to a heightened state of immune vigilance.  The next section reviews the 
remarkable collection of protein collectively known as the complement system. 
 




The complement system (Fig. 1.1) is the major humoral molecular arm of 
innate immunity. The term “complement” was first introduced by Paul Ehrlich in the 
late 1890s and reflected its long-established role in complementing the actions of 
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antibodies. The complement system is now known to consist of approximately fifty 
serum and cell-surface proteins that act in a highly orchestrated fashion (3). The 
importance of the complement system for human health is a consequence of what are 
now recognized as its many physiological roles, which can be divided into three 
main overlapping categories: host defense against pathogens, maintenance of 
homeostasis and enhancement of the adaptive immune responses.  
          Complement-mediated host protection entails elimination of pathogens 
through the key process of opsonization whereby a cell is coated in activation-
specific complement protein fragments. These then mark the cell out for destruction 
via phagocytosis. Direct cytolysis may also occur through activation of the terminal 
pathway of complement leading to formation of the membrane attack complex 
(MAC) (Figs. 1.1 and 1.3).  The clearance of apoptotic cells and necrotic or 
metabolic cell debris can also occur through complement-mediated opsonization and 
phagocytosis hence allowing complement to fulfill its role in the maintenance of 
homeostasis. Likewise, immune complexes are opsonised by complement that is thus 
regarded as an important effector arm of antibody-driven immunity (4).  Through the 
release, upon complement activation, of anaphylatoxic peptides, complement is pro-
inflammatory and mediates chemotaxis and activation of leukocytes supporting its 
role in elimination of both pathogens and immune complexes. Finally activation-
specific fragments of complement proteins are ligands for receptors on B-cells and 




                            
Figure 1.1 The three activation pathways of the complement system: The classical, mannose-
binding lectin (MBL) and alternative pathway. All three converge at the point of formation of 
the C3 convertase and cleavage of C3. Each pathway can further induce the formation of the C5 
convertases. Activation of C5 to C5b can further instigate the late steps which culminate in the 
formation of the MAC which can cause lysis and cell death (Figure from (5)). 
 
 
Figure 1.2 The three main physiologic activities of the complement system (adapted from (4)). 
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Three pathways of the complement system (Fig. 1.1) are responsible for its 
activation: the classical pathway, the mannose-binding lectin pathway and the 
alternative pathway. Each of the three pathways is activated through a different route 
(Fig. 1.3). Antibody-antigen complexes are the main means of instigating the 
classical pathway. On the other hand, direct recognition of microbial carbohydrate 
motifs triggers the lectin pathway. By contrast with these pathways, which are 
triggered by specific recognition events, the alternative pathway works on a basis of 
selective protection of host surfaces. Thus, it is always activated at a low level and is 
thereby continuously probing every accessible surface for a lack of host-specific 
markers.  For this reason, it is sometimes called the “tick-over” pathway (6) and it is 
maintained in a suppressed state in the healthy individual by regulatory proteins that 
are able to distinguish between host and non-host cells (or particles). As discussed 
below, it is very rapidly amplified in the absence of regulators as may occur on a 
bacterial surface.  
           All three pathways depend upon proteolytic cascades which results in rapid 
amplification of the initial response. In addition, all three pathways converge in the 
formation of the potentially cytolytic MAC. The enzymes that drive these cascades 
are initially circulating as inactive molecules in plasma. They become activated 
towards their substrates upon proteolytic cleavage followed by formation of 
complexes through exposure of nascent protein-protein recognition sites. By-
products of cleavage serve to augment adaptive immune responses and to mediate 
inflammation.  
            As may be seen from figure 1.3, all three pathways converge at the cleavage 
of C3 to C3b. This reaction is performed by the binary complexes, called C3 
convertases, consisting of activated fragments of C3 and factor B in the alternative 
pathway, or C4 and C2 in the classical pathway. The formation of C3b is a 
prerequisite of formation of the C5 convertases that cleave C5 to C5b, another key 
step in the complement pathway. C5b formation then triggers the non-enzymatic 
self-assembly of the MAC (7). 
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 Figure 1.3 Depiction of the complement cascade. Activation can occur through three routes and 
factors that can instigate the complement cascade are shown on the figure. Terminal events 
include the formation of the membrane-attack complex, C3b opsonization and phagocytosis and 
recruitment of inflammatory cells (Figure modified from (8)). 
 
1.2.2 The three activation pathways of the complement system 
 
1.2.2.1 The classical pathway 
 
The binding of the six globular headgroups of the C1q component (a hexamer 
of trimers) of the C1 complex of complement to the Fc portions of antibodies-bound-
to-antigens (e.g. on the surface of an invading microorganism) initiates the classical 
pathway. A conformational change of the collagenous stem of C1q causes 
autoactivation (by conformational change and proteolysis) of the tightly associated 
C1r components that subsequently cleave and thereby activate the neighbouring C1s 
components. The activated form of C1s cleaves C4 to generate C4b that can attach to 
the bacterial surface via a short-lived thioester group.  Cleavage of C4 also creates a 
new binding surface for C2 and formation of the pro-convertase complex, C4b2. As 
part of this complex, C2 is also susceptible to cleavage by activated C1s. This leads 
to the formation of C4b2a which is the C3 convertase of the classical pathway (4).  
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1.2.2.2 The lectin pathway 
 
The lectin pathway is similar to the classical pathway except that it is 
triggered not by antibody-antigen complexes but by pathogen-associated molecular 
patterns (PAMP) such as the mannose moieties on a pathogen surface.  Instead of C1 
mannose-binding lectin in tight association with the serine proteases mannose-
binding lectin-associated proteases 1 and 2 (MASP1 and MASP2) is utilized as the 
recognition protein. MASP1 and MASP2 act in a similar manner to C1r and C1s of 
the classical pathway and (in an analogous fashion to the actions of the C1 complex) 
lead to the formation of C4b2a, which is of course the C3 convertase complex (4). 
Thus the formation of C4b2a and cleavage of C3 to C3b is the point of convergence 
of both classical and lectin pathways.  
 
1.2.2.3 The alternative pathway  
 
As previously mentioned this pathway is always activated at a low level and 
in the absence of regulators can be rapidly amplified. The C3 convertase of the 
alternative pathway is composed of orthologous proteins C3b (from C3 (Fig. 1.4) 
that is similar to C4) and Bb (from factor B that is similar to C2). A version of C3 in 
which the internal thioester has been hydrolysed, called C3(H2O), resembles C3b in 




Figure 1.4 Crystal structures of C3 and C3b showing all of the 13 domains and the 
rearrangement they undergo upon formation of C3b (PDB access codes: C3: 2A73; C3b: 2I07 ) 
α’NT, N-terminus of the α-chain; ANA, anaphylatoxin domain; CUB, complement C1q/C1s, 
uEGF, BMP1; LNK, linker; MG, macroglobulin; TED; thioester-containing domain (9), (10).   
 
          Upon cleavage by the C3 convertase and removal of the ANA domain 
(generating C3a which is an anaphylatoxin), C3b undergoes extensive interdomain 
conformational changes (Figs. 1.4 and 1.5) exposing and activating the 
abovementioned thioester. This is highly reactive (unlike C3(H2O) in which the 
thioester has been hydrolysed) towards nucleophiles and reacts rapidly either with 
solvent water or with a hydroxyl or amine groups on a near-by surfaces (5), (9), (11), 




Figure 1.5 Schematic representation of the domain rearrangement C3 undergoes upon 
activation. The blue line in (D) corresponds to the unfolded N-terminal region of iC3b. The 
orange arrows represent the mobility range of the key moiety in the TED domain. (Figure 
adapted from (13)). 
 
A similar conformational change/activation process occurs without cleavage of C3a-
this much slower process leads to the tick-over convertase complex, C3(H2O)Bb 





Figure 1.6 Schematic representations of the two activation mechanisms of C3 and its products. 
In both cases C3 undergoes conformational changes. The tick-over mechanism results in the 
formation of C3(H2O) (through a stable intermediate denoted C3(H2O)*). Activation of C3 by 
the C3 convertase results in the formation of C3b (similar to C3(H2O) and the anaphylatoxin  
C3a. C3b gets processed further to form - in a sequential manner - iC3b (following removal of 
C3f), C3c and C3dg (Figure from (5)). 
 
          Formation of C3(H2O) is a spontaneous (if rare) event and occurs ubiquitously 
albeit at a low level. C3(H2O), like C3b, can bind to factor B. In the context of a 
complex with C3(H2O) (or C3b) factor B is a substrate for a highly specific serine 
protease, factor D generating C3(H2O)Bb, the so-called initiating C3 convertase (Fig. 
1.7) that cleaves C3 to C3b. These C3b molecules can further nucleate formation of 
C3bBb complexes that can – unless they are down-regulated - produce additional 




Figure 1.7 Schematic representation of the C3 convertase formation. Factor B associates with 
the surface-bound C3b in a Mg
2+
-dependent manner and is then activated by factor D; the Ba 
fragment then dissociates form the complex. CCP, complement control protein; SP, serine 
protease; VWA, von Willebrand factor A (Figure and legend from (5)). 
 
 Both classical and alternative C3 convertases can cleave more C3 molecules 
to C3b, which can form more C3 convertases, thus leading to the amplification loop 
that explains the very fast response of the complement system (14). Additionally, 
both C3b and C4b molecules are opsonins helping to target foreign cells or other 
dangerous particles for phagocytosis. 
 
1.2.2.4 Terminal events 
 
In the absence of regulators, the bimolecular C3 convertases C3bBb and 
C4b2a interact with further C3b molecules to form the trimolecular C5 convertases. 
The C5 convertase of the classical/lectin pathway is designated C4b2b3b whereas 
that of the alternative is C3bBb3b. The C5 convertases cleave C5 (note that C3, C4 
and C5 have high sequence similarity but differ in that C5 has no thioester moiety). 
This leads to the formation of the small C5a fragment and C5b. C5a along with C3a 
and C4a are anaphylatoxins, which are capable of initiating inflammatory responses. 
Formation of C5b is the first step towards the formation of the MAC. C5b interacts 
sequentially with C6, C7, C8 and multiple copies of C9 to form the MAC which 
creates a membrane-penetrating pore that leads to lysis of cell membranes (7). 
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Crucially, the MAC is unlikely to form on host cell surfaces thanks to their 
protection by natural regulators of all three pathways - this is the basis for specificity 
of the complement system. In the presence of regulators such as membrane cofactor 
protein (MCP) and FH, C3b is cleaved into inactive iC3b by factor I (FI) while the 
life-times of C3 and C5 convertases are curtailed (i.e. their decay is accelerated). 
These activities are termed cofactor activity (for FI) (CA) or decay-accelerating 
activity, respectively (DAA) (Fig. 1.8). iC3b remains attached to the surface as it 
contains the TED domain. In the presence of complement receptor type 1 (CR1) (or 
FH at low salt) iC3b gets further cleaved by FI into C3dg and C3c, and finally C3dg 
is cleaved by non-specific proteases to leave C3d; C3d corresponds almost 
exclusively to the TED (Fig. 1.8). 
 
Figure 1.8 The central event in complement activation is the cleavage of C3 to C3b by C3 
convertase, accompanied by attachment to surfaces mediated by the TED. In the presence of 
additional complement regulatory molecules, C3b may be further degraded sequentially to 
iC3b, C3c, C3dg and C3d. C3d corresponds to the TED and remains bound to the surface 
(Figure and legend from (15)). 
 
In conclusion, the activation of complement can occur very rapidly via 
multiple pathways and a positive-feedback loop, and complement is essential given 
its potential to damage healthy host tissues as well as pathogenic or dangerous ones. 
In particular, deficiencies in regulators are a source of numerous disease symptoms 
(see section 1.7) that could be ameliorated if therapeutic means of complement 
inhibition were available.  
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1.3 Regulators of complement activation (RCA) 
     
A fine balance between activation and regulation of the complement system 
must be maintained at all times so as to not jeopardize the healthy state of the host. 
This is achieved through a panel of regulatory proteins. These regulators, which can 
act both in fluid phase and on cell-surfaces, are mostly members of the regulators of 
the complement activation (RCA) family. They comprise multiple domains which 
consist entirely or almost entirely of the so-called complement control protein (CCP) 
modules which are arranged in a “beads-on-a-string” fashion. For example FH, a 
soluble regulator of the alternative pathway consists solely of twenty CCP modules. 
On the other hand, MCP (contains four CCP modules), DAF (contains four CCP 
modules), CR1 (usually contains 30 CCP modules) and C4BP (contains 59 CCP 
modules) consist almost entirely of the abovementioned module type. C4BP for 
example has seven α-chains, with eight CCP modules per chain, and one β-chain 
which contains 3 CCP modules. The α-chains have an additional C-terminal region 
that forms disulfide bonds with a C-terminal region in the β-chain resulting in the 
mature protein (16). The table below (Table 1.1) summarizes some of the regulators 




Table 1.1 Regulators of complement activation (RCA) (3). 
 
          FH is unique in the RCA family in that it can act both in fluid phase and on 
cell surfaces (18) unlike membrane-restricted regulators (17). It ensures that 
complement-mediated damage arising from C3b amplification is directed away from 
host tissue and is particularly important for the protection of surfaces not enclosed by 




FH is encoded by the CFH gene in the RCA gene cluster on chromosome 
1q32 (19). It is a 155-kDa soluble single-chain glycoprotein (20) expressed mainly 
by the liver and secreted into plasma where it circulates abundantly at concentrations 
of 116-562 μg/ml (0.8-3.6 μM) (21). The mature polypeptide consists of 1213 amino 
acids that may be divided into 20 CCPs of about 60 residues each. FH is the pivotal 
soluble regulator of the alternative pathway of the complement system (22). It has 
the following principal roles when acting in fluid phase and/or on self surfaces: it 
hinders the formation of the alternative pathway C3 convertase by competing with 
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factor B for binding to C3b, it accelerates the decay of the C3 convertase complexes 
(C3bBb) that do succeed in forming (i.e. DAA) and it acts as cofactor for FI-
mediated cleavage of C3b into inactive iC3b (CA). The table below (Table 1.2) 
summarizes the role, mechanism and outcome of the main tasks of FH. 
 
 
Table 1.2 Summary of the three main roles of FH, their mechanisms and the outcomes in the 
context of regulating the alternative pathway of complement for protection of the host.  
 
1.4.1 Functionally relevant binding sites of FH and its importance in the 
complement pathway 
 
It is of utmost importance that the complement system distinguishes between 
self and non-self surfaces and in this respect FH plays a crucial role. Since it is the 
only alternative pathway regulator that can act both in fluid phase and on cell 
surfaces, host cells that lack surface-bound regulators must rely upon FH for their 
protection.  
           The selectiveness towards host surfaces displayed by FH can be attributed to 
the existence of polyanions, such as glycosaminoglycans (GAGs) and sialic acid, on 
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mammalian cell surfaces (23). Earlier studies had suggested a sialic acid/GAG 
binding site located within FH-19-20, (24), (25) another one within FH-7 (26), (27) a 
third within FH-9 (28) and a fourth within FH-12-15 (29). However, more recent 
studies (30) showed that FH-9 (when produced without expression artifacts) does not 
encompass a GAG-binding site. Moreover, the whole of the region 10-15 failed to 
show any significant affinity for heparin (30). This leaves two well-established and 
universally agreed GAG-binding sites: on FH-19-20 and in FH-7 (Fig. 1.9).   
          A binding site for C3b is located within FH-1-4 and a crystal structure of that 
region in complex with C3b (Fig. 1.13) has been solved (31). Interestingly, these four 
modules are necessary and sufficient, in isolation from the remainder of FH, to 
perform the fluid-phase cofactor and decay-accelerating functions of FH although 
they do not distinguish between C3b bound on a self surface and C3b in fluid phase 
or on a complement-activating surface. At the C-terminal end of the molecule, FH- 
19-20 binds both C3b and polyanions (32). A third C3b-binding site in FH-12-14 
was suggested (33) but more recently discounted as a primary C3b-interaction site 
(30). Finally, FH-6-8 showed a very much weaker affinity for C3b (Fig. 1.10) than 
the N-terminal and C-terminal sites (30) so it is not considered a primary C3b-
binding site either. 
           Thus, in summary, the N-terminal (FH-1-7) and C-terminal regions (FH-19-
20) of FH are predominantly responsible for CA and DAA and for self-surface 
discrimination by FH. It is suggested that some degree of avidity is conferred by 
simultaneous binding of the sites of the two termini (30). If these are binding to the 
same C3b molecule then the effect is presumably facilitated by the bent-back 
conformation of the central region of FH (30).  On the other hand, it is possible that 





Figure 1.9 Functionally relevant binding sites for FH.  
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1.4.2 Structure of FH 
      
The 20 domains that comprise FH consist of between 51 and 63 amino acid 
residues. Each has four invariant cysteines (I-IV) along with a near-invariant 
tryptophan between CysIII and CysIV. Other highly conserved residues include 
glycines, prolines, and various hydrophobic residues (Fig. 1.11) (34), (35). Each 
repeating sequence folds into a β-sheet rich domain, with two disulfide linkages 
(between CysI and CysIIII and between Cys II and CysIV) and has been called the 
complement control protein (CCP) module. The use of the term module arises from 
the occurrence of similar 3D structures, sharing the same underlying consensus 
sequence, in numerous proteins with diverse functions (16). This module is 
particularly dominant, however, in the RCA proteins (see also section 1.3) that 
control complement, hence the name CCP.  
          Figure 1.10 shows the first NMR structure of a CCP module, FH-16 (36). The 
N- and C- termini lie at opposite poles of the module; this is consistent with a 
“beads-on-a-string” arrangement of the 20 CCPs in the context of full length FH. 
Figure 1.12 shows a multiple sequence alignment of the 20 CCPs that comprise FH. 
 
Figure 1.10 Cartoon representation of the NMR structure of FH-16. The N-terminus is on the 
left and the C-terminus on the right. The disulfide bonds are shown in beige while the consensus 





Figure 1.11 Multiple sequence alignment of 20 CCP modules in sequence of complement FH. 
One-letter codes are used throughout. Invariant Cys residues and almost invariant Trp residues 
are highlighted by boxes. Horizontal lines indicate disulfides within CCP modules (Figure and 
legend modified from (38)).  
 
          Several methods have been employed to gain structural knowledge of FH. It is 
too large a protein to be studied directly by nuclear magnetic resonance (NMR) 
spectroscopy while there are no reports of successful crystallization trials. Its 
modular composition lends it to a dissection strategy and there are numerous 
structures for various small fragments of FH (see Fig. 1.12). 
 
1.4.3 Structures and characteristics of the CCP modules that comprise FH 
 
Three-dimensional high-resolution structures have been determined by X-ray 
crystallography and/or NMR, in the context of fragments up to four CCPs, for all the 
CCPs in FH apart from 9, 10, 11, 14 and 17. In general, each CCP was shown to 
have a prolate ellipsoid shape of dimensions approximately 4 nm by 2 nm by 1.5 nm. 
The 20 CCPs of FH are joined by short linkers. Since CysI and CysIV lie very close 
to the beginning and end of each of the CCPs, linkers are normally defined as lying 
between CysIV of module (i) and CysI of module (i+1). By this definition the linkers 
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of FH are between three and eight residues in length.  In reality module boundaries, 
as judged from three-dimensional structures, extend beyond these cysteine residues 
by a residue or two (36), (37). 
NMR studies suggested FH-1-2 and FH-2-3 (39) exist in elongated 
conformations with little tilt between adjacent modules (Fig. 1.12) and this was 
backed up by a subsequent X-ray structure of FH-1-4 (in complex with C3b) that 
also showed a strongly tilted kinked FH-3-4 intermodular angle (31). This overall 
arrangement was further validated by a subsequent FRET study (40). Crystal 
structures of fragments of FH corresponding to FH-6-7 (41), (42) revealed an overall 
elongated shape. By way of contrast, an NMR-derived structure of FH-12-13 
revealed a rigid 80
o
 “V-like” bend between the modules (43) (Fig. 1.12) Earlier 
NMR work on FH-15-16 failed to find more than a single NOE (distance restraint) 
between modules suggesting intermodular flexibility (44). Both X-ray and NMR 
studies showed that  FH-19-20 (27), (45) adopt a rod-like shape, while X-ray studies 
on FH-18-20 showed that this region is “J”- shaped in which a ~122
o
 tilt is 
introduced between FH-18 and 19 (Fig.1.12). Low-resolution small-angle X-ray 
scattering (SAXS)-based studies showed however that in solution, FH-18-20 adopts 
multiple conformations mediated by flexibility between 18 and 19 (46).  SAXS was 
also employed to study FH-11-14, 10-15 (43) and 8-15 (15). All pointed to a 
compact conformation of these regions which is consistent with these central 
modules (linker lengths within the 10-15 region are - in order - 6, 6, 8, 7 and 5) 
promoting a bent-back structure of FH that could be functionally important (see 
below). Finally, low resolution data on the regions 1-5, 6-8 and 16-20 pointed to not 
compactly arranged structures which in turn agrees with the high resolution 





Figure 1.12 High resolution crystal and NMR structures for fragments of FH as indicated on the 
structures.  The structures are shown in cartoon and semitransparent surface representation. 
The FH-15-16 structure shown is one conformer of many possibilities since only a single NOE 
could be found between the modules. Full length FH is shown in the middle. PDB accession 
codes are as follows: FH-1-2 NMR structure: 2RLP; FH-2-3 NMR structure: 2RLQ; FH-1-4 
Crystal structure: 2WII; FH-6-8 Crystal structure: 2UWN; FH-18-20 Crystal structure: 3SW0; 
FH-12-13 NMR structure: 2KMS; FH-15-16 NMR structure: 1HFH; FH-19-20 NMR structure: 
2BZM. 
 
          A bent-back overall average conformation for full-length FH is supported by 
various studies. Initially, a doubled-over appearance of the FH molecule was shown 
by SAXS and analytical ultracentrifugation (AUC) (49), while transmission electron 
microscopy (EM) (50) broadly agreed with the observation since the majority of the 
FH molecules observed on the grid appeared folded-back upon themselves. This 
would bring the two ends, N- and C- terminal regions that harbor the functional sites, 
close to one another. This can be further supported by the rather extended nature of 
the two termini of FH. 
          It is a matter of contention as to whether FH exists (and functions) in a 
monomeric, dimeric or higher order oligomeric form. It was inferred from scattering 
data and AUC analysis that FH exists predominantly as a monomer (49). Subsequent 
studies using the same techniques showed that there were a proportion of dimers, as 
well as higher order oligomers present (the resultant KD for self-association was 
estimated to be 28 μM) (51).    
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In line with the favored bent-back conformation of FH, it was interesting that 
the protein became more extended with increase in salt concentration (52). Finally, 
the presence of metal ions such as zinc at higher concentrations induced 
oligomerization of FH (53). 
          FH encompasses nine potential N-glycosylation sites, of which eight - on FH-
9, 12, 13, 14, 15 (2 sites), 17 and 18 are occupied mostly by non-fucosylated 
diantennary disialylated glycans (54), (55). Consistent with their locations away from 
functional sites, glycans do not appear to be required for function but their absence 
may have an impact on the solubility and stability of the protein. 
 
1.4.4 Structure of FH-1-4 in complex with C3b  
 
The crystal structure of FH-1-4 (31) with C3b showed a large contact 
interface consisting of four surface regions spanning the length of FH-1-4 (Fig. 1.13).  
The structure facilitates hypothetical mechanisms of DAA and FI CA of FH. It was 
suggested on the basis of the structure that FH-1-2 is predominantly responsible for 
competing with factor B, and perhaps also for the decay-accelerating function since 
by binding to the α’NT, MG2 and MG6-7 C3b domains, they could displace Bb from 
C3bBb by electrostatic repulsion and steric obstruction (31). In fact, the structure 
does not shed very much light on decay acceleration since it does not explain how 
FH-1-4 could access its binding site unless Bb vacates its binding site first. One 
possibility is that the complex of C3b with Bb is in fact dynamic with Bb modules 
peeling away from time to time allowing individual FH modules to take their place in 
an inchworm-fashion. 
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Figure 1.13 Overall structure of C3b in complex with FH-1-4 (PDB access code 2WII). C3b is 
shown in ribbon and the various domains are indicated. FH is shown in surface representations 
with its domains labeled. Residues that normally participate in the formation of the thioester 
(sidechains of Cys988 and Gln991) are shown as red spheres. In this study C3b was treated with 
iodoacetamide after generation by limited trypsinization (31) (Figure adapted from (31)).  
 
1.4.5 Structure of FI and modeling of ternary complexes 
 
 The recent crystal structure of FI and the subsequent modeling of the ternary 
complex consisting of FI, FH-1-4 and C3b, (Fig. 1.14), allowed for an insightful 
proposed model for FH CA. Briefly, initially FH-1-4 of FH bind to C3b. This 
platform then enables FI to dock in the area formed around FH-1-3-bound to C3b. 
The binding of FI promotes allosteric activation of the light chain serine protease 
domain (SP) which then enables for the first cleavage of C3b to take place (56).  
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Figure 1.14 Modeling of the ternary complex of C3b, FH-1-4 and FI. FI is shown in cartoon 
representation (PDB access code: 2XRC); C3b and FH-1-4 are shown in cartoons and semi-
transparent surfaces. The C3b are color coded as follows: C345C domain is shown in light 
bronze; the CUB domain in pink; the thioester-containing domain in light green; and the linker 
domain, C3 α’N-terminal domain and macroglobulin domains of C3b in light gray (Figure and 
legend from (56)). 
 
1.4.6 A model for engagement of FH on self surfaces 
 
The efficacy of FH in engaging with surface-attached C3b is greatly 
enhanced in the presence of the host’s abundantly distributed polyanionic markers. 
Two independent studies presented crystal structures of the complex between C3d 
and FH-19-20 (15), (57). The results, together with the crystal structure of FH-1-4 of 
FH (31) with C3b, (Fig. 1.15) elucidated how FH could engage trivalently, with two 
sites on C3b and a third site involving GAGs on a self-surface. A merged 
superimposed model for the ternary complex of C3b with FH-1-4 and 19-20 showed 
that these the two FH segments bind to C3b adjacent to one another but they occupy 
distinct sites consistent with simultaneous binding. Furthermore the majority of FH-
20 was available for interaction with GAGs, consistent with the concept of the C-
terminus binding to both C3b and GAGs (15). An earlier study set to test this concept 
showed by NMR-chemical shift mapping that when a heparin sulfate analog was 
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titrated in a sample containing purified 
15
N-lebeled FH-19-20 the chemical shifts of 
several residues were perturbed. These residues were mapped onto FH-20 and 
specifically in a region with complementary charge distribution. Furthermore, the 
same study showed, by NMR combined with computational docking, that the C3d 
part of C3b bound mostly to FH-20, at the opposing face of the GAG binding site 
(25). A bent-back central region of FH (FH-8-15) – consistent with the SAXS data – 
would enable FH to exhibit this binding mode (Fig.1.16). The possibility that FH-19-
20 binds both C3b and a nearby C3d, when these are appropriately oriented, has also 
been suggested. This cannot be ruled out (57) although it does require a particular 
juxtaposition of the two molecules on a surface that might be rather rare. Most likely, 
FH is able to bend back upon itself in such a way that FH-1-4 can perform CA and 
DAA while FH-19-20 exercise discrimination between host and non-host polyanions 




Figure 1.15 Potential model of FH engagement with surface-bound C3b. The FH-19-20-C3d 
structure (shown in red and cyan, pdb access code: 3OXU) superimposed (C3d on TED) onto 
the FH-1-4-C3b structure (tan and gray). This FH model has been constructed by juxtaposition 
or superposition of the structures of FH-5 (yellow) and FH-6-8 (yellow-orange) and the SAXS-
shape envelopes pf FH-8-15 (bright orange) and FH-15-19 (orange). Structures are shown in 
cartoon representation and SAXS shape envelopes are shown in mesh. The FH-1-4 SAXS shape 





1.5 Central region of FH 
 
As mentioned in the previous section, several studies by SAXS, AUC, EM 
and NMR suggested that a folded-back conformation of the FH molecule is favored 
that brings the two ends close to one another. This is interesting since the functional 
regions of FH sites involved in binding to the convertases and recognizing host-cell 
surfaces are located towards either end of the molecule. It remains uncertain whether 
such a putative bend is the result of an accumulation of small tilts between many 
modules or whether it is brought about by several large tilt angles involving the 
longer linkers between the central FH modules. This region, FH-8-15, devoid of 
recognition sites, could be of architectural importance, required for ensuring the two 
functional ends of the protein are able to cooperate in recognizing and de-activating 
convertases on host surfaces. It is unknown whether they represent a fully flexible 
tether that simply imposes a maximum distance between the ends, a rigid section that 
imposes a defined shape on FH, or a region that acts like a hinge able to open and 
close.   
          The FH-10-15 region deviates from the remaining CCP modules in terms of 
size and intermodular linker length. In contrast with three-to-five residues within 
linkers in the non-central part, linker lengths of up to eight amino acids are 
encountered within this central region. 
 
1.5.1 Structural information on the central region of FH 
 
The NMR-derived structure of FH-12-13 shows that the surface of FH-12 is 
predominantly electronegative (43). FH-13 is an unusual module as manifested 
through some notable features. First of all, it is the smallest CCP module known, just 
51 amino acids long. It is connected to FH-12 by the longest linker, eight residues, in 





), project to the side of the module and contribute to a striking 
electropositive surface patch. The NMR-derived data tally with observations from 
size-exclusion chromatography, AUC and SAXS. All are consistent with the 
conclusion that a rigid 80
o
 angle is formed between the two modules (43) (Fig.1.16).  
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FH-11-14, 10-15 and 8-15 were also subjected to biophysical studies. AUC and 
SAXS agree as to the monomeric state of all of these proteins in solution. For FH-11-
14 and FH-10-15, size-exclusion chromatography excluded the possibility of fully 
elongated shapes but was consistent with a compact conformation (43). SAXS data 
support the presence of mutually tilted modules. The SAXS data for modules 10-15 
suggest that the tilts between the modules are not in the same direction. This suggests 
a zigzag arrangement rather that a smooth bend. Both AUC and SAXS showed that 
FH-10-15 although containing two extra CCPs compared to FH-11-14 forms a less 
elongated structure thus implying that FH-10 and 15 tilt towards 11-14 (43). Thus, 
these central modules adopt a compact overall structure that seems to exhibit little 
intermodular flexibility (43) (Fig. 1.16). FH-8-15 was described based on SAXS as 
relatively compact and bent back which is consistent with the observations made for 
FH-11-14 and 10-15 (15) (Fig. 1.16). 
The unusual organization of the CCPs that comprise the central region, 
relative to one another, along with the rigid defined bend of FH-12-13 give rise to the 
question of whether flanking CCP module pairs such as FH-10-11, FH-11-12 and 
FH-13-14 would exhibit such structural features, for example in terms of defined 





Figure 1.16 Structural analysis of the central region of FH by NMR and SAXS. (A) NMR-
derived structure of FH-12-13 (PDB access code: 2KMS) (43). (B), (C), (D) SAXS-derived shape 
envelopes for FH-11-14, FH-10-15 and FH-8-15 respectively (43), (15). 
 
1.6 FH protein family 
 
 The FH protein family consists of FH, FH-like protein 1 (FHL-1) and five 
FH-related proteins (FHR-1, -2, -3, -4, -5). All members are composed solely of CCP 
modules. FHL-1 is a FH splice variant consisting of the first seven N-terminal 
modules of FH and a C-terminal four-amino acid extension, and displays similar 
functional regulatory activities to FH (58), (59), (60). The functional role of the FHR 
(FHR1-FHR5) is not yet fully characterized. The FHR proteins are encoded by their 
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own genes, located in the regulators of complement activation cluster. They are built 
from five to nine CCP modules and some have been shown to bind to C3b and 
polyanions (61), (62). FHR-1 was shown to regulate C5 convertases (63) while FHR-
4 may bind to C-reactive protein and take part in opsonization of necrotic cells (64). 
These proteins circulate in plasma at much lower levels than the main regulator FH.   
 
1.7 FH and disease 
 
          When the complement pathway is not properly regulated, pathological 
conditions are likely to arise. Specifically, with respect to FH, mutations or 
polymorphisms in the gene of FH have been found to be associated with 
membranoproliferative glomerulonephritis type II (MPGN2), atypical haemolytic 
uraemic syndrome (aHUS) and age-related macular degeneration (AMD) (65). In a 
different context of disease occurrence in which FH is involved, the ability of this 
regulator for immune surveillance is utilized by an extended array of microbes in 
order to achieve immune invasion (66). 
 
1.7.1 Age-related macular degeneration 
 
Age-related macular degeneration (AMD) is the leading cause of loss of 
vision in the Western world for individuals of 50 and above. Complement 
dysregulation plays an important role in its pathogenesis. Specifically, the Tyr402His 
polymorphism that lies in FH-7 as well as in FHL-1 (which equates to the first 7 
CCP modules of FH) increase the risk of contracting AMD up to seven-fold (in 
homozygotes). FH-7 encompasses one of the polyanion-binding sites in FH. Early 
stage AMD is characterized by the formation of drusen, lipoproteinaceous deposits, 
between the retinal pigment epithelium (RPE) and Bruch’s membrane. The Y402H 






1.7.2 Membranoproliferative glomerulonephritis type II 
 
          Membranoproliferative glomerulonephritis type II (or Dense Deposit Disease, 
DDD), is a rare condition characterized by dense deposits within the glomerular 
basement membrane (GBM). These deposits consist to a large extent of C3c. In 
addition, C3 serum levels are distinctively low. The disease has been associated with 
mutations in the CFH gene. Reduced levels of FH in plasma, or deficiency in its 
ability to regulate the alternative complement pathway, result in excessive 
complement activity with repercussions distinct in the GBM. In both MPGN II and 
AMD, accumulations of complement-containing debris occur within the kidney and 
eye, respectively (65). 
 
1.7.3 Atypical haemolytic uraemic syndrome 
 
          Haemolytic uraemic syndrome is characterized by hemolytic anemia and often 
ends in acute renal failure. The typical form is associated with infections by contrast 
with the atypical form, aHUS, which occurs in 5-10 % of HUS patients. aHUS is 
connected to mutations or polymorphisms in the CFH gene, the majority of which 
cluster in the C-terminal region, FH-19-20, i.e. in the aforementioned polyanion and 
C3b-binding sites. In this case, the mutant FH molecules appear to be capable of 
normal activity in plasma but cannot protect host cells from lysis (thus uncontrolled 
complement activation takes place on cell surfaces). This is consistent with an 
important role of the C-terminus in distinguishing host versus foreign surfaces (65). 
 
1.7.4 Pathogen invasion 
 
Many pathogens disguise themselves from the complement system by 
mimicking properties of the host cell surfaces or by binding to FH and other 
regulators thus facilitating their escape from complement-mediated destruction. The 
number of invading agents that have been shown to bind to FH is constantly 
increasing. These include amongst others Streptococcus pneumoniae (S. 
pneumoniae), Streptococcus pyogenes (S. pyogenes) and Neisseria meningitidis (N. 
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meningitidis). One of the strategies employed, for example, by S. pneumoniae for 
escaping the immune system is by expressing a major virulence factor: the surface 
protein PspC which binds to FH and minimizes C3b deposition on pneumoccoci 
(66).   
          The following sections (section 1.9 onwards) discuss the topic of complement 
evasion by pathogens with particular focus on S. pneumoniae and more specifically 
on the interaction with FH via its surface –attached virulence factor, the PspC 
protein. 
 
1.8 Concluding remarks 
 
          Complement is an important and potent immune surveillance system which, 
however, has to be tightly regulated by natural fluid-phase and steady-state 
regulators. FH is the main regulator of the always activated alternative pathway and 
ensures the protection of the host by acting both in fluid-phase and on cell surfaces. 
           The crystal structures of FH-1-4-C3b, and FI shed light on the corresponding 
interactions and the implicated mechanisms. The crystal structure of FH-19-20 with 
C3d and subsequent model extrapolation to C3b provided a structural basis for 
engagement by FH of C3b on a self surface. Binding studies demonstrated the 
cooperative binding of the two termini to C3b and polyanions such as GAGs. This 
bivalency is facilitated by a bent-back conformation that FH adopts. Indeed FH-8-15 
is arranged in a compact, unique manner, unlike any other seen in the RCA family 
and enables the two functional ends to come close. FH can then perform its 
biological tasks. The only high-resolution structure available for the central region is 
that of FH-12-13. It is evident that the unique architecture of the 8-15 part needs to 
be further elucidated at an atomic level as the question of how it promotes overall 
biological activity of FH still remains. Taking this one step further, it may also help 
understand more about the molecular basis of the use of FH by pathogens in order to 





1.9 The use of the complement system as an evasion strategy by pathogens  
 
To survive in the harsh environment of the bloodstream nearly all pathogens 
(of vertebrates) have evolved means to evade complement-mediated destruction. 
Some pathogens take this strategy further and actively subvert the complement 
system to gain entry into a host cell where they can avoid triggering complement 
activation altogether while they divide and multiply. Many pathogens produce 
proteins that directly interfere with the initial steps of activation, i.e. they act to block 
C3b amplification. Others target the terminal pathway by, for example, blocking 
MAC assembly (67). Some produce enzymes that proteolytically degrade 
complement components, or they produce proteins that interact with host 
complement proteins and thereby block their actions (68). 
          Furthermore, some bacterial proteins remain on the bacterial cell surface where 
they recruit and tether host regulators such as FH, FHL1, and C4 binding protein 
(C4BP) (67). This strategy is advantageous to the microorganism as the natural 
regulators are already present at high levels. Figure 1.17 schematically illustrates 
these and other examples employed by pathogens for protection from complement. 
(68), (69). Examples of pathogens that bind to complement inhibitors include S. 
pneumoniae, S. pyogenes, Escherichia coli (E. coli), Haemophilus influenzae (H. 





Figure 1.17 Examples of how pathogens can interfere with complement in order to increase 
their survival chances. The regulators FH and C4BP can be recruited onto the pathogen surface 
where they inhibit formation of the convertases and participate in FI-mediated degradation of 
C3b and C4b. Furthermore secreted pathogen proteins can degrade complement components. 
All these lead to incompetent opsonophagocytosis arising from decreased C3b opsonization and 
chemotaxis. Finally lysis through the formation of the membrane attack complex (MAC) may 
also be compromised (Figure and legend adapted from (69)). 
 
1.10 S.  pneumoniae 
 
          S. pneumoniae (pneumococcus) is a Gram-positive bacterium that resides 
naturally in the human upper respiratory tract flora in low numbers (70). However it 
is also an important pathogen causing several serious infections such as pneumonia, 
meningitis and septicemia (71). Severe infections have been associated with high 
mortality rates and death. Upon occurrence, clearance of such infections is dealt with 
by both the innate and the adaptive immune responses (72). Upon activation by the 
presence of pneumococci, complement-mediated phagocytosis takes place (73), (74). 
The major phagocytic cells of the gas-exchange areas of the lung are the human 
alveoral macrophages. Pneumococci bind to their surface, become internalized and 
are killed by phagolysosomes and it has been demonstrated that this process and its 
outcome can be compromised in the absence of opsonization with complement (75). 
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1.11 Evasion of complement by pneumococci 
 
 The classical and the alternative pathways of complement are predominantly 
responsible for clearance of pneumococci (73), (74). The bacteria are Gram-positive 
hence inherently resistant to MAC-mediated lysis. Since multiple constituents of the 
complement system target S. pneumoniae for destruction, these bacteria have 
evolved more that one evasion mechanism. They can compromise the alternative 
pathway C3 convertase (see below) and thereby reduce opsonisation with C3b (74). 
In addition, pneumococci can secrete toxins that attack host tissue and are able to 
activate the classical pathway (76), (77). Finally they can recruit host regulators onto 
their surface thus escaping complement-mediated opsonophagocytosis (78), (79), 
(80).  
 
1.11.1 Virulence factors 
 
Several virulence-associated factors are involved in the aforementioned 
mechanisms, which provide resistance to the immune response. Some of these will 
be mentioned in this section.  
          Pneumolysin is an intracellular toxin that does not become secreted until lysis 
of the pneumococci occurs by the action of autolysin (an enzyme that can break 
down the peptidoglycan layer of the cell wall). Mutant strains that do not express 
pneumolysin are non-virulent. This potent toxin can, for example, attack host tissue 
and cells, it can activate the classical pathway “with a concomitant reduction of 
serum opsonic activity” (77) and cause inflammatory responses; this being key to 
pneumoccocal-induced pathogenesis (77). 
          Cell-surface virulence proteins produced by pneumococci have become the 
subject of many studies due to their potential use as vaccine antigens. These proteins 
can be divided into three groups: choline-binding proteins, lipoproteins and proteins 
that are attached to the cell wall via an LPXTG motif (where X is any amino acid). 
For example, choline-binding proteins include PspA (Pneumococcal surface protein 
A), and PspC (Pneumococcal surface protein C). PspC has been reported to bind the 
polymeric immunoglobulin receptor that transports secretory IgA (81), to C3 (82) as 
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well as FH (83), (84), (85). The study of the interaction of PspC with FH is a main 
objective of the current project, and therefore will be discussed in more detail below.  
 
1.11.2 Pneumococcal surface protein C (PspC)  
 
          The pspC locus of S. pneumoniae is polymorphic. Sequencing data from 43 
strains enabled the organization of the variants into 11 groups. Groups 1-6 are the 
classical PspC proteins, anchored to the bacterial cell wall by a C-terminal choline-
binding domain; groups 7-11 utilize a C-terminal LPXTG motif (86) for this purpose. 
The domain organization of the classical PspC proteins is as follows (see Fig. 1.18): 
a leader peptide and an N- terminal domain is followed by one or two repeats 
designated R1, R2 then a proline-rich region (87) and, finally, the choline-binding 
domain. In for example, strain D39 of capsular serotype 2, there is a 96-residue N-
terminal domain followed by R1 and R2, each of 107 amino acids, then a 97-residue 
proline-rich region (Fig. 1.20) and lastly, the C-terminal choline-binding domain 
made up from 10 repeats of 20 amino acids (88). The R domains of PspC are highly 
conserved in sequences when compared to other pneumococcal strains (89). In strain 
TIGR4, for example, the R1 and R2 domains each comprise three α-helices that 
altogether form a flat, raft-like structure. Furthermore, the N-terminal region of PspC 
proteins is α-helical and has a stable fold. Thus, the whole of the NR1R2 region 




Figure 1.18 Schematic illustration of the domain organization of the PspC protein of strain D39, 




Figure 1.19 shows a multiple sequence alignment of the N-terminal domain of PspC 






Figure 1.19 Sequence alignment of the N-terminal PspC of strain D39 with the PspC allelic 
variants as indicated on the left of the alignments. Identical residues are shown shaded. Dashed 
lines indicate the gaps that were introduced for optimal alignment. Amino acid positions are 
marked on the right according to the relative distance from the first amino acid following the 
signal sequence (Figure and legend from (88)). 
 
1.12 FH binding motif on PspC 
 
The ability of PspC to bind FH is an important mechanism by which 
pneumococci can resist complement-mediated phagocytosis. Furthermore, it has 
been demonstrated that FH retains many functional abilities even after engaging with 
PspC (90). As described in subsequent paragraphs, several recent studies have set out 
to pinpoint the domains of PspC and FH that mutually contribute to this key 
interaction.  
          Initial studies used Western blotting to map FH binding region on PspC. These 
experiments used a fragment corresponding to residues 1-225 of an isogenic strain of 
D39, a fragment corresponding to residues 1-445 and another spanning residues 225-
445 of PspC. All fragments were incubated with FH. Only the 225-445 fragment did 
not bind, hence the FH-binding domains in PspC must reside within residues 1-225 
of the α-helical N-terminal domain (90); this includes the N-terminal domain 
extended to the R1 repeat, figure 1.18). 
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 A subsequent study further localized the FH-binding region. Using Western 
blots, the wild-type D39 strain showed strong binding to FH while a mutant that 
lacked the 89-amino acid region of the N-terminus showed no appreciable binding. 
Furthermore mutants in which the R1, R1/R2 or proline-rich regions were deleted 
suggested these regions did not contribute to binding. Thus the N-terminal 89-amino 
acid region is essential for FH-binding activity. Similar conclusions arose from use 
of epi-immunofluoresence microscopy of intact pneumococci (88). 
          By isothermal titration calorimetry (ITC) a KD of <1 nM was observed for the 
interaction of FH with the N-terminal region of PspC and a formation of a 1:1 
complex between the two was inferred (88). Spot-synthesized peptide analysis 
identified a 12-amino acid stretch within the N-terminal (ALNIKLASAIKTK, amino 
acids 88-99 in PspC of strain D39) which is required for binding to FH, however a 
synthetic peptide representing this 12-amino acid motif alone was incapable of 
mediating binding (88).  
          A separate study suggested the proline-rich region was important for PspC 
binding to FH. Specifically, ELISA assays demonstrated that a construct (residues 1-
445) lacking the C-terminal choline-binding domain showed two-threefold higher 
affinity for FH than a shorter construct (residues 1-371) additionally lacking the 
proline-rich region (91). Finally a study using PspC deletion mutants and surface 
plasmon resonance narrowed down the FH-binding site to the N-terminal residues 
38-158, of PspC (87).  
 
1.13 PspC-binding regions on FH  
 
Several studies have attempted to identify the FH domain/s responsible for 
interacting with PspC. This section will briefly present the findings to date, 
particularly with respect to PspC from the virulent S. pneumoniae strain D39 (since 
this was also the focus of the present work).  
In 2002, Duthy et al. localized the PspC binding site on FH to FH-8-15 by 
ELISA assays while FH-1-7 and 16-20 did not show discernible binding (91). In 
order to further localize the site within the FH-8-15 region FH-10-12, 8-12, 8-13 and 
8-14 (which were produced recombinantly and expressed in Pichia pastoris (P. 
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pastoris)) were tested for binding. Only 8-13 and 8-14 showed interaction. The 
binding, however, for 8-14 was roughly two-thirds the binding of 8-13. It was 
therefore suggested that the additional CCP 14 in the 8-14 construct may be 
obstructing the binding site residing in FH-13 while on the other hand it seems that 
addition of CCPs 14-15 to the 8-13 construct can remove this inhibition resulting in 
the increased binding demonstrated by FH-8-15. Based on the comparable binding 
shown by 8-15, it appeared that some complex higher order structure might exist in 
the 13-15 region of FH. Such a conclusion was further reinforced by whole-cell 
ELISA, which confirmed that the presence of both modules 13 and 15 was required 
in the constructs in order for optimum binding to occur. This could mean (and 
remains to be tested) that the two sites act together to form the complete site while 
displacing the weaker-binding 8-14 from PspC, or that a second dite exists in FH-15.  
Finally in this study, heparin, C3b and sodium chloride did not inhibit the FH-PspC 
interaction. This result indicates that the heparin (GAG)-binding site and C3b-
binding site do not overlap with the PspC-binding site (91).  
          In 2004, Dave et al. concluded that the binding site for PspC (strain D39) was 
located within FH-6-10, and that FH did not lose its functional activities in the 
presence of PpsC. In more detail, ligand dot-blotting assays localized the PspC-
binding site on FH between modules 6 and 10 (including FH-6 and FH-10) because 
all recombinant truncated constructs that contained FH-1-10 bound to PspC and  the 
FH mutant lacking  FH-6-10 (rFH Δ6-10) failed to show binding. Moreover, 
inhibition of haemolysis was observed both upon addition of FH as well as a mixture 
of FH and PspC (90).  
In 2007 Hammerschmidt et al. investigated the effect of bacterial cell-surface 
bound FH on pneumococcal adhesion to host cells. Bacteria-bound FH enhanced 
adherence to host cells (both epithelial and endothelial) especially when the amount 
of capsular polysaccharide was low. With respect to identifying the PspC-binding 
site in FH, SPR was used. For this experiment PspC2.1 (produced by strain 
ATCC33400, capsular type 1) was immobilized and the FH deletion constructs FH-
1-7, 8-11, 11-15, 8-20 and 15-20 were tested for binding. It was surmised that two 
binding sites exist within FH located in FH-8-11 and FH-19-20 (88).  
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 A follow-up study by Agarwal et al. in 2010 investigated how pneumococci 
can be ingested by epithelial cells through a novel mechanism involving FH acting as 
a bridge between pathogen and host cells. Specifically, it was proposed that S. 
pneumoniae recruits FH via sites in 8-11 and 19-20 recognized by PspC. The FH 
polyanion-binding region in FH-19-20 then mediates binding of FH to host cells. 
Through the dynamics of the actin cytoskeleton and kinase activities of signal 
transduction molecules, pneumococci use a FH-integrin complex for invasion (92). 
(FH can interact with integrin receptors, CR3 (92)). 
 
1.14 Concluding remarks 
 
Pathogens have developed sophisticated mechanisms to escape their 
destruction by the host’s complement system. Virulence determinants displayed on 
the surface of pathogens can recruit regulators like FH in order to survive. Examples 
of such invaders - other than S. pneumoniae - are N. meningitidis (93), S. pyogenes 
(94), H. influenzae (95) and Borrelia burgdorferi (B. burgdorferi) (96). Figure 1.20 






Figure 1.20 Schematic summary of some of the pathogens that recruit the complement regulator 
FH. FH is shown bound to C3b on a surface. CCPs within FH that bind to the pathogens are 
indicated color-coded for each pathogen (83), (93), (94), (95), (96).  
 
          S. pneumoniae is a harmful pathogen and one mechanism by which it can 
evade complement is by recruiting FH. It expresses PspC, a surface protein and chief 
virulence factor which binds FH through its α-helical N-terminal domain. Regions in 
FH that mediate this interaction have been mainly localized in the regions FH-6-10 
and 19-20. Figure 1.21 schematically summarizes the PspC-binding sites on FH. In 
summary, although partially conflicting data exist regarding the location of the PspC 
binding site with the complement regulator FH, it appears that most of the sites 





Figure 1.21 Schematic summary of the locations of the PspC binding sites on FH as determined 
by three studies in particular. FH is shown in complex with C3b in this representation bound on 
a surface. FH-6-10 constitutes one region encompassing the PspC binding site as demonstrated 
by Dave et al. (90) and is highlighted by a green curvy line in the figure. FH-8-11 and 19-20 
correspond to the PspC-binding-site-containing domains as determined by Hammerschmidt et 
al. (87) and are highlighted by cyan curvy lines. Finally FH-13-15 emerged as the binding site 
containing region by studies from Duthy et al. (91) and is highlighted by a pink curvy line.  
 
Overall it appears (see Figs. 1.20 and 1.21) that important bacterial protein-
binding regions in FH are domains 6-7, the middle compact region and the C-
terminal 19-20 region. This observation has mechanistic implications. For example, 
the FHbp of N. meningitidis binds with a very high affinity to FH-6-7 and mimics the 
mechanism by which host cells regulate complement activation on their surface using 
amino acid residues instead of charged sugars (FH-7 contains a GAG-binding site) 
(93). The FH C-terminal region contains binding sites for both C3b and polyanionic 
components while the central region is devoid of such recognition sites. With respect 
to PspC of S. pneumoniae the binding sites are located in regions 6-15 and 19-20 (as 
determined by three studies in particular) following the same pattern as the other 
pathogens (87), (90), (91). 
          Understanding the exact molecular mechanisms of the interactions of PspC 
with FH could prove to be a significant step towards developing new vaccines. 
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Indeed, the FH-binding fragment of PspC has been investigated as a vaccine 
candidate and its use in combination with other antigens could lead to successful 
vaccine development (97). What is more, light will be shed on how FH operates in 
the context of several biological processes, thus expanding our understanding on the 
works of this structurally unique and increasingly important complement regulator.  
 
1.15 Overall goals of the project 
 
The complement regulator, FH, controls the positive feedback cycle of C3b 
production both in the fluid phase and on cell surfaces. While in the former case, FH 
prevents futile depletion of C3 and factor B, in the latter case it is critical for 
protecting self surfaces from harm by complement. It is not surprising that sequence 
variations in FH are linked to disease or that FH and rationally engineered analogues 
have therapeutic potential. The overall goal of this project is to understand how the 
central region of FH may promote the overall biological efficacy of the intact 
protein. 
FH engages simultaneously with GAG/polyanions and C3b (and its 
fragments) on a self surface through binding sites in FH-1-7 and 19-20. The central 
region, FH-10-15, contains the longest linker lengths and smallest modules and 
forms a compact, potentially hinge-like structure.  This region has not been as fully 
characterized as the terminal regions and forms the main focus for the current 
project. 
 One of the sophisticated strategies by which pathogens circumvent the 
complement system is by recruiting FH. While most seem to latch onto FH-6-8, 
which contains a GAG-binding site, or FH-18-20, which contains both a GAG and a 
C3b-binding site, some bacterial proteins bind to FH-8-15 which does not include 
such regulatory regions. This intriguing observation led to a second focus of the 
current work – the study of how PspC interacts with the central region of FH. The 





Figure 1.22 Representation of the FH molecule bound to C3b. CCPs that have a functional role 
and to which pathogens bind are highlighted as follows: FH-6-8 in pink circles, FH-8-15 in green 
circles and FH-19-20 in cyan circles. 
 
1.16 Specific aims 
 
A combination of high-resolution data combined with lower-resolution 
techniques will be used to allow more accurate modeling of the spatial organization 
of the CCPs of the central region. Biophysical techniques will also be used to 
investigate an intuitively attractive hypothesis, that binding of the pathogen protein 
PspC to FH may stabilize a preferred conformation that optimizes its complement-
regulatory activities.  
 
1. The first aim is to determine the solution structures of FH-10-11 and FH-11-12 so 
as to determine whether these are “V-shaped”, like FH-12-13, and to allow a model 
of FH 10-13 to be created by concatenation of bimodule structures. 
 
2. SAXS data will be collected on those fragments as well as FH-10-12, providing 
orthogonal validation of intermodular tilt angles and the spatial arrangement of 
modules. The NMR-derived structural data will be used in order to distinguish 
between two existing SAXS-derived models of FH-10-15 structure. 
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3. The interaction between FH and PspC will be studied to resolve conflicting reports 
in the literature regarding which FH modules are involved. Furthermore the 
interactions of complexes consisting of FH-PspC constructs with the C3 fragments 
C3b, C3c and C3d will be investigated. The objective here is to determine whether 
PspC really binds to two sites in FH and to test the hypothesis that it stabilizes a 























































This study entailed production of recombinant proteins corresponding to 
segments of complement regulator FH, and of S. pneumoniae virulence factor PspC 
(see section 2.5, Fig. 2.9). The FH-derived protein segments were produced in the 
yeast expression host P. pastoris whereas the PspC constructs were produced from 
genetically modified E. coli. Procedures for cloning, digestion and transformation 
reactions, culture growth and manipulation of protein samples are described in this 
chapter, along with methods for NMR-based structural studies and SPR-based 
functional assays. 
 
2.1 DNA amplification, manipulation, cloning and transformation 
 
2.1.1 Polymerase chain reaction  
 
The polymerase chain reaction (PCR) was used to amplify the coding 
sequences for FH constructs 4-6, 10-11 and 14-15, for sequencing reactions and for 
screening colonies for the expected insert. The PCR was also used to effect insertion 
of a new stop codon in the case of a PspC construct that possessed originally four 
residues beyond the native C-terminus. 
 The FH constructs were amplified using primers designed by Dr C. Q. 
Schmidt (formerly of this lab) and are listed in Table 2.1. Primers used for the 
touchdown PCR reaction were purchased from Sigma-Genosys. M13 and alpha-
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Table 2.1 Primer oligonucleotide sequences. The restriction-enzyme sites are highlighted in 
bold. Tm corresponds to the calculated melting temperature of each primer without the 
restriction enzyme site. F and R refer to the forward or reverse direction of the primers, 
respectively. The M13 primers were used to screen colonies after cloning into TOPO vector and 
sequencing. The alpha-factor F and AOX1 R were used for screening after sub-cloning into the 
pPICZαΒ vector and sequencing. 
 
In the case of the PspCN construct with an N-terminal His-tag and a C-
terminal GSGC tetrapeptide artifact (His-tag PspCN-GSGC), the primers used for 
site-directed mutagenesis and subsequent sequencing are listed in Table 2.2. All 
primers were purchased from Invitrogen. Melting temperatures were calculated using 







Table 2.2 Primer oligonucleotide sequences used for the site-directed mutagenesis and 
sequencing reactions for His-tag PspCN-GSGC. Melting temperatures are shown for each 
primer as calculated using the Sigma-Genosys online primer calculator. 
 
2.1.1.1 Generation of coding sequences for the FH constructs 
 
For generation and amplification of sequences coding for FH constructs, 1 μl 
aliquots of 10 μM solutions of forward and reversed primers were mixed with 2 μl of 
the template DNA (40 ng/μl), 5 μl Pfu  reaction buffer 10x (Fermentas), 1 μl 
deoxynucleotide triphosphates (dNTPs) (2.5 mM, Invitrogen), and 1 μl Pfu 
polymerase (2.5 U/ml, Fermentas) in a microcentifuge (PCR) tube and then the 
volume was adjusted to 50 μl by adding 39 μl of molecular biology-grade H2O. A 
gene for full-length FH (prepared from human cDNA by Dr C. Q. Schmidt) served as 
template DNA. 
The PCR cycling parameters summarized in Table 2.3 were employed. In 
each case a subsequent PCR reaction was performed on the purified product of the 





























































C) TIME (min:s) REPETITIONS 
Initialization 95 1:00 1x 













Elongation 72 1.00 min/kb DNA 
Denaturation 95 00:30 20x 
Annealing Tm -4.86 00:30 
Elongation 72 1.00 min/kb DNA 
Final Elongation 72 5 - 
Hold 4 hold - 
 
Table 2.3 PCR cycling parameters. Based on the melting temperatures, Tm, of the primers the 
annealing temperatures are determined after having taken into consideration the restriction 
sites. Because the resulting Tms of forward and reverse primer sequences were different, the 




2.1.1.2 Screening of E. coli colonies by PCR for the FH constructs 
 
Following overnight growth, construct FH-10-11 and seven colonies for each 
of constructs FH-4-6 and FH-14-15 were picked and cells were transferred to 
microcentrifuge tubes that contained 20 μl EB buffer (10 mM Tris-HCl, pH 8.5) as 
well as to new plates. Samples were heated in the PCR machine to 95 
o
C for 3 min 
for the purpose of bacterial lysis and solubilisation of the plasmid DNA. In separate 
microcentrifuge tubes, 2 μl of the above samples were mixed with 1.5 μl of forward 
and reversed primers (10 μM, see Table 2.1) and 5 μl of PCR Master Mix
 
(Promega) 










C) TIME (min:s) REPETITIONS 
Initialization 95.0 01:00 1x 
Denaturation 96.0 00:30 
 
29x 
Annealing 50.0 00:30 
Elongation 60.0 01:00/kb DNA 
Hold 4.0  – 
 
Table 2.4 PCR screening cycling parameters 
 
2.1.1.3 Sequencing reactions for the FH constructs 
 
Samples for DNA sequencing were submitted to the GenePool (Ashworth 
Laboratories, School of Biological Sciences, University of Edinburgh). For 
submission of the PCR product, 1 μl of DNA (200 μg/ml) was mixed with 1 μl  
(10 μM) of the appropriate forward or reverse primers (M13 F and R supplied with 
the TOPO
 
cloning kit, or alpha-factor F and AOX1 R in the case of pPICZαB 
vector), 4 μl Big Dye (Applied Biosystems) and 14 μl molecular biology-grade H2O 
(Sigma), to a final volume of 20 μl. The PCR was performed according to the 




C) TIME (min:s) REPETITIONS 
Initialization 95 00:30 1x 
Denaturation 96 01:00 24x 
Annealing 50 00:30  
Elongation 60 04:00 
Hold 4 hold – 
 





2.1.1.4 Site-directed mutagenesis for the PspC construct 
 
For site-directed mutagenesis of His-tag PspCN-GSGC, the QuickChange 
Site-Directed Mutagenesis Kit (Stratagene) was used and the instructions that came 
with it were followed. In short, 1 μl of template DNA (coding for His-tag PspCN- 
GSGC, 125 ng/μl) was mixed with 5 μl Pfu buffer, 1 μl Pfu turbo polymerase 
(Agilent Technologies), 1.3 μl of forward and reverse primers (10 μM), 1 μl 
deoxynucleotide triphosphates (dNTPs), 2.5 mM (Invitrogen), 1.5 μl DMSO 
(Stratagene) and the final volume was adjusted by adding 37.9 μl molecular biology- 
grade H2O. The PCR cycling parameters summarized in Table 2.6 were employed. 
The aim of this PCR was insertion of a stop codon at a specific point; therefore  
18 cycles were repeated according to manufacturer’s (Stratagene’s) instructions. 
Following the PCR reaction, the products were digested with DpnI (20,000 U/ml, 
NEB) in order to digest the parental DNA template (it targets 5’-Gm
6
ATC-3’ and is 
specific for methylated and hemimethylated DNA). 5 μl were added and the  






C) TIME (min:s) REPETITIONS 
Initialization 95 2:0 1x 
Denaturation 95 1:0  
18x Annealing 55 1:0 
Elongation 68 10:00 
Hold 4 hold – 
 
Table 2.6 PCR cycling parameters for QuickChange site-directed mutagenesis method. 
 
2.1.1.5 Sequencing of the PspC construct following site-directed mutagenesis 
 
For sequencing of the His-tagged PspCN construct after site-directed 
mutagenesis, the following procedure was followed: The digested PCR product from 
the mutagenesis reaction was transformed into E. coli BL21(DE3) cells (Lucigen) 
and 4 colonies were subjected to purification of plasmid DNA after an overnight 
growth at 37 
o
C. Of the resultant DNA, 300 ng were mixed with 4 μl BigDye, 1 μl 
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T7 promoter or T7 terminator primer (to final concentration of 10 μM each, 
Invitrogen) and adjusted to a final volume of 20 μl with molecular-biology grade 
H2O (Sigma). The PCR cycling parameters summarized in Table 2.7 were 
subsequently employed. 
 
STEP TEMPERATURE (oC) TIME (min:s) REPETITIONS 
Initialization 95 1:00 1x 
Denaturation 96 00:30  
30x Annealing 50 00:30 
Elongation 60 1:00 
Hold 4 hold – 
  
Table 2.7 PCR sequencing cycling parameters for the PspCN construct following site-directed 
mutagenesis. 
 
2.1.2 Agarose gel electrophoresis for nucleic acids 
 
A 1.0-1.2 % agarose solution in 50 ml Tris-acetate-EDTA (TAE) buffer was 
prepared (1-1.2 g agarose was weighed) and the solution was brought just to the boil 
until the agarose had completely dissolved, using a microwave oven. It was then 
cooled to 50-60 
o
C prior to adding 5 μl of SYBR-safe stain, purchased from 
Invitrogen
®
, to a final concentration of 0.5 μg/ml. The rack with the agarose gel was 
placed in a gel tank and was completely covered with 1x Tris-acetate-EDTA (TAE) 
buffer. The DNA samples were then mixed with loading buffer and placed in the 
wells.  Alongside the samples, molecular-weight markers were loaded, covering the 
required size range. The gel was run at 125 V for approximately 40 min and then 
illuminated with an ultraviolet lamp to view the DNA bands. 
 
2.1.3 DNA purification and plasmid DNA extraction 
 
The QIAprep Miniprep or QIAfilter Maxiprep kits for plasmid extraction and 
the QIAquick Spin kit for extraction and purification of DNA from agarose gels were 
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all purchased from QIAGEN. All procedures were carried out following the supplied 
protocols.  
 
2.1.4 DNA quantification - estimation of DNA concentration by UV 
spectroscopy 
 
Nucleic acids have an absorption maximum at 260 nm therefore 
quantification of the DNA samples was achieved by UV spectroscopy. (Eppendorf 
BioSpectrometer, Eppendorf). Samples contaminated by protein or single-stranded 
DNA/RNA have a maximal absorption at 280 nm. In order to asses the purity of the 
DNA samples the ratios A[260]//A[280] and A[260]//A[320] were calculated. The higher the 
ratio the less contaminated the sample, and values of 1.8 for A[260]//A[280] and 2.0-2.2 
for A[260]//A[320]  signified adequately pure DNA samples.  
 
2.1.5 TOPO cloning reaction for the FH constructs 
 
To clone the PCR product into the plasmid vector, pCR
 
4Blunt-TOPO, the 
Zero Blunt TOPO PCR Cloning Kit for Sequencing (Invitrogen) was used. For the 
cloning reaction, 2 μl of the fresh PCR product was mixed with 0.5 μl of the salt 
solution and 0.5 μl of vector solution (supplied with the cloning kit).  The sample 
was centrifuged and left at room temperature for 15 min. The 3-μl resultant mixture 
was used to transform One Shot
®
 Top 10 chemically competent E. coli cells 
(Invitrogen), following the protocol and utilizing the reagents provided in the TOPO 
cloning kit. From the transformed cells, aliquots of 50 and 100 μl were spread on 
Luria-Bertani (LB) (see Appendix section A for composition of media) agar plates 
containing kanamycin (kanamycin sulfate, Gibco) (100 μg/ml, w/v) and were left to 




2.1.6 Restriction enzyme single- and double-digests for the FH constructs 
 
Double digestion was performed on the TOPO vector carrying the required 
DNA insert to facilitate further sub-cloning of the insert into the pPICZaB vector. 
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Single digestion or, alternatively, linearization was performed on the pPICZaB 
vector containing the desired DNA insert to facilitate integration into the P. pastoris 
genome. The reactions were preformed using NEB
 
enzymes and buffers as follows: 
For the double digests, 4.8 μl of NEB buffer 3 (10 % v/v) were mixed with 0.5 μl of 
BSA (1 % v/v), 48 μl of a solution of the TOPO
 
vector containing the DNA insert, 
1.2 μl restriction endonuclease 1, XbaI (20 U/μl), and 1.2 μl restriction endonuclease 
PstI (20 U/μl) yielding a total reaction volume of 55.7 μl. For the single 
digest/linearization, 20 μl of NEB buffer 3 (10 % v/v) were mixed with 2 μl BSA  
(1 % v/v), 200 μl pPICZaB vector containing the DNA insert, 4 μl SacI (20 U/μl) 
restriction endonuclease and 4 μl H2O yielding a total reaction volume of 230 μl. 
Each solution was mixed and incubated at 37 
o
C for 3 h and 6 h, for the double- and 
single-digests, respectively. The restriction endonucleases were inactivated at the 
temperature and time indicated by NEB. The restriction digests were analyzed by 
agarose gel electrophoresis to ensure success of the digestion. Resultant DNA 
fragments were purified and concentrated by phenol-chloroform extraction followed 
by ethanol precipitation or by gel extraction using the QIAquick gel-extraction kit 
(QIAGEN). 
 
2.1.7 Ethanol precipitation for the FH constructs 
 
The volume of the DNA solution was estimated and the salt concentration 
was adjusted by adding 3 M sodium acetate, pH 5.2, to a final concentration of 
 0.3 M. The solution was mixed and 2-2.5 volumes of ice-cold ethanol (100%) were 
added, then the sample was mixed and placed on ice for 1 h. The DNA was 
recovered by centrifugation at 13000 rpm for between 15 and 30 min at 0 
o
C 
(Eppendorf Centrifuge 5415 R). The supernatant was carefully removed with an 
automatic pipette and the tube was filled halfway (750 μl) with 70 % aqueous 
ethanol. Then it was centrifuged (Eppendorf Centrifuge 5415 R) at 13000 rpm for  
5 min at 4 
o
C and again the supernatant was carefully removed. Finally, the open 
tube was stored at room temperature until the pellet had dried. It was then 
resuspended in the desired volume of water. 
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2.1.8 Phenol chloroform extraction for the FH constructs 
 
Phenol-chloroform extraction was performed as follows. An equal to the 
sample volume of phenol: chloroform: isoamyl alcohol (in a ratio 25:24:1, saturated 
with 10 mM Tris, pH 8.0, 1 mM EDTA) was added. The contents of the tube were 
mixed until an emulsion formed. The mixture was then centrifuged on a bench-top 
microfuge (Eppendorf Centrifuge 5415 R) at 13000 rpm for 2 min at room 
temperature. The aqueous phase was transferred into a new tube and the interface 
and the organic phase were discarded. The abovementioned steps were repeated until 
no protein was visible at the interface of the organic and aqueous phase. An equal 
volume of chloroform was added and steps 2-4 were repeated. Finally, the DNA was 
recovered by ethanol precipitation. 
 
2.1.9 Ligation reactions for the FH constructs 
 
Approximately 50 ng of cut pPICZαB vector were combined with a three-
fold molar excess of DNA insert to a volume of 10 μl. Then 7 μl of molecular 
biology-grade H2O were added as well as 2 μl 10x Quick ligation buffer, (NEB
 
) and 
1 μl T4 DNA ligase (400 U/μl, NEB)  to a final volume of 20 μl. The solution was 
mixed, centrifuged briefly and incubated at room temperature for 15 min. Following 
this, transformation of E. coli Top10 cells was performed (see below) and cells were 
spread on LB zeocin plates (25 μg/ml) and left to grow overnight at 37 
o
C.   
 
2.1.10 Transformations of plasmids into chemically competent E. coli cells 
and culture growth for the FH constructs 
 
The chemically competent cells that were used were purchased from 
Invitrogen
 
and were stored at -80 
o
C. A vial of frozen competent cells was thawed on 
ice then 3 μl of the TOPO cloning reaction mixture was added and the contents were 
gently mixed by swirling the tube. It was then incubated on ice for 30 min, placed in 
a pre-warmed water bath at 42 
o
C without shaking for 90 s and then returned to ice 
for 5 min. An aliquot of 250 μl of super optimal growth with catabolite repression 
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(SOC) medium (Invitrogen), pre-warmed to room temperature, was added and the 
tube was capped tightly then shaken in a horizontal position in an incubator set to  
37 
o
C, 200 rpm, for 1 hour. Antibody-selective LB agar plates, containing either  
25 μg/ml zeocin or 100 μg/ml kanamycin, were pre-warmed for 30 min at 37 
o
C. 
Then 100-150 μl aliquots of the transformed cell cultures were streaked onto the 
plates that were incubated overnight at 37 
o
C in a non-shaking incubator.   
Subsequently, single colonies were used to inoculate 5 ml of the appropriate 
LB media containing zeocin or kanamycin at the above concentrations. These were 
incubated overnight at 37 
o
C with shaking at 250 rpm. The resulting cultures were 
used for any required DNA analysis.  
 
2.1.11 Digestion of the pE-SUMOPro Kan vector and the genes of interest for 
the PspC constructs 
 
Synthetic genes for PspCN and PspCNR1 were designed with an XbaI site (to 
allow cloning into the pE-SUMOPro Kan vector (LifeSensors) digested only with 
XbaI) and were supplied (codon optimized), cloned into the pMA-T vector, by 
GeneArt.  
The pE-SUMOPro Kan vector was digested as follows: 2 μl of vector (1 μg) 
were mixed with 2 μl 10x NEB buffer number 4, 1 μl BsaI HF (for high-fidelity) 
(20,000 U/ml, NEB), 0.5 μl 100x BSA (100x, 10 mg/ml) and 15 μl molecular 
biology-grade H2O. The reaction was incubated at 37 
o
C for 1.5 h followed by heat 
inactivation of the enzyme (65 
o
C for 20 min). The digestion of the two synthetic 
genes was carried out as follows: 17 μl of dissolved gene (1.7 μg) were mixed with  
2 μl 10x NEB buffer number 4, 0.5 μl BsaI HF (NEB), 0.5 μl XbaI (20,000 U/ml, 
NEB) and 0.5 μl 100x BSA. The reaction was incubated at 37 
o
C for 1.5 h and the 
enzyme was subsequently heat inactivated by incubation at 65 
o







2.1.12 Ligation of the PspC inserts into the pE-SUMOPro Kan vector and 
transformation of E. coli Top10 cells 
 
An aliquot of 1 μl of linearized pE-SUMOPro Kan vector was mixed with  
3 μl of linearized synthetic gene plasmid, 1 μl 5x DNA-dilution buffer (Rapid DNA 
Dephos and Ligation Kit, Roche), 5 μl 2x T4 DNA ligation buffer (Roche) and 0.5 μl 
T4 DNA Ligase (5 U/ml, Roche). The reaction was incubated at room temperature 
for as long as required for the Top10 chemically competent cells to thaw 
(approximately 10-20 min). Of the ligation reaction, 2 μl were then used to transform 
the cells as follows: an aliquot of 2 μl of ligation reaction was added to the cells and 
mixed gently by swirling the tube. The cells were then incubated on ice for 30 min 
and were subsequently heat-shocked at 42 
o
C for 30 s. To the cells was added 250 μl 
SOC medium and then they were placed in a shaking incubator set at 37 
o
C for 1 h. 
Samples of  20 and 200 μl of the reaction were then plated out on antibody-selective 





2.1.13 Inspection of colonies for correct insert for the PspC constructs cloned 
into pE-SUMOPro Kan vector 
 
Ten colonies for PspCN and 10 colonies for PspCNR1 were chosen from the 
LB agar plates to inoculate 5 ml of LB broth containing 30 μg/ml kanamycin and 
with the same loop (for each of the colonies) to inoculate 3 ml of LB broth 
containing 100 μg/ml carbenicillin (carbenicillin disodium salt, Apollo Scientific 
Ltd.). The cultures were left to grow overnight at 37 
o
C. Cultures that did not grow 
on carbenicillin then underwent purification of plasmid DNA. The resultant DNA 
was then digested as follows: 17 μl of the DNA were mixed with 2 μl of  
10x NEB buffer number 4, 1 μl XbaI (20,000 U/ml) and 0.5 μl 100x BSA. The 
reaction was incubated at 37 
o
C for 90 min and was finally subjected to agarose gel 




2.1.14 Transformation of constructs cloned into pET-15b in BL21 (DE3) E. 
coli cells 
 
A glycerol stock of the DNA for the His-tag PspCN-GSGC version of PspCN 
transformed in the E. coli strain BL21 (DE3) prepared by Dr A. Herbert (the DNA 
was originally ordered from GeneArt), as well as the freshly prepared DNA for the 
His-tag PspCN construct (following site-directed mutagenesis using the DNA form 
the His-tag PspCN-GSGC construct as a template) were used for re-streaking on LB 
agar plates containing 50 μg/ml carbenicillin. The plates were left to grow overnight 
at 37 
o
C. Single colonies were used to inoculate 5 ml of LB broth containing  
50 μg/ml carbenicillin and the cultures were left to grow overnight in a shaking 
incubator set at 37 
o
C. The plasmid DNA was subsequently purified and used to 
transform BL21 (DE3) E. coli cells (Lucigen). The transformation protocol followed 
(provided by Lucigen) was as follows: The cells were thawed on ice, 1 μl of the  
15 and 47 ng/μl DNA stock were added to 40 μl of cells for each DNA 
concentration, and the whole was stirred briefly with the pipette tip. The cells were 
then incubated on ice for 30 min, heat shocked for 45 s at 42 
o
C and returned to ice 
for 2 min. A volume of 960 μl of express recovery medium was then added and the 
tubes were placed in a shaking incubator at 37 
o
C for 1 h. Subsequently,  
50 and 100 μl aliquots of the transformation reaction were plated on LB agar plates 
containing 50 μg/ml carbenicillin and were left to grow overnight at 37 
o
C. Single 
colonies were used to inoculate LB media for the large-scale expressions. 
 
2.1.15 Production of the recombinant FH constructs in P.  pastoris  
 
2.1.15.1 Overview of P. pastoris as an expression system 
      
P. pastoris is a yeast expression host that was used to produce recombinant 
FH-derived fragments. For expression in this system, the insert is placed under the 
control of a very strong, inducible promoter (explained below). As a eukaryotic 
expression system, P. pastoris has important advantages over prokaryotic ones, such 
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as the abilities to carry out post-translational modifications, glycosylation, correct 
protein folding, proteolytic processing and disulfide bond formation (98), (99). 
As a methylotrophic yeast, P. pastoris utilizes methanol as a sole carbon 
source through a methanol metabolic pathway comprising a set of enzymes. The 
initial step in the metabolism of methanol occurs when the enzyme alcohol oxidase 
(AOX) induces the oxidation of methanol to formaldehyde and the formation of 
hydrogen peroxide - a harmful by-product. To avoid the toxic effects of hydrogen 
peroxide this process takes place in a specialized organelle called the peroxisome 
that isolates this toxic compound from the rest of the cell. The second enzyme, 
catalase, is mostly located in the peroxisome and serves to rapidly catalyze 
decomposition of hydrogen peroxide to less reactive gaseous oxygen and water 
molecules. Alcohol oxidase has a poor affinity for O2 and in order to compensate for 
that the yeast cells produce very high amounts of this enzyme. Consequently the 
promoters concerned are exceptionally strong and are exploited to obtain high yields 
of inducible recombinant proteins.  
This organism has two genes that code for alcohol oxidase AOX, AOX1 and 
AOX2. AOX2 is 97 % similar to AOX1. However the resultant growth following 
uptake of methanol, and hence the activity of alcohol oxidase, is much faster when 
the AOX1 gene is responsible. When methanol is the carbon source for the growth of 
P. pastoris, AOX1 is expressed at very high levels while being regulated at the level 
of transcription. Regulation involves two mechanisms: repression/derepression and 
induction. In the first case, the presence of glucose represses transcription even if 
methanol is present.  For this reason, growth on glycerol (derepression) is 
recommended during protein production work, which is performed before induction 
with methanol which is essential for AOX1 expression. There are two different 
methanol-metabolizing P. pastoris phenotypes: MUTs and MUT
+
. The strain which 
phenotypically is MUT
S
 (methanol utilization slow) results from the loss of the 
AOX1 gene and hence the majority of alcohol oxidase activity. This strain relies on 
AOX2 and grows on methanol slowly. The strain with phenotype MUT
+
 (methanol 
utilization plus) refers to the wild-type ability of strains to grow on methanol as a 
sole carbon source. The P. pastoris strain used for this project was KM71H 




With P. pastoris as an expression system, heterologous proteins can either be 
expressed intracellularly or secreted. The fact that P. pastoris secretes low levels of 
native proteins, combined with the minimal media used for its growth, results in the 
majority of  total protein in the media being the recombinant protein of interest, 
effectively serving as a first purification step. As far as post-translational 
modifications are concerned, P. pastoris has the potential to perform most 
modifications associated with higher eukaryotes.  These include O- and N-linked 
glycosylation and disulfide bridge formation, the latter being of particular relevance 
to the current work since CCP modules have two disulfide bonds per CCP.  
To utilize the strongly inducible AOX1 promoter for gene expression, the 
plasmid pPICZαB was used as a vector.  This plasmid carries the DNA encoding the 
alpha-factor secretion signal peptide that is fused to the insert to ensure the target 
protein is secreted. Using this vector ensure that once the heterologous protein-
encoding sequence has been integrated into the genome of P. pastoris, the AOX1 
promoter is responsible for expression and expression is modulated through 
controlled methanol feeds during cell cultures (98), (99), (100), (101). 
In some cases the N-terminus of the expressed protein may include, usually, 
one or two non-native Glu-Ala repeats. Two steps are required for the processing of 
the alpha-factor signal sequence. The first step involves cleavage by the KEX2 gene 
product, with the final Kex2 cleavage occuring between Arg and Gln in the 
following sequence: Glu-Lys-Arg* Glu-Ala-Glu-Ala (* is the site of cleavage) (102). 
The second step involves cleavage of the Glu-Ala repeats by the STE13 gene product 
(103). There are cases where Ste13 cleavage is not efficient thus leaving the 
aforementioned non-native N-terminal repeats. 
 
2.1.15.2 Preparation of P. pastoris cells 
 
The following procedure was employed: Starting from a re-streaked plate of 
P. pastoris strain KM71H cells, 10 ml of Yeast Extract Peptone Dextrose (YPD) 
medium were inoculated with a single colony and left to grow overnight at 30 
o
C. A 
batch of 250 ml of fresh YPD medium was poured into a 1-L flask, inoculated with 
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0.1-0.5 ml of the overnight culture and the cells were again left to grow overnight 
until they reached an OD600 of ~1.3. The cells were centrifuged for 5 min at  
1500×g, 4 
o
C, and then resuspended in 250 ml of ice-cold sterile water. The cells 
were again centrifuged for 5 min, 1500×g, 4 
o
C, and resuspended in 125 ml of ice-
cold sterile water. The cells were again centrifuged as above and resuspended in  
10 ml of ice-cold 1 M sorbitol. Cells were again centrifuged as above, and 
resuspended in 0.5 ml of ice-cold 1 M sorbitol. 
 
2.1.15.3 Transformation by electroporation 
 
The following protocol was used: An 80-μl aliquot of the cells were mixed 
with 5-10 μg of linearized DNA, in 5-10 μl of sterile water, and transferred into an 
ice-cold 0.2-cm electroporation cuvette. The cuvette with the cells was incubated on 
ice for 5 min. The cells were pulsed for 5 s (settings on the BioRad gene pulser II: 
charging voltage 1500 V, capacitance 25 μF, resistance 200 mΩ). Immediately after 
pulsing, 1 ml of ice-cold 1 M sorbitol was added and the contents of the cuvette were 
transferred into a 15-ml tube. The tube was incubated for 3 h at 30 
o
C without 
shaking. Aliquots of 150 and 350 μl of the contents of the 15-ml tube were spread on 
Yeast Extract Peptone Dextrose Medium (plus Sorbitol) (YPDS) plates containing 
100 μg/ml and 300 μg/ml zeocin and were left to grow at 30 
o
C for three days until 
colonies were visible. 
 
2.1.15.4 FH constructs 8-9, 13-14, 10-15 and 8-15 
 
P. pastoris clones (in strain KM71H) expressing FH-8-9, FH-13-14 and FH-
10-15 were provided by Dr C. Q. Schmidt. These were expressed either in shaker 
flasks or in fermentors as outlined in the sections below (2.1.15.5 and 2.1.15.6) and 
were purified as described in section 2.2.6. In the case of unlabeled production of 
FH-10-15 and FH-8-15 crude P. pastoris supernatant also provided by Dr C. Q. 
Schmidt was the starting point and was thereafter purified. The results of all 
purification procedures are presented in Chapter 3.  
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2.1.15.5 Mini-scale expression (trial expression) of recombinant proteins in 
              P. pastoris 
 
This procedure was carried out as follows: A single colony was used to 
inoculate 5-10 ml buffered minimal glycerol (BMG) in a 50-ml tube and was placed 
in a shaking incubator set to 250-300 rpm, 30 
o
C for two days. The cells were spun at 
1500×g for 10 min (Sorvall
 
RC6 PLUS, rotor: SH-3000), and resuspended in 3 ml 
buffered minimal methanol (BMM) and the 50-ml tube was returned to the incubator 
once the temperature was set to 15 
o
C. During this induction period, 100% methanol 
was added every 24 h to maintain a final concentration of 0.5 % (v/v). This was 
carried out for two days. On the third day, methanol to 0.5 % (v/v) was added in the 
morning followed by methanol to 1.2 % (v/v) in the evening. The cells were 
harvested by centrifuging at 4000×g for 20 min (Sorvall
 
RC6 PLUS, rotor: SH-
3000). Prior to purification, phenylmethanesulfonyl fluoride (PMSF, 100 mM in 
isopropanol) and ethylenediaminetetraacetic acid (EDTA, 500 mM, pH 8.2) were 
added to final concentrations of 0.5 mM and 5 mM respectively. 
 
2.1.15.6 P. pastoris recombinant protein expression in shaker flasks 
 
The procedure was carried out as follows: A single colony was used to 
inoculate 25 ml BMG in a 500-ml sterile baffled flask and this was placed in a 
shaking incubator (250-300 rpm), 30 
o
C. After 24 h 500 ml of fresh BMG was added 
in an empty, sterile 2-L baffled flask and inoculated with 25 ml of the overnight 
culture, returned to the incubator, and left to grow for two-three days. The cells were 
spun for 5 min at 1500×g (Sorvall
 
RC6 PLUS, rotor: SLA-3000), resuspended in  
125 ml of BMM and the flask was returned to the incubator, once the temperature 
was set to 15 
o
C. During this induction period, 100% methanol was added every 24 h 
to maintain a final concentration of 0.5-1.2 % (v/v). The cells were harvested by 
centrifuging at 4000×g for 20 min (Sorvall
 
RC6 PLUS, rotor: SLA-3000). Prior to 
purification PMSF and EDTA were added to final concentrations of 0.5 mM and  
5 mM respectively. 
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2.1.15.7 P. pastoris recombinant protein production in fermentor  
  






C-enriched media, was 




N-HSQC/TROSY spectra in the case of FH-13-14 and FH-10-15. Compared to a 
shaker flask there are advantages that come with a fermentor growth. First, typically 
expression levels are higher in the controlled environment that fermentation 
provides, such as control of temperature, pH, agitation and oxygen, especially for 
proteins that are secreted. Second, the level of transcription from the AOX1 promoter 
can be greater when the cells are fed with methanol at growth-limiting rates 
compared to excessive feeding in shaker flasks. Finally, when methanol is 
metabolized, high levels of oxygen are needed for the successful expression of the 
gene of interest (101). Hence, the possibility of monitoring and adjusting accordingly 
the oxygen in a fermentor culture is advantageous.       






C-labeled protein samples, which differed in the initial buffer volume and 
composition and the isotopic labeled reagents added. All fermentations were carried 
out in two-liter cylindrical Bioflow 3000 (New Brunswick scientific) fermentor 
vessels. 
 
2.1.15.7.1 Preparation of P. pastoris cells that contained the gene of interest 
 
From the glycerol stock, under sterile conditions, a small amount of cells was 
spread on a YPD plate and left to grow at 30 
o
C until colonies appeared (this took 
approximately three-four days). A single colony was used to inoculate 10 ml of fresh 
BMG, and this was placed in a shaking incubator (30 
o
C, 250 rpm) for 24 h. A batch 
of 150 ml of fresh BMG were poured into a sterile 500-ml baffled flask, inoculated 
with the 10 ml and placed back in the incubator for approximately 24 h. The cells 
were spun for 5 min at 1500×g and resuspended in 20 ml of fermentor media or 










2.1.15.7.2 Preparation of fermentor growth media; fermentor vessel; initial set-up of 
Bioflow 3000.  
 
This preparatory step started on the day at which the 150 ml of BMG were 
inoculated with the 10-ml first culture, and was carried out as follows: 













15N-enriched media 15N, 13C-enriched media 
0.75 g CaSO4 x 7 H2O 
12 g MgSO4 x 7 H2O 
8 g K2SO4 
20 ml 100 % glycerol 
60 ml 1 M potassium 
phosphate buffer, pH 6.0 
740 ml dH20 
0.56 g CaSO4 x 7 H2O 
9 g MgSO4 x 7 H2O 
6 g K2SO4 
– 
45 ml 1 M potassium 
phosphate buffer pH 6.0 
555 ml dH20 
Final volume 800 ml 600 ml 
 
Table 2.8 Basal salts and media used for the fermentation buffers. 
    
The media were added into the fermentor vessel. Following this, the vessel 
was assembled, the probes for the dissolved oxygen (DO), pH, as well as the filter 
for the air, were attached and the whole was autoclaved. After having cooled down, 
the DO probe was attached to the main unit of the Bioflow 3000 and was left to 
charge overnight. In addition, the supply for air was turned on so that air flowed 
continuously through the sterile filter, and the impeller speed was set to 200 rpm. 
The pH probe was also attached, as was the temperature probe and a feeding line for 
base (2 M KOH) used to maintain pH levels stable at 5.0. To the vessel were added 
0.5 ml Antifoam 204 (Sigma Aldrich) and 3.5 ml filter-sterilized (0.2-μm cut-off) 
fermentation trace salts (PTM1 salt, Amresco), and the temperature was set to 30 
o
C. 
 After the overnight period, for 
15
N-enrichment, 7-8 g 
15
N-(NH4)2SO4 
(ISOTEC, Sigma-Aldrich) were dissolved in roughly 20 ml dH2O and sterile-filter 








(NH4)2SO4 was dissolved in 20 ml distilled H2O and 15 g 
13
C-Glucose in about 45 ml 
distilled H2O and both were again sterile-filter injected (20 μm filter) into the media. 
 Once temperature and pH conditions had stabilized, the relative percentage 
of dissolved oxygen was normalized to 100. The impeller speed was set (between  
300 and 1000 rpm) so as to preserve a relative oxygen level of 40 % during the 
period of growth and induction. (Note that when the cells are metabolizing the 
carbon source, the dissolved oxygen levels drop below 40 % initially, then increases 
and remains relatively stable until the cells have consumed the food, at which point 
the dissolved oxygen level increase above 40 %. To compensate, the impeller speed 
increases to near 1000 rpm when dissolved oxygen levels are low but decreases and 
remains stable at 300 rpm when they are high.) After these preparations the vessel 
was inoculated with the cells.  
For the 
15
N-enriched fermentations: After inoculating and incubation for 16 h, 
based on inspection of the impeller speed and dissolved oxygen level, the cells were 
fed 40 ml autoclaved glycerol accompanied by 0.48 ml PTM1 trace salts (both were 
sterile-filter injected). Once the glycerol source had been exhausted, roughly after 
one day, the temperature was reduced to 15 
o
C and allowed to stabilize. Subsequently 
methanol feeds (accompanied by addition of PTM1 salts) were instigated by an 
initial feed of 0.5 % of culture volume. Induction was then promoted by the first of 
two 1.2-1.3 % feeds. At this point it was important not to overfeed with methanol so 





C-enriched fermentation: once having inoculated and after one-
day growth period, cells were fed 1.0 g of 
13
C-glycerol (ISOTEC, Sigma-Aldrich) 
diluted in 3 ml distilled H2O (sterile-filter injected). The importance of this step 
derives from the fact that all of the glucose should have been consumed before the 
addition of methanol as glucose represses the AOX1 promoter. Once glycerol had 
been consumed, 
13
C-MeOH (ISOTEC, Sigma Aldrich)  feeds followed, 0.5 % (of the 
culture volume) for the first feed, 1.25 % for the second, and 1.25 % for the third, 
with the timing based on careful observation of agitation rates and dissolved oxygen 
levels. 
In both cases, the cell culture was subsequently harvested by centrifugation at 
8000×g for 20 min. Then, the supernatant was decanted into clean centrifuge bottles 
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and was spun again at 8000×g for 30 min (Sorvall
 
RC6 PLUS, rotor: F9S-4x1000y). 
Sterile filtration of the supernatant ensued and finally EDTA (500 mM, pH 8.2) and 
PMSF (100 mM in isopropanol) were added prior to purification (to final 
concentrations of 5 mM and 0.5 mM respectively). 
 
2.1.16 Production of the recombinant PspC constructs in E. coli 
 
2.1.16.1 Overview of E. coli as an expression system 
 
E. coli is the most frequently used prokaryotic expression system as its fast 
growth rate; its good levels of protein production and its simple growth conditions 
make it an attractive option for production of heterologous proteins. 
For the production of proteins a plasmid is transferred into an E. coli cell that 
contains a chromosomal copy of the gene that encodes T7 RNA polymerase. This 
allows regulated expression from the T7 promoter (104). The host strains are 
lysogens of bacteriophage DE3 and carry a DNA portion that includes the lacI gene, 
the lacUV5 promoter and the gene for T7 RNA polymerase (105), (106). Once a DE3 
lysogen is formed, the lacUV5 promoter directs transcription of the T7 RNA 
polymerase. This occurs upon induction with isopropyl-β-D-thiogalactopyranoside 
(IPTG) (107). When IPTG is added to a bacterial culture that has reached mid-log 
phase (before the cells have reached saturation), T7 RNA polymerase production is 
induced. IPTG, which is a lactose analog, operates by binding to the lacI repressor. It 
induces its dissociation of repressor from the operator thus allowing transcription 
from the promoter. When sufficient amounts of the polymerase are produced, it binds 
to the T7 promoter and transcribes the gene of interest.  
For the purpose of this study, two types of vectors were used, pET-15b and 
pE-SUMOPro Kan (LifeSensors). One of the features of the pET-15b vector is that it 
contains the highly efficient ribosome-binding site from the phage T7 protein which 
is used for expression of target genes that lack their own ribosomal site. The vector 
encodes an N-terminal His-tag sequence followed by a thrombin cleavage site and it 
has three cloning sites. In the present study the gene was provided by GeneArt and 
was cloned using the NdeI and BamHI site. The use of pE-SUMOPro Kan vector 
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results in the cloning and expression of the gene of interest as a fusion to SUMO. It 
has been shown that protein fusions enhance the expression and solubility of 
recombinant proteins (108). SUMO is an 11-kDa protein and a member of the 
ubiquitin-like protein family that regulates several cellular processes (109). SUMO 
will attach to Lys residue sidechains and its use results in change in protein function 
and activity. The advantages associated with fusing the target protein to SUMO are 
increased expression level, solubility, and the option of easy subsequent cleavage of 
SUMO which is facilitated by its recognition by SUMO protease (Ulp) (110), (111). 
This final option ultimately results in the production of native protein with no 
additional residues. 
 
2.1.16.2 Optimization of E. coli strain and induction conditions for constructs cloned 
in pE-SUMOPro Kan vector 
 
The DNA preparations that tested positive for the correct insert were 
individually used to transform different E. coli strains. Two E. coli strains were used, 
namely, BL21 (DE3) and BL21 (DE3) –pLysS. The procedure followed for the 
transformation of the BL21 (DE3) –pLysS strain was identical to that already 
described for the E. coli TOP10 cells in section 2.1.10. For the transformation of the 
BL21 (DE3) strain the protocol provided by Lucigen was followed (already 
described in section 2.1.14). Thus 20, 100 and 200 μl of BL21 (DE3) and 20, 200 μl 
of (DE3) –pLysS were plated on LB agar plates containing 30 μg/ml kanamycin and 
were left to grow overnight at 37 
o
C. The test inductions were performed in an 
identical manner for both strains and both PspC constructs. For the first set of 
conditions which were 3 h induction periods at 37 
o
C, single colonies from the 
transformations described above were used to inoculate 5 ml of LB broth containing 
30 μg/ml kanamycin, and the cultures were placed in a shaking incubator set at 37 
o
C 
until the OD600 reached ~0.8. Samples of 0.5 ml were taken at this point. The cultures 
were induced with IPTG (Promega) to a final concentration of 1 mM and left to grow 
for 3 h at 37 
o
C. Following this, two 0.5-ml samples were taken for testing of total, 
and soluble or insoluble, recombinant protein products. The 0.5-ml samples taken 
prior to induction and one of the two 0.5-ml samples taken after induction for testing 
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the total fraction of expressed proteins were processed as follows: the samples were 
spun at 13000 rpm for 5 min and the pellets were resuspended in 250 μl SDS-
containing PAGE loading buffer. The samples were then incubated at 95 
o
C for  
5 min during which time they were mixed at 1-min intervals. They were then spun 
for 5 min at 13000 rpm and loaded on an SDS-PAGE gel. The remaining 0.5-ml 
samples were subjected to the following procedure: They were spun for 5 min at 
13000 rpm and the supernatants were discarded. The pellets were resuspended in  
125 μl BugBuster MasterMix (Novagen), the tubes were placed in a shaking 
incubator set at 37 
o
C for 10 min, they were then spun again and the supernatants 
were transferred to separate tubes to which 0.5 ml of SDS-PAGE loading buffer was 
added for loading on an SDS-PAGE gel in order to test the soluble fraction of the 
expression. The pellets from that stage were resuspended in 0.5 ml BugBuster 
MasterMix (Novagen), were incubated for 5 min at 95 
o
C, while being mixed at  
1-min intervals. They were subsequently spun for 5 min at 13000 rpm, the 
supernatants were discarded and the procedure for lysing pellet was repeated. The 
final pellets were resuspended in 250 μl SDS-PAGE loading buffer for loading on an 
SDS-PAGE gel in order to determine the insoluble fraction of expressed protein. 
The second set of induction conditions were overnight induction at 18 
o
C. 
The procedure followed was identical to that of the first set of conditions with the 
apparent exception of temperature and induction time, and the IPTG which was 
added at final concentration of 0.25 mM. 
 
2.1.16.3 E. coli recombinant protein expression in shaker flasks 
 
Single colonies form the transformations of the BL21 (DE3) cells were used 
to inoculate 10 ml LB broth containing 30 μg/ml kanamycin or 50 μg/ml 
carbenicillin. The cultures were left to grow overnight in a shaking incubator set at 
37 
o
C. Aliquots of 1-2.5 ml of culture were then used to inoculate 500 ml of LB 
broth, which contained 30 μg/ml kanamycin or 50 μg/ml carbenicillin. The cultures 
were left to grow in a shaking incubator at 37 
o
C. Once the OD600 reached ~0.6, the 
temperature was reduced to ~20 
o
C and the cells were induced with IPTG to final 
concentrations of 0.25 mM (in case of the constructs having been cloned in the pE-
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SUMOPro Kan vector) and 0.5 mM (in the case of the constructs having been cloned 
in pET-15b vector). The cultures were left to grow overnight, were then harvested by 
centrifugation at 6000×g for 15 min and the supernatant was discarded. 
After harvesting the E. coli cultures, the cell pellets were weighed. BugBuster 
MasterMix (Novagen) was then added at a ratio of 5 ml/g pellet accompanied by 
EDTA-free protease inhibitors cocktail (protease inhibitor cocktail set V, EDTA-
Free, Calbiochem). The cells were mixed until a uniform resuspension was achieved 
and were then placed on rolling platforms (Roller SRT1, Stuart Scientific) at 4 
o
C for 
2 h. They were subsequently sonicated at 15-s intervals for a total of 5 min (Soniprep 
150, Sanyo, at amplitude of 10 microns). They were finally spun at 16000×g for  





2.2 Manipulation and purification of the protein samples 
 
2.2.1 Estimation of protein concentrations by UV Spectroscopy 
 
Protein samples have a maximum UV absorbance at 278-280 nm, hence UV 
spectroscopy was utilized for this purpose (Eppendorf BioSpectrometer, Eppendorf). 
The ratios A[280] /A[260], and A [280]/A[320] were used to asses the purity of the samples. 
The protein concentrations were calculated according to the Beer-Lambert’s law 
equation: A= εbc, were ε is the molar extinction coefficient (calculated by ExPASy, 
ProtPram tool), b the pathlength and c the concentration. 
 
2.2.2 Concentration of protein samples 
 
2.2.2.1 Concentration by trichloroacetic acid (TCA) precipitation (for SDS-PAGE) 
  
A 20 % (v/v) TCA solution was added to the sample, at an equal volume. The 
mixture was incubated on ice for 1 h. It was then spun in a bench-top micro-
centrifuge (Eppendorf Centrifuge 5415 R) at 13000 rpm for 30 min at 4 
o
C. The 
supernatant was discarded. An aliquot of 300 μl of ice-cold acetone was added and 
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the whole was mixed. It was then spun at 13000 rpm for 5 min at 4 
o
C. The pellet 
was air-dried at 95 
o
C for 5-10 min. The sample was finally resuspended in SDS-
containing gel-loading buffer in preparation for loading onto an SDS-PAGE gel. 
 
 2.2.2.2 Concentration by membrane concentrators and buffer exchange 
 
With respect to all the single and double-isotopically labeled protein samples, 
concentration was achieved solely by this method. It was also used for the various 
buffer exchanges and was exclusively used for all the PspC constructs. The sample 
was carefully decanted in 6- or 20-ml Vivaspin concentrators (Sartorius 
Mechatronics UK Ltd) with the appropriate molecular weight cut-off membrane 
(5000-10000) Da. In the case of concentration it was then centrifuged at 4000×g, 
until the volume was ~400 μl at which point the sample was transferred into a 
microcentrifuge tube. Finally, the membrane of the concentrator was washed with  
~100-200 μl of the same buffer, and this volume was added to the same tube. In the 
case of buffer-exchange, the sample was again centrifuged at 4000×g to a volume of 
500-600 μl. Buffer was then added up to a volume of 5-6 ml and the sample was 
again centrifuged under the same conditions. This was repeated three times. 
 
2.2.3 Sodium dodecyl –sulfate polyacrylamide gel electrophoresis (SDS-             
 PAGE) 
 
Polyacrylamide gels (4-12 % Bis-Tris Gel) were purchased from (NuPAGE
®
 
Novex Bis-Tris Mini Gels). Depending on the various numbers of wells and gel 
thicknesses, samples were mixed with the appropriate volumes of loading buffer 
(4x), and reducing agent (10x) and were heated at 95 
o
C for 2 min (in a heating 
block) prior to gel loading. Protein markers with molecular weights in the  
10-150 kDa range (Precision Plus Protein Standards, Kaleidoscope, Bio-Rad) were 
run alongside the samples. The gel was run in 1x NuPAGE MES-buffer (Invitrogen) 
at 180 V for approximately 50 min. The gel was then washed with water. 




, CA, USA) for at least 1 h. Following this, the stain was discarded, and the gel 
was left to destain for a minimum of 3-6 h or overnight.  
 
2.2.4 Enzymatic cleavage of N-linked glycans for the FH constructs 
 
Endo Hf enzyme (New England BioLabs) (a recombinant fusion of 
endoglycosidase H and maltose binding protein) was used for the removal of the 
mannose-rich N-linked carbohydrate residues from the proteins. Endo Hf can cut 
between the two first GlcNAc molecules, leaving the protein with one GlcNAc 
moiety per glycosylation site. Variable numbers of units of Endo Hf (10
6
 U/ml) were 
used at 37 
o
C for 1-3 h, depending on the amount of sample to be treated. 
 
2.2.5 Cleavage of SUMO from the SUMO-ylated proteins 
 
Cleavage of SUMO-PspCN and SUMO-PspCNR1 was performed by adding 
100 μl of SUMO protease (or ULP1-Ubiquitin like protease, 10 U/μl, produced in the 
lab by Dr A. Herbert). The protease was added in a dialysis tube containing the 
protein to be cleaved and was left at 4
o 
C overnight in 20 mM potassium phosphate 
buffer, 500 mM NaCl, 20 mM imidazole buffer, pH 7.0. 
 
2.2.6 Protein Chromatography 
 
The solvents and buffer reagents used for the purification of the protein 
constructs were purchased from Sigma-Aldrich and Fisher Scientific. All columns 
used were purchased from GE Healthcare. The gel-filtration column (for size-
exclusion chromatography) was pre-packed. For the initial purification step of the 
majority of the FH constructs, cation-exchange chromatography was employed.  
4-5 ml SP-Sepharose were packed into graduated Econo-Pac polypropylene columns 
(BioRad Laboratories), or 30 ml SP- or Q-Sepharose in an XK 26 column 
(Pharmacia Biotech) for the cation and anion exchange chromatography respectively. 
Prior to loading on the ion-exchange column the supernatant was diluted accordingly 
and pH adjusted appropriately (see below) so as to achieve binding to the column.  
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For size-exclusion chromatography, the sample was concentrated and buffer-
exchanged using membrane concentrators.  
For ion-exchange chromatography, based on the pI of the proteins as 
calculated by ExPASY ProtParam tool, the pH of the supernatant and the column 
were set ~2-3 units lower or higher than the pI in the case of cation and anion 
exchange, respectively.  This was to ensure the protein would be positively or 
negatively charged and, through electrostatic interactions, would bind to the 
negatively charged SP-Sepharose or positively charged Q-Sepharose. The packed 
columns were equilibrated with between 2 and 4 column volumes of the appropriate 
binding buffer. After harvesting (prior to loading) the supernatant was diluted either 
with the same buffer or distilled water and was then applied to the column (this 
reduced the salt concentration so as not to weaken the interactions between sample 
and resin). Elution of the protein was then achieved by applying the same buffer but 
containing 1 M NaCl. This was done either on the bench or using the ÄKTA-design 
FPLC system (pump P-920, UV detector unit UPC-900). In the latter case a gradient 
of the buffer was applied, from 100 % binding buffer to 100 % buffer with 1 M salt 
(linear gradient). The flow-rate used was 3.5 ml/min and the volume of the fractions 
collected was 2.5 ml. 
Immobilized metal-affinity chromatography was employed as the first 
purification step in the case of the PspC constructs, which were expressed with a His- 
tag. A 5-ml HiTrap IMAC HP column (GE Healthcare) pre-packed with IMAC 
Sepharose High-Performance resin charged with Co
2+
 was used. The binding buffer 
consisted of 20 mM potassium phosphate buffer, pH 7.0, supplemented with 0.5 M 
NaCl to inhibit non-specific binding and 20 mM imidazole to minimize the binding 
of unwanted host cell proteins. This buffer was used to equilibrate the column and to 
dilute the lysate obtained after harvesting. The elution buffer was made by adding 
imidazole to the binding buffer to a final concentration of 0.5 M. The lysate was 
applied on the pre-equilibrated column manually using a syringe and the protein was 
then eluted using the ÄKTA-design FPLC system (pump P-920, UV detector unit 
UPC-900), and a linear gradient from 20 mM to 500 mM imidazole. The flow-rate 
used was 5 ml/min and the volume of the fractions collected was 2.5 ml. 
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Size-exclusion chromatography was employed as a subsequent purification 
step using the gel-filtration chromatography column, HiLoad 16/60  
(16 mm x 600 mm) Superdex 75, 120 ml, prep grade. Prior to loading the column 
was equilibrated with 1.1-1.6 column volumes of the appropriate buffer. Based on 
the SDS of the fractions from the SP/Q-Sepharose elutions as well as the Co
2+
-
affinity chromatography, selected fractions were chosen and concentrated in 
membrane concentrators. They were then buffer-exchanged into the appropriate 
buffer and 0.5-1 ml samples were applied to the column using the ÄKTA-design™ 
FPLC system (pump P-920, UV detector unit UPC-900). The flow-rate used was  
1 ml/min and the volume of the fractions collected was 1.5 ml. 
It is noted that due to a problem that occurred regarding the autozero function 
of the FPLC system that was used for the purification of the proteins, some of the 
chromatograms presented in Chapter 3 display measurements on the y-axis that have 
negative values instead of zero. 
 
2.2.7 Mass spectrometry 
 
The Scottish Instrumentation and Resource Center for advanced Mass 
Spectrometry (SIRCAMS) facility of the University of Edinburgh provided a mass 
analysis service. Prior to submission, the sample was prepared as follows:  A 
minimum of 10 μM concentration of the protein sample in ~20 μl of 20 mM 
potassium phosphate buffer or phosphate-buffered saline (PBS) was transferred to a 
microcentrifuge tube and was briefly centrifuged (13000 rpm). Mass analysis was 
achieved using LC-MS, LC-MS Dionex U300 HPLC 500 μM PSDVB monolyth 
column-Fourier-transform ion cyclotron resonance mass spectrometry (FT-ICR MS). 
The results served as a verification of the mass of the proteins. In addition, in the 
case of proteins produced in P. pastoris, it provided information regarding the 
formation or not of disulfide bonds and whether none, one or two expression artifacts 
(i.e. Glu-Ala from the P. pastoris expression system) were present. Finally, apart 
form LC-MS accurate mass analysis, trypsin digest was performed where considered 
necessary (again by SIRCAMS) in order to identify matching peptides within the 
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protein samples (trypsin potentially cuts to the C-terminal side of Lys and Arg unless 
the next residue is Pro). 
 
2.3 NMR studies 
 
All of the spectra reported in this thesis were collected on a Bruker AVANCE
 









N-FH-11-12 which was acquired on a Bruker AVANCE 14.1-
Tesla (600 MHz) spectrometer. Both instruments were fitted with 5-mm triple-
resonance probes/cryoprobes. All 1D, 2-D and 3-D spectra were recorded at 25 
o
C 
(298 K). All the experiments were setup with the guidance of Mr. Juraj Bella with 
the exception of several 1-D and 2-D 
15
N-HSQC experiments that were setup by the 
author unassisted. The pulse sequences employed in this study were written by Dr 
Dušan Uhrin.  Experimental parameters and procedures for setting up experiments 
were taken from http://nmrlinux.chem.ed.ac.uk/highfield/highfield.html. 
 
2.3.1 Data processing and analysis  
 
Topspin (Bruker SpectroSpin) was used for experimental set-up, data 
acquisitions and initial data processing on the instrument. The data were 
subsequently transferred onto the Linux-based computer cluster and processed 
offline using software provided by the CCPNMR (Collaborative Computational 
Project for the NMR community) (112). Thus data were processed using AZARA 
(W. Boucher, Department of Biochemistry, University of Cambridge, UK), after 
which spectra were visualized and assignments achieved using ANALYSIS (version 
2.0.7 initially and version 2.1.1 subsequently) (112). 
 
2.3.2 Processing of the data 
 
Within AZARA, a parameter file called ser.ref and a script input file called 
scr were produced. The scr file contains various commands such as Fourier 
transformation, phasing and baseline correction. Depending on the specific 
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requirements of each experiment, the appropriate alterations were made in the scr 
file. This was subsequently applied to process experiments and the resultant 
spectrum visualized using the commands “plot2” in the case of the 2D spectra and 
the command “planes” in the case of the 3-D spectra. When a satisfactory result was 
achieved the output spectrum resulting from the processing, called spc, was loaded 
into ANALYSIS for assignment. 
 
2.3.3 NMR experimental parameters for the FH and PspCN constructs 
 
Table 2.9 summarizes the NMR experimental parameters for the spectra 
presented in Chapters 3 and 4 for constructs FH-11-12, FH-13-14, FH-13, FH-10-15, 


















































Dim 1: 13.98 
Dim 2: 24.80 
Dim 1: 8389.26 
Dim 2: 1507.84 
Dim 1: 4.096 






















Dim 1: 11.00 
Dim 2: 28.00 
Dim 1: 8802.82 
Dim 2: 2270.15 
Dim 1: 4.30 


















Dim 1: 16.93 
Dim 2: 35.99 
Dim 1: 13550.14 
Dim 2: 2918.86 
Dim 1: 6.62 
























Dim 1: 13.95 
Dim 2: 60.00 
Dim 1: 11160.71 
Dim 2: 4863.81 
Dim 1: 5.45 

















Dim 1: 13.95 
Dim 2: 60.00 
Dim 1: 11160.71 
Dim 2: 4863.81 
Dim 1: 5.45 




















Dim 1: 11.00 
Dim 2: 60.00 
Dim 1: 8802.82 
Dim 2: 4863.81 
Dim 1: 4.30 






H ─ 32 32768 ─ Dim 1: 15.03 Dim 1: 12019.23 Dim 1: 0.37 1 
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Table 2.9 NMR experimental parameters for the FH and PspC constructs 
$ From Ilias Matis 
# 
From Dr C. Q. Schmidt 
& 
free induction decay (FID) 
1 Double-pulsed field gradient spin-echo 
2 Watergate 
3 Dephasing of water magnetization by coherence selection pulsed field gradients 
 
2.3.4 NMR structural studies   
  
The construct FH-10-11 was the most experimentally tractable and was used 
for structural determination by NMR. 2-D and 3-D double and triple-resonance NMR 
experiments were recorded on the double-labeled sample as a basis for structure 





labeled samples were prepared (using the same methods). The NMR experiments 
required for the structural studies (Tables 2.9 and 2.10) were therefore recorded in 
three sets, each on a recently expressed and purified sample.  
In addition to FH-10-11, NMR was also used to solve the solution structure 
of FH-11-12. This construct was produced by Ilias Matis (in this group) who also 
collected the NMR data and carried out the majority of the assignments as part of his 
MSc project. However due to lack of time on that project, the remaining steps needed 
to produce the 3-D structure were undertaken by the author. Specifically, corrections 
were made where necessary in the assignments and cross peaks in the NOESY 
spectra were re-picked and re-assigned. 
The information provided hereafter regarding the assignment strategy applies 
to FH-10-11 while the same approaches were used - as required - for the corrections 
of the assignments and the picking of the NOESY spectra in the case of FH-11-12. 
For FH-10-11 and FH-11-12, CYANA and CNS-based structure calculations were 
performed. 
   
2.3.4.1 Sample preparation for FH-10-11 
 
The construct FH-10-11 was produced from P. pastoris and purified as 
described above (and reported in Chapter 3). The samples were concentrated in 
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centrifugal concentrators and were buffer-exchanged into 20 mM potassium 
phosphate buffer, pH 6.6. Aliquots of D2O and NaN3 solutions were added to final 
concentrations of 5-10 % (v/v) and 0.01 % (w/v) respectively. For the 
13
C D2O 
NOESY and the slowly exchanging amide experiments, the samples were freeze-
dried overnight and subsequently dissolved in 99.6 % D2O. 
 
2.3.4.2 Collection of the NMR data 
 
Tables 2.10 (for 2-D spectra) and 2.11 (for 3-D spectra), list the experiments 





































Table 2.10 Summary of the 2D acquired spectra utilized for the structural studies. 
2 Watergate 
3 Dephasing of water magnetization by coherence selection pulsed field gradients 
4 Watergate using a composite off-resonance pulse 























N 4 512 
Dim 1: 11.00 
Dim 2: 28.00 
Dim 1: 8802.82 
Dim 2: 2270.15 
Dim 1: 4.43 










C 12 1024 
Dim 1: 11.00 
Dim 2: 34.21 
Dim 1: 8802.82 
Dim 2: 6882.31 
Dim 1: 4.30 
Dim 2: 6.72 
3 
(HB)CB(CGCD)HD 




Carom 256 256 
Dim 1: 11.00 
Dim 2: 40.02 
Dim 1: 8802.82 
Dim 2: 8051.53 
Dim 1: 4.30 
Dim 2: 31.45 
4 
(HB)CB(CGCDCE)HE 




Carom 256 256 
Dim 1: 11.00 
Dim 2: 40.02 
Dim 1: 8802.82 
Dim 2: 8051.53 
Dim 1: 4.30 











Carom 16 1024 
Dim 1: 11.00 
Dim 2: 40.02 
Dim 1: 8802.82 
Dim 2: 8051.30 
Dim 1: 8.60 















Size of FID 
(Dim 2) 





















4 256 128 
Dim 1: 11.00 
Dim 2: 6.67 
Dim 3: 27.99 
Dim 1: 8802.82 
Dim 2: 5336.18 
Dim 3: 2269.63 
Dim 1: 4.30 
Dim 2: 20.84 










N 16 512 1024 
Dim 1: 11.00 
Dim 2: 63.00 
Dim 3: 27.99 
Dim 1: 8802.82 
Dim 2: 12674.27 
Dim 3: 2269.63 
Dim 1: 5.26 
Dim 2: 8.42 










N 4 512 256 
Dim 1: 11.00 
Dim 2: 63.00 
Dim 3: 27.99 
Dim 1: 8802.82 
Dim 2: 12674.27 
Dim 3: 2269.63 
Dim 1: 0.33 
Dim 2: 8.42 









N 4 512 256 
Dim 1: 11.00 
Dim 2: 10.50 
Dim 3: 27.99 
Dim 1: 8802.82 
Dim 2: 2112.38 
Dim 3: 2269.63 
Dim 1: 5.26 
Dim 2: 8.42 










N 16 512 256 
Dim 1: 11.00 
Dim 2: 10.50 
Dim 3: 27.99 
Dim 1: 8802.82 
Dim 2: 2112.38 
Dim 3: 2269.63 
Dim 1: 5.26 
Dim 2: 8.42 










C 16 128 256 
Dim 1: 11.02 
Dim 2: 6.67 
Dim 3: 34.20 
Dim 1: 6613.76 
Dim 2: 4000 
Dim 3: 5159.96 
Dim 1: 5.26 
Dim 2: 33.67 












ain Dim 2: 6.67 
Dim 3: 28.00 
Dim 2: 4001.60 
Dim 3: 1702.42 
Dim 2: 33.67 










N 8 128 256 
Dim 1: 11.02 
Dim 2: 63.01 
Dim 3: 28.00 
Dim 1: 6613.76 
Dim 2: 9505.70 
Dim 3: 1702.42 
Dim 1: 5.26 
Dim 2: 33.67 











C 16 512 512 
Dim 1: 22.01 
Dim 2: 10.50 
Dim 3: 34.21 
Dim 1: 17605.63 
Dim 2: 8403.36 
Dim 3: 6882.31 
Dim 1: 4.10 
Dim 2: 8.42 











N 16 512 256 
Dim 1: 11.00 
Dim 2: 10.54 
Dim 3: 28.00 
Dim 1: 8802.82 
Dim 2: 8403.36 
Dim 3: 2270.15 
Dim 1: 4.10 
Dim 2: 8.42 
Dim 3: 8.55 
2 
 
Table 2.11 Summary of the 3D acquired spectra utilized for the structural studies.  
2 Watergate 
3 Dephasing of water magnetization by coherence selection pulsed field gradients 
5 Purging gradients plus storing the water magnetization along the z axis just before the acquisition
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2.3.4.3 Overview of resonance assignment 
 










N-labeled protein is 
achieved on the basis of a suite of 3-D NMR experiments. Several 3-D experiments 
use the 2-D 
15
N-HSQC as a reference or root spectrum. This experiment correlates 
the amide nitrogen of each amino acid residue with its attached proton, hence 
yielding a two-dimensional spectrum with each cross-peak occurring at the 
intersection of an amide nitrogen chemical shift and the chemical shift of its attached 
proton (Fig. 2.1). The 3-D experiments exploit their third dimensions to allow these 
correlations to be extended, through-bond, to other atoms or indeed to a group of 
atoms that corresponds to a spin system. Hence by combining sets of three-
dimensional experiments, overlapping strips (each corresponding to correlations with 
a particular amide group) can allow for a string of spin systems to be arranged in 
order, which will then be matched to a sequence of residues in the polypeptide chain, 
as described in more detail below. Following this, TOCSY experiments are useful for 
extending the assignment to the sidechain of every amino acid residue. For the 
HCCH-TOCSY, which was the experiment solely used for this purpose, the 
reference experiment is the 
13
C-HSQC, which correlates each carbon with its 
attached aliphatic proton/protons both in the backbone and the sidechain. A special 
set of NMR experiments is used to assign aromatic atoms since these lie within their 









C-NOESY respectively.  Peaks in these 
experiments arise based on the nuclear Overhauser effect (NOE), and are used to 









N-HSQC spectrum.  Each cross-peak (grey dot) represents an 
amide proton. 
 








The backbone assignment was carried out by using two complementary pairs 
of experiments: CBCANH and CBCA(CO)NH, and HNCO and HN(CA)CO. Both 
pairs correlate the i-1 residue with the i residue (Fig. 2.2). As a result, the atomic 
assignment was made for the Cα, Cβ and the CO resonances as well as the amide 
nitrogen and proton. The method by which the i-1 residue is correlated with the i 
residue for the two pairs of experiments is explained below. 
 
 
Figure 2.2 Nomenclature referring to sequential amino acid residues. 
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In the case of the CBCANH-CBCA(CO)NH pair, in the first experiment, 
magnetization is transferred to 
15




Cα/βi-1, hence for each 
NHi group there are Cα and Cβ peaks from both residue i and i-1. The stronger ones 
usually correspond to the Cα and Cβ of the i residue, whereas the weaker generally 





Cα/βi-1 only, resulting in a strip where only the Cα and Cβ of the 
preceding residue are visible. Comparisons of the positions of peaks in overlaid strips 
with those in other overlaid strips thus allowed sequential assignments to be made 
quite rapidly (Fig. 2.4). 
With respect to the HNCO and HN(CA)CO pair, in an analogous manner as 
described above, sequential links can be set for the CO of the i-1 and the i residues 
because in the first case only the CO of the preceding residue is visible in a strip and 
in the second case two CO peaks are visible, of the i and the i-1 residue. This pair of 
experiments exhibits higher resolution and less overlapped spectra thus allowing 
potential ambiguities associated with the CBCANH and CBCA(CO)NH experiments 
to be resolved. 
 Figure 2.3 shows a sequential “walk” between Pro621 and Glu625 of FH-10-
11. Each strip contains information about which carbons are in residuei and which 
are in residuei-1 as found by overlapping peaks arising in the two spectra for the pair 




Figure 2.3 Strips that are placed in sequential order and correspond to Pro621-Glu625 within 
the sequence of FH-10-11. Peaks that are light pink (positive phase) or light blue (negative 
phase) correspond to the CBCANH experiment, whereas peaks that are blue (positive phase) or 
green (negative phase) arise from the CBCA(CO)NH experiment. Horizontal lines show the 
sequential backbone-connectivities between the two complementary set of experiments. 









Figure 2.4 Schematic representation of magnetization transfer and the corresponding 
15
N-
HSQC (A), CBCANH (C) and CBCA(CO)NH (B)  3D experiments. The magnetization transfer 








N shifts-cross peaks in the 
15
N-HSQC.   
*Figure is reproduced from Ph.D. thesis: “The structure of an active N-terminal fragment 
of human complement factor H” by Hocking, HG, 2008, University of Edinburgh. 
 
2.3.4.5 Assignment of sidechain resonances 
 





C assignment. The 
15
N-TOCSY correlates aliphatic sidechain 
proton resonances from residue i, with root resonances HN and NH of the same 
residue. The H(C)(CO)NH-TOCSY and (H)C(CO)NH-TOCSY experiments 
correlate aliphatic proton and carbon shifts of the residue i-1 residue with the root 
resonances of residue i. Due to insufficient data obtained in these three experiments 
the majority of the sidechain assignment was carried out using the HCCH-TOCSY 
experiment. This experiment correlates the aliphatic proton shifts with the root 
resonances of the same residue. The experiments CBCANH, CBCA(CO)NH and 
HBHA(CO)NH were used in order to find the Cβ/Ηα and Cβ/Hβ peaks in the 
13
C-
HSQC as described above. These peaks were then used to navigate in the HCCH-
TOCSY spectra, ending up at the root resonance of that peak. There were occasions 
when peaks could not be found in the 
13
C-HSQC using the above method. A solution 
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to this was the following: From a candidate peak on a strip from the HCCH-TOCSY, 
navigation back to the 
13
C-HSQC ensued and this was overlaid with the HCCH-




H chemical shift 
of that peak in the 
13
C-HSQC spectrum (Fig. 2.5). 
 
 
Figure 2.5 Schematic representation of the magnetization transfer (indicated by arrows) and the 
corresponding 3D spectra used for the assignment of aliphatic sidechain residues. Correlations 
are shown between the 
13
C-HSQC (A) and the HCCH-TOCSY (B). 
*Figure is reproduced from Ph.D. thesis: “The structure of an active N-terminal fragment 
of human complement factor H” by Hocking, HG, 2008, University of Edinburgh. 
 
2.3.4.6 Assignment of resonances of aromatic residues: tryptophan, tyrosine, 
phenylalanine and histidine 
 
The protons of tryptophan, tyrosine, phenylalanine and histidine residues are 
subject to the aromatic ring-current effects and have higher chemical shifts, typically 
between 6-8 ppm, thus making them distinguishable from most other (non-amide) 
protons. In addition, protons from the aromatic rings of the corresponding residues 
occupy separate spin systems (from the remainder of the residue). Three specialized 
2-D experiments were used for the aromatic chemical shift assignment. First, an 
aromatic 
13
C-HSQC spectrum was collected which has Cδ and Cε chemical shifts in 
one dimension and the corresponding Hδ and Hε in the second dimension. The other 
two experiments, (HB)CB(CGCD)HD and (HB)CB(CGCDCE)HE correlate the Cβ 
chemical shifts with shifts from the protons of the rings: Hδ and Hε. In cases where 




used to identify missing shifts. In most cases the aromatic sidechains are buried 
within the interior of the protein thus giving clear NOESY strips that can provide 
useful information about the chemical shifts of the corresponding aromatic protons. 
 
2.3.4.7 Prediction of proline cis-trans peptide bond conformation 
 
The construct FH-10-11 contains twelve proline residues while FH-11-12 
contains ten. In general, in proteins the trans- conformation of the peptide bond is 
energetically more favorable than the the cis- conformation, due to steric repulsion 
that arises between the peptide bond and the sidechain. However, due to the cyclic 
nature of proline sidechains there is an appreciable incidence of cis-conformations of 





Cγ] has been proposed as an indicator of cis- and trans- 
conformation (124). The statistical values of this chemical shift difference have been 
shown to be 4.51 ppm ± 1.17 ppm and 9.64 ppm ± 1.27 ppm, for trans- and cis- 
conformations respectively (125). The tables below show the correspondent results 
for FH-10-11 and FH-11-12 (Tables 2.11 and 2.12). The resultant conformations 
were cross-verified by using the 
13
C-NOESY spectra. In cis- isomers the Hα of a Pro 
residue will have a strong cross-peak with the Hα of the preceding residue while in a 
trans- isomer the Hδ of a Pro residue will have a strong cross-peak with the Hα of 



























572 32.190 27.177 5.013 trans 
580 31.672 27.202 4.470 trans 
599 31.710 27.898 3.812 trans 
606 32.297 27.732 4.565 trans 
618 33.532 25.322 8.210 cis 
621 33.030 27.016 6.014 trans 
632 30.838 27.985 2.853 trans 
633 30.060 26.954 3.106 trans 
634 32.390 27.219 5.171 trans 
661 31.717 27.879 3.838 trans 
668 32.326 27.604 4.722 trans 
682 33.033 26.188 6.845 trans 
 

























632 30.755 28.179 2.576 trans 
633 29.960 27.024 2.936 trans 
634 32.586 27.127 5.469 trans 
661 31.956 28.350 3.606 trans 
668 32.596 27.295 5.301 trans 
682 33.235 26.013 7.222 trans 
695 32.419 27.325 5.094 trans 
707 30.621 26.288 4.333 trans 
708 34.857 24.772 10.085 cis 
742 32.631 26.150 6.481 trans 
 
Table 2.13 Summary of chemical shifts and prediction of proline peptide bond conformation for 
FH-11-12.  
 
2.3.4.8 Picking and assignment of NOE cross-peaks 
 
It should be noted here that in the case of FH-10-11 there was insufficient 
signal-to-noise in the 
13
C-NOESY spectrum recorded in the standard (10% v/v D2O) 
NMR buffer. Hence, the 
13
C-NOESY resulting from a more concentrated protein 
sample in 99.6% v/v D2O was exclusively used for picking and assignment. 
 The reference spectrum for the 
15
N-NOESY was, again, the 
15
N-HSQC. 
From each peak in the latter, navigation in the 
15
N-NOESY yielded a strip for each 
root resonance (amide). All the non-noise peaks in that strip were picked (except 
those corresponding to water) and assigned to that root resonance, by overlaying 
planes of the 
15
N-NOESY with its reference 
15
N-HSQC. This results in assignment in 
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two dimensions. In a similar manner the picking and assignment for the 
13
C-NOESY 
was done, only in this case the reference spectrum was the 
13
C-HSQC and the 





planes with the HCCH-TOCSY. Figure 2.6 shows an example of how a NOE cross- 




Figure 2.6 Representation of two symmetry-related amide proton cross-peaks in two 
hypothetical strips of the NOESY spectrum. Proton A experiences “through space” dipolar 
coupling with proton B resulting in a NOE cross-peak at the proton frequency of B. Proton B 
also experiences a corresponding effect resulting in a NOE cross-peak at the proton frequency 
of A. The two symmetry related cross-peaks are indicated by an arrow.  
 
For the assignment of the second dimension proton shifts, when two 
symmetry-related NOE cross peaks could be identified unambiguously, the 
assignment was regarded as firm. In case of lack of clarity regarding assignment, the 
peaks were left unassigned. Peak lists for the two NOESY experiments and chemical 
shift tables for all the atoms were exported, alongside the amino acid sequence, from 
the appropriate CCPNMR ANALYSIS project and used for the structure calculations 
in CYANA (126). This required a set of pre-written scripts to be correctly amended 









The software CYANA (126) was employed for the initial structure 
calculations for FH-10-11 and FH-11-12. CYANA combines the automated 
assignment of NOESY spectra with subsequent structure calculations performed in 
torsion-angle space. It has been shown however that refinement of protein structures 
in a thin layer of water solvent significantly improves quality indices, important for 
the overall assessment of the final structures. Due to the absence of that feature in 
CYANA, the software CNS was employed for the intermediate and final structure 
calculations. Structure calculations in CNS are performed in cartesian space. The 
water-refined structures from CNS yielded the final NMR ensembles for FH-10-11 
and FH-11-12. Figure 2.7 schematically illustrates the basic steps followed for the 




Figure 2.7 Flow-chart of the most important steps of structure calculations in CYANA and 
subsequently in CNS in order to obtain the NMR ensembles for FH-10-11 and FH-11-12. 
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2.3.4.9.2 Structure calculations in CYANA 
 
For the initial structure calculations and automated NOE assignment of the 
NOESY spectra the structure-calculation software CYANA version 2.1 was used for 
FH-10-11 and FH-11-12 (126). The CYANA 2.1 software, is based on DYANA 
(127) and embeds the CANDID algorithm (for Combined automated NOE 
assignment and structure determination) for automated NOESY assignment (128). 
This ambiguous assignment is then followed by structure calculations using torsion-
angle dynamics.  
 
2.3.4.9.2.1 Automated NOESY assignment 
 
 Within CYANA (126) seven cycles of NOE cross peak assignment that 
proceeded in an iterative approach resulted in the assignment of an initially partially 
assigned NOESY spectrum. The initial NOE assignments created were weighed with 
respect to several filtering criteria, such as self-consistency with the entire NOE 
network. Spurious cross-peaks were eliminated and a 3-D structure was calculated. 
The impact of incomplete and/or erroneous input data was effectively minimized by 
the presence of two “safeguard” features incorporated in the program: constraint 
combination and network anchoring. In constraint combination, distance constraints 
are generated with combined assignments from different, in general unrelated, cross 
peaks thus minimizing the potential occurrence of erroneous restraints originating 
from NOE artifacts; this is applied only in the two first cycles. Furthermore, the 
concept of ambiguous distance constraints that exist in CYANA is important for 
dealing with the preliminary chemical shift-based NOESY cross-peaks assignments. 
Briefly, every NOESY peak is handled as a superposition of the signals from each of 
its multiple assignments. The resultant summed distance between a pair of atoms is 
always shorter than any of the individual distances used in the sum. Therefore when 
the correct assignment exists an ambiguous constraint is not misinterpreted when 
incorrect assignment possibilities may also be present. This property of ambiguous 
distance constraints further implies that (with constraint combination) the combined 
constraints will have lower probabilities of being incorrect. In network anchoring, 
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each preliminary chemical shift-based assignment is rated on the basis of how well 
the corresponding NOE-connectivity fits in a consistent set of neighboring NOE-
based networks. This assessment of the self-consistency of the NOE assignments is 
independent of the 3-D structure that is generated after every cycle. The network 
anchoring filter can detect false restraints that could potentially result in artificial 
protein constraints.  
 
2.3.4.9.2.2 Structure calculations 
 
 The structure calculations are performed in such a way that the potential 
energy target function is minimized whilst satisfying the experimental distance 
restraints. A conformation that satisfies the restraints more closely than another one 
will lead to a lower target function. The energy minimization function uses simulated 
annealing in torsion-angle space, ultimately resulting in a global energy minimum for 
the polypeptide. In torsion angle dynamics empirical restraints such as bond lengths, 
bond angles and chiralities, are maintained at their optimal value. In all cycles except 
for cycle seven, swapping of pairs of diastereoscopic atoms was performed during 
the simulated annealing for the unassigned stereospecific atom pairs (e.g. methylene 
groups).  
After the completion of the seven-cycle NOE assignment and structure 
calculations, several quality-control criteria are provided that allow assessment of the 
resulting structures and will be presented in the NMR chapter. Figure 2.8 illustrates 
the seven-cycle automated NOE cross-peak assignment and 3D structure calculation 




Figure 2.8 Automated NOE cross-peak assignment and 3D structure calculation performed by CYANA (adapted from (126)). 
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2.3.4.9.3 Structure calculations in CNS 
 
The calculations performed using CYANA resulted in the assignment of the 
NOESY spectra, the generation of distance restraints and the calculation of 3-D 
NMR-derived structures. Several validation programs were routinely employed to 
assess quality features of the resultant NMR ensembles. Those features include 
Ramachandran plot statistics and packing quality. To avoid unsatisfactory quality 
results, arising when electrostatic and Van der Waals interactions are treated 
unrealistically, refinement of 3-D protein structures in explicit solvent is 
recommended as this has been shown to significantly improve structural quality 
criteria (129). This refinement approach was not an option in CYANA; however it 
has been implemented in the CNS structure calculation software. Therefore CNS 
version 1.2 (130) was used in this study for the final structure calculations. Due to its 
lack of automated NOE assignment capability (as implemented in the Edinburgh 
Biomolecular NMR Unit) however, it was not used for the initial calculations. The 
restraint output file generated from the CYANA calculations was therefore imported 
(through FormatConverter, a facility of ANALYSIS) into ANALYSIS, and 
converted into CNS format and then exported for implementation in the CNS 
calculations. 
The structure calculations in CNS are performed in cartesian space during 
which a global minimum region is searched for the total energy function Ftot. Ftot 
consists of the following energy terms: Ftot=Fcovalent + Frepel + FNOE . In this equation 
Ftot represents the effective potential energy, Fcovalent maintains correct bond lengths, 
angles, planarities, chiralities, Frepel describes the non-bonded interactions and is a 
repulsive function that prevents overly close contacts between atoms (131), (132) 
and FNOE refer to the experimental NOE restraints. The basic features of the protocols 
used in the CNS calculations comprised a generation of a molecular topology file 
which essentially included information on the primary structure of the proteins, a 
template/random starting structure, prochiral swapping (swapping of methylene, 
methyl and amide protons belonging to sidechains so as to prevent energy 
minimization from getting trapped in local energy minima) and finally refinement.  
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In every round of CNS calculations, 100 structures were calculated in total 
for FH-10-11 and FH-11-12. These structures were subsequently ranked according to 
overall and NOE energies. The converged structures were checked for violated NOE 
restraints (NOE violations > 0.5 Å). When a satisfactory output was accomplished  in 
which no violations occurred > 0.5 Å - in this case for the 20 lowest energy 
structures (by using a script that as an output indicates violations  > 0.5 Å that have 
arisen between specific sets of restraints within the corresponding  member/s of the 
20 conformers), and a substantial number of structures showed convergence (around 
20 structures, by plotting the overall and NOE-derived energy against all 100 
structure numbers within “gnuplot”), the selected structures were subjected to water 
refinement within CNS. For that purpose the RECOORD protocols 
(http://www.ebi.ac.uk/msd/recoord) were used. During the calculations, a 7 Å thin 
layer water shell was created around the proteins while the refinement took place in a 
full molecular dynamics force field including electrostatic and Lennard-Jones non-




Two relaxation pathways are involved in the return of the spins to the 
equilibrium state following an NMR excitation pulse: the spin-lattice (or 
longitudinal) and spin-spin (or transverse). Insight into the backbone dynamics of a 
protein can be obtained by measuring time constants: T1 for spin-lattice and T2 for 
spin-spin, since relaxation depends on the molecular motion. In this study, in 




N-NOE enhancements were 
measured for FH-10-11 and FH-11-12 (using a 600 MHz spectrometer for both).  
For T1, a series of interleaved 
15
N-HSQC, one for each value of the relaxation delay 
time τ was measured. These τ values were used to obtain the T1 values and for FH-
10-11 were 51.2 ms, 301.2 ms, 501.2 ms, 601.2 ms, 751.2 ms, 851.2 ms and  
901.2 ms while for FH-11-12 51.2 ms, 301.2 ms, 501.2 ms, 601.2 ms, 701.2 ms, 
801.2 ms and 901.2 ms. All amide peaks from each 
15
N-HSQC spectrum were picked 
in ANALYSIS while peaks with very weak signals or peaks located in overlapped 
regions were excluded. The Rates Analysis function in ANALYSIS was used to 
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determine the T1 values by an exponential fit of the cross-peak height as a function of 
relaxation delay times (133).  
As for T1, for T2 a series of interleaved 
15
N-HSQC experiments were recorded 
for each τ value. The τ values used for FH-10-11 were 16.96 ms, 33.92 ms, 67.84 ms, 
101.76 ms, 118.72 ms, 135.68 ms and 152.64 ms while for FH-11-12 16.96 ms, 
33.92 ms, 67.84 ms, 84.8 ms, 101.76 ms, 118.82 ms and 135.68 ms. A similar 





N-NOE experiment is a more sensitive measure of 
the dynamics than the T1 and T2 relaxation rates measurements and probes mobility 





 saturation conditions followed by an experiment under steady-state 




N-NOE build up occurs during the 
steady-state saturation. Spectra were once again processed in AZARA and assigned 
in ANALYSIS. The function Data Analysis/ Heteronuclear NOE was used in this 
case. The more mobile  the amide bond  (on the ns scale), the lower the cross-peak 
intensity, as spins that exhibit fast motion relative to that of the overall molecule will 
show a decreased NOE intensity compared to the reference spectrum. 
 
2.3.4.11 Programs for visualization, acquisition of structural characteristics 
and assessment of the NMR structures 
 
The program MOLMOL (136) 2k.2 was used for initial calculation of the 
RMSD values for the structures of FH-10-11 and FH-11-12. The molecular 
visualization system PyMol (137) was used to visualize coordinate files (in PDB 
format) and to generate molecular structure images for this thesis. Secondary 
structural elements were calculated using STRIDE (138). Electrostatic analyses and 
the corresponding molecular structure images were generated using GRASP (139). 
Lipophilic and hydrophilic representations (and images) were generated using 
MOLCAD (140) module of SYBYL v6.9. The solvent-accessible surface area and 
the buried surface area at the intermodular junctions were calculated using the server 
GETAREA (141) as well as VADAR (142). Comparisons of the closest-to-mean 
CCP module structures of FH-10, 11 and 12 against all CCPs with known structures 
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within the complement system were performed using the structural alignment 
program Combinatorial Extension (143). Categorization of the CCP modules 10, 11 
and 12 to a specific sequence cluster was determined according to Soares et al. (144). 
Intermodular angles for the ensembles of the NMR structures were determined as 
previously described (44), (145). Dr D. Soares performed the following analyses 
(and provided the corresponding images): Inter-modular angles, VADAR, GRASP, 
MOLCAD, overlay with other CCPs. Assessment of the final ensembles for FH-10-
11 and FH-11-12 was achieved by using PROCHECK (146).  
 
2.4 SAXS data collection and analysis 
 
Synchrotron radiation X-ray scattering data were collected on the X33 
beamline of the EMBL (DESY, Hamburg) by Dr H. D. T. Mertens with the 
assistance of the author, using a 1M PILATUS pixel detector (Dectris, Switzerland) 
and eight frames of 15-s exposure time.  Samples were analysed at 20 °C, using 
protein concentrations (for FH-10-11, FH-11-12 and FH-10-12) of 0.3 – 10.7 mg/ml 
in PBS buffer. The sample-to-detector distance was 2.7 m covering a range of 
momentum transfer 0.08 ≤ s ≥ 6.0 nm
-1 
(where s=4πsin(θ)/λ with 2θ being the 
scattering angle and λ=0.15 nm being the wavelength). Dr H. D. T. Mertens 
performed the processing and analysis of the data (fit of the NMR structures of FH 
fragments to the SAXS data, analysis of flexibility, ab initio shape determination and 
molecular modelling). A purified sample of FH-10-12 was provided by Dr C. Q. 
Schmidt. 
 
2.5 Studying the interaction between PspC and FH 
 
2.5.1 Overview  
 
The PspC-derived fragments (PspCN and PspCNR1) were produced in E. coli 
by recombinant means as described in Section 2.1.16. The sequences for both PspCN 
and PspCNR1 are based on S. pneumoniae strain D39, serotype 2. FH and C3b were 
purchased, as plasma-purified preparations, from Complement Technology, Texas. A 
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series of purified FH fragments were produced from recombinant strains of P. 
pastoris as described in Section 2.1.15.  Purified samples of FH-6-8Y and FH-19-20 




Figure 2.9 Summary of proteins employed in current study of interactions between (fragments 
of): PspC, FH and C3. Representations of PspC in which the N-terminal region, the R1 and R2 
repeats, the Proline-rich region (P) and the Choline-binding domain (CBD) are highlighted and 
sequence numbers are shown. (A) The fragments of the N-terminal region, designated PspCN, 
(B) The fragments designated PspCNR1.  
 
Surface plasmon resonance (SPR) was carried out using a Biacore T200 
sensitivity-enhanced instrument (GE Healthcare). For the first tranche of 
measurements – regarded as a preliminary study - His-tagged PspCN-GSGC was 
used. This construct encompassed a C-terminal non-native extension, GSGC. For the 
second tranche a His-tagged PspCN construct was used in which the GSGC sequence 
is absent. For the third tranche – which was regarded as providing the most definitive 
data - versions of both PspCN and PspCNR1 were used. These either contained only 
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native sequence or were produced as fusions with SUMO. These three tranches of 
experiments were carried out using the buffers provided by GE Healthcare. These, 
which were provided as 10x concentrated stocks and subsequently diluted to 1x 
solutions prior to use, were either PBS (containing 0.1 M phosphate buffer with  
27 mM KCl and 1.37 M NaCl which when diluted yields a pH 7.4) or HBS-P
+
 
(containing 0.1 M HEPES, 1.5 M NaCl and 0.5 % surfactant P20 which also yields 
pH 7.4 when diluted). All samples were filtered prior to use (Ultrafree
 
- MC, 
centrifugal filter devices, Millipore). Data were processed using BIACORE T200 
evaluation software version 1.1. 
An NTA chip (i.e. with a matrix consisting of carboxymethylated dextran 
pre-immobilized with nitrilotriacetic acid (NTA) (Series S Sensor chip NTA, GE 
Healthcare) was used. For conditioning of the chip, prior to immobilization of the 
His-tagged PspC constructs and commencement of the experiments, the following 
procedure was performed: first 50 mM NaOH was injected repeatedly to remove any 
non-bonded dextran until a relatively stable baseline was observed which was then 
followed by 350 mM EDTA in 1 M NaCl pH ~8 to prevent any Ni
2+
-dependent 
precipitation event on the chip. This was followed by between five and ten injections 
with 500 μM NiCl2 (for a healthy NTA chip and saturated capture of Ni
2+
 typically 
40-60 Response Units, (RU), are expected), followed by the His-tagged protein  
(PspCN-GSGC, PspCN, SUMO-PspCN, SUMO-PspCNR1 or SUMO) followed by 
350 mM EDTA in 1 M NaCl in order to obtain a more stable surface. 
The C1 chip was also used (Series S carboxymethylated matrix-free C1 
sensor chips, GE Healthcare). Sensor surfaces were prepared by immobilizing human 
C3b, C3c and C3d in three of the four flow cells using standard amine coupling. 
Flow cell 1 served as the reference and was prepared by performing a control 
coupling reaction, i.e. one in the absence of any proteins. 
 
2.5.2 First tranche 
 
For the first tranche of experiments, the construct His-tag PspCN-GSGC was 
immobilized on the NTA chip. Once the conditioning was completed and a stable 




 - typically ~55 RUs were observed – meaning this was the 
maximum response obtained. PspCN was flowed at a concentration of 500 μM and  
~ 400 RUs were immobilized on flow cell 2 while flow cell 1 was the reference 
surface and was prepared in the absence of proteins. All experiments were performed 
at 25 
o
C using PBS, 0.01 % (v/v) surfactant P20, supplemented with 50 μM EDTA. 
0.5 μM solutions of FH constructs 10-11, 10-15, 8-15, 19-20 as well as full-length 
FH were injected in duplicates over all flow cells using a contact time of 90 s, a 
dissociation time of 900 s and a flow rate of 30 μl/min. After every injection the chip 
was stripped with 350 mM EDTA in 1 M NaCl (180 s injection at 30 μl/min) 
followed by 50 mM NaOH (30 s at 30 μl/min), followed by two consecutive 
injections of 0.5 % w/v SDS (30 s at 30 μl/min) and finally a 350 mM EDTA in  
1 M NaCl injection (30 s at 30 μl/min) before applying the next sample. 
 
2.5.3 Second tranche 
 
For the second set of experiments the construct His-tagged PspCN (i.e. no 
GSGC C-terminal extension) was used. Once again the His-tag was utilized for 
immobilization on a NTA sensor chip. Initially, the NTA chip was prepared as 
previously described and PspCN was immobilized at a level of 90 RUs on flow cell 2 
while flow cell 1 served as a no-protein reference. All experiments were performed 
at 25 
o
C using PBS (pH 7.4), 0.01 % (v/v) surfactant P20, supplemented with 50 μM 
EDTA. Solutions containing 0.5 μM full-length FH and FH constructs 6-8Y, 8-9, 10-
15, 8-15, and 19-20 were injected in duplicates over all flow cells using a contact 
time of 90 s, a dissociation time of 1200 s and a flow rate of 30 μl/min. After every 
injection the chip was stripped as previously described in section 2.4.2.  
 
2.5.4 Third tranche 
  
For this part of the experiments immobilization of SUMO-PspCN, SUMO-
PspCNR1 and SUMO alone (which was the control) – all of these proteins being 
His-tagged - was performed on an NTA sensor chip. The NTA chip was conditioned 
as previously described. It was then charged with Ni
2+
 (typically ~55 RUs were 
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observed). SUMO-PspCN (15 nM) was immobilized on flow cell 2, SUMO-
PspCNR1 (15 nM) and SUMO (50 nM) was immobilized on flow cell 3. Flow cell 1 
was the reference and was prepared in the absence of proteins. All experiments were 
performed at 25 
o
C using HEPES-buffered 150 mM Saline (pH 7.4), 0.05 % (v/v) 
surfactant P20, supplemented with 50 μM EDTA.  
 
2.5.4.1 Binding of the various complement proteins to the SUMO-ylated proteins 
 
FH constructs 6-8Y, 8-9, 10-15, 8-15, 19-20 as well as full-length FH and 
C3b were injected in duplicates over all flow cells using a contact time of 180 s, a 
dissociation time of 900 s and a flow rate of 50 μl/min. The concentrations used were 
50 and 500 nM for all proteins with the exception of full-length FH which was 
injected only at 50 nM. After every injection the chip was stripped as already 
described before applying the next sample.  
 
2.5.4.1.1 FH-8-9  
 
 FH-8-9 was injected at increasing concentrations; 0, 5, 10, 25, 50, 100, 250 
and 2x500 nM. The contact time was 240 s, the dissociation time 1200 s and the 
flow-rate 50 μl/min. After every injection the chip was stripped as already described 
before applying the next sample. Dissociation constants were determined by fitting 





The procedure was carried out in similarly way to that used for FH-8-9. The 
FH-8-15 concentrations used were 0, 0.25, 0.5, 1, 5, 10, 25, 50, 75, 2x 100 nM. The 
contact/ dissociation times, flow rates, regeneration strategies/conditions and 




2.5.4.1.3 Full length FH  
 
The procedure was carried out in a similar way as for FH-8-9 and FH-8-15. 
The concentrations used were 0, 0.25, 0.5, 1, 5, 10, 25, 50, and 2 x 75 nM. The 
contact/ dissociation times, flow rates, regeneration strategies/conditions and 
determination of dissociation constants were those already mentioned for FH-8-9 and 
FH-8-15. 
Another series of experiments was aimed at determining whether the PspCN: 
FH complex, or indeed PspCN on its own, interact directly with C3 or its fragments. 
For these experiments, the native-sequence PspC constructs, PspCN and PspCNR1, 
were prepared by proteolytic cleavage of the N-terminal SUMO tag. Steady-state 
affinity experiments were performed using C1 sensor chips. Full-length FH, PspCN, 
PspCNR1 and the complexes FH-PspCN and FH-PspCNR1 were injected at 
increasing concentrations, as described in detail below. All experiments were 
performed at 25 
o
C using HEPES-buffered 150 mM saline, 0.05 % (v/v) surfactant 
P20, supplemented with 50 μM EDTA.  
For full-length FH solutions of 0, 0.02, 0.05, 0.1, 0.2, 0.5, 1 and 2 μM were 
injected. A contact time of 120 s was used, followed by a dissociation time of 600 s 
using a flow rate of 30 μl/min, over all flow cells. The chip was regenerated between 
sample injections by two injections of 1 M NaCl for contact times of 30 s. 
Dissociation constants were calculated by fitting steady-state binding levels derived 
from the background-subtracted traces to a one-to-one binding model. 
PspCN and PspCNR1 were each injected separately at concentrations of 0, 0.022, 
0.055, 0.11, 0.22, 0.55, 1.1 and 2.1 μM. The procedure for measuring dissociation 
constants was carried out in an identical way to that employed for full-length FH. 
For the study of the interactions of the FH-PspCN and FH-PspCNR1 
complexes with C3b, C3c, C3d, a stoichiometry of 1:1.1 FH: PspC construct was 
used.  The small excess was intended to ensure that nearly all of FH was engaged in 
complex formation with PspCN or PspCNR1. The concentration series used 
consisted of the following mixtures of FH and PspC constructs: 0 μM and 0 μM,  
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0.02 μM and 0.022 μM, 0.05 μM and 0.055 μM, 0.1 μM and 0.011 μM, 0.2 and 0.22 
μM, 0.5 μM and 0.55 μM, 1 μM and 1.1 μM and 2 μM and 2.2 μM. An identical 
























































A full explanation of the rationale behind the selection of protein domains for 
analysis in the current study, and the choice of expression hosts, was provided in 
Chapters 1 and 2. Initial work entailed recombinant production, and assessment of 
suitability for structural studies, of the following proteins: FH-4-6, FH-10-11 and 
FH-14-15 (Fig. 3.1). Subsequently, 
15
N-labeled samples of FH-10-11 were prepared 
for further exploratory NMR studies along with 
15
N-labeled FH-13-14 and FH-10-15.  






C-labeling conditions in 
order to allow determination of 3-D solution structure by NMR. Finally, FH-8-9 and 
8-15 were produced for SPR-based binding studies. 
The fragments PspCN and PspCNR1 from S. pneumoniae were produced and 
purified at a later stage of the project because they had been reported to interact with 
the central region of FH (see Chapter 1). Thus these constructs were intended for 
binding studies. As summarized in figure 3.1, PspCN corresponds to the N-terminal 
domain of PspC, while PspCNR1 also includes the first of the R repeats, R1. Several 
versions of these proteins were produced as summarized in Table 3.5, (section 3.3): 
(i) His-tag PspCN-GSGC which encompassed a His N-terminal tag and a C-terminal 
non-native amino acid addition (i.e. GSGC); (ii) His-tag PspCN, which was the same 
as (i) but lacked the C-terminal amino acid addition; (iii) the SUMO-PspCN and (iv) 
the SUMO-PspCNR1 fragments, fusions with SUMO that were employed for the 
final set of definitive binding experiments.   
Pure and properly folded proteins were required for structural studies (using 
NMR and SAXS) and the binding analyses (using SPR) carried out in this project. 
Moreover, multiple-milligram quantities of isotopically labeled protein were needed 
for the NMR work. With this in mind, two expression hosts - one eukaryotic and the 
other prokaryotic – were exploited for the production of recombinant proteins.  
The methylotrophic yeast P. pastoris has, for many years, been the 
expression host of choice in this laboratory for production of proteins containing 
multiple CCP modules, each of which has two disulfide bonds. Thus it was the 
obvious choice for production, in the present study, of the FH fragments. As 
explained more fully in Chapter 2, this eukaryotic expression system provides the 
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option of fusing the target protein sequence to a cleavable secretory signal, thus 
ensuring secretion into the media from which it may be purified easily.  Yet like a 
prokaryote, P. pastoris requires only minimal nutritional media.  On the downside,  
P. pastoris has a tendency to attach high-mannose sugars to N-glycosylation sites.  
These are normally subjected to post-production enzymatic removal. For example 
incubation with EndoHf of a protein bearing high-mannose N-linked glycans results 
in near-complete deglycosylation, leaving a single GlcNAc at each N-glycosylated 
site.  
E. coli was the logical choice for production of the N-terminal region of the 
bacterial protein and virulence factor PspC that appears not to require any post-
translational modifications. The use of E. coli also allowed facile production of 
fusion proteins to ease subsequent purification. As outlined above, in the current 
work, SUMO and His tags were utilized as fusion partners. 
 
 
Figure 3.1 Summary of the FH and PspC segments employed in this study. (A) Representation 
of the FH molecule.  Constructs produced by the author are highlighted in color while those that 
were not are indicated with brackets. (B) Representation of the PspC molecule in which the 
domains chosen for this study are indicated.  
 
3.1 Production, purification and characterization of the FH constructs. 
 
The table below (Table 3.1) summarizes the FH constructs produced and/or 
purified in this study, their N-terminal non-native sequences, and the numerical 
position of each construct within the sequence of native FH. 
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Table 3.1 Summary of the FH constructs produced in this study. The numbering is based on the 
encoded protein sequence including the 18 amino acid residues of the natural signal sequence. 
Sequences are from UniprotKB/Swiss-Prot entry P08603.  
 
Table 3.2 (parts 1-3) present a summary of the protein production efforts 
undertaken in this study for the FH constructs, while Table 3.3 summarizes the 
expected and experimentally determined – where available - molecular weight for 
each of the constructs. 
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Table 3.2 Overview of the FH constructs produced in this study (part 1). 
 
 
Table 3.2 Overview of the FH constructs produced in this study (Part 2). 
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Table 3.2 Overview of the FH constructs produced in this study (Part 3). 
 
 
Table 3.3 Summary of the expected and experimentally determined molecular weights for the 
FH constructs produced in this study. 
# 
The expected molecular weight, in kDa, is calculated based on the amino acid sequence 
including the N-terminal AG cloning artifact. 
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$
 An additional 203 Da may be attributed to the single GlcNAc moiety presumed to be left 
attached at each of the utilized N-glycosylation sites following EndoHf treatment (FH-8-9 has 
one glycosylation site, FH-13-14 has two, FH-14-15 has three, FH-10-15 has five and FH-8-15 
has six). In addition there might be one or two EA (Glu-Ala) N-terminal dipeptide units (each 
corresponding to 200.2 Da) originating from the P. pastoris expression system present in all 
constructs. 
 
3.1.1 Construct FH-4-6 
 
3.1.1.1 Mini-scale expression   
        
Six colonies of this construct were tested in mini-scale expression trials (see 
section 2.1.15.5 for details and figure 3.2 for results).  
                                                 
 
 
Figure 3.2 Gradient SDS-PAGE of spin-concentrated (initial volume prior to concentration:  
500 μl) protein samples. Lanes 1, 2, 3, and 4 correspond to two colonies under reduced and non-
reduced conditions. An arrow indicates the band that probably corresponds to FH-4-6. 
Remaining lanes correspond to other samples, not relevant to this section. 
 
According to SDS-PAGE, all lanes contain bands at about the expected molecular 
weight for FH-4-6, ~21 kDa. Production levels were judged to be poor based on the 
strength of the stained bands but protein of an appropriate size was detectable in the 
SDS-PAGE of spin-concentrated samples. This outcome encouraged a scale-up to 
medium-scale production of protein in shaker flasks. 
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3.1.1.2 Medium-scale protein production 
 
The supernatant of a shaker-flask culture (volumes of media: ~500 ml BMG 
followed by 125 ml BMM) was harvested, PMSF and EDTA were added (unless 
stated otherwise these were added to the crude supernatants of all the FH constructs-
to inhibit proteolysis- presented hereafter) then subjected to cation-exchange 
chromatography at pH 4.5 (see Materials and Methods section 2.2.6). Protein-
containing fractions were concentrated, buffer-exchanged into PBS and loaded onto a 
size-exclusion chromatography column (Fig. 3.3).  
 
Figure 3.3 Purification of FH-4-6 using a HiLoad 16/60 Superdex 75 column. (A) 
Chromatogram of the size-exclusion chromatography. (B) Gradient SDS-PAGE gel of the 
fractions corresponding to the higher peak in (A). Lanes 2-5 were loaded with aliquots from the 
fractions indicated by a black bar on the chromatogram in (A).  R and NR indicate reducing 
and non-reducing conditions, respectively, and unless stated otherwise this applies to all the 
SDS-PAGE gels presented henceforth.  
 
The size-exclusion chromatography profile revealed several peaks. For the 
triple module (~ 22 kDa), elution is expected at ~70 ml, corresponding to the peak in 
this chromatogram marked with an asterisk. Very small quantities are present, 
however, as reflected in the low absorbance readings. Subsequent SDS-PAGE of the 
fractions indicated with a black bar (in Fig. 3.3) all contain a dominant band which 
appears at ~20 kDa, the appropriate size for the triple CCP module. It was, however, 
decided not to pursue this investigation further due to the low yield and given the 
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multiple samples required (with deuteration etc.)  for solving directly the structure of 
a triple module. 
 
3.1.2 Construct FH-8-9 
 
A glycerol stock of a P. pastoris KM71H clone expressing FH-8-9 was re-
streaked on a YPD agar plate containing 100 μg/ml zeocin and single colonies were 
chosen to inoculate BMG/BMM minimal media for medium-scale production in 
shaker flasks, as described in Materials and Methods (section 2.1.15.6) (the total 
volume of BMM for the induction was 750 ml). The purification procedure is 
described in Materials and Methods (section 2.2.6) and summarized in figure 3.4. 
The first step was anion-exchange chromatography using a Q-Sepharose column 
while the second step was size-exclusion chromatography on a HiLoad 16/60 
Superdex 75 column. Where a third purification step was required size-exclusion 
chromatography was performed again. This entire procedure was undertaken twice 
(i.e. in two batches) in order to obtain the desired amount of protein, and 
representative results are shown below for batch 2 only (while the data for batch 1 
may be found in the supplementary CD (section 1.1)).  
A point to note regarding the purification strategy was the serial re-loading (3 
in total) of the flow-through onto the Q-Sepharose column to recover adequate 
material. Most of the protein appeared to be in the flow-through of Q-Sepharose 
loadings 1 and 2 (see Fig. 3.4). Presumably this occurred due to overloading of the 
column (for example if many contaminants were present) therefore exceeding its 
capacity. Alternatively, the supernatant may have contained a significant amount of 
salt therefore the protein of interest did not successfully bind to the column (initially 
a three-fold dilution of the crude supernatant was performed, loading 1). Data will be 
presented only for the final loading (loading 3, see Fig. 3.4) on the Q-Sepharose 
column which corresponded to a final six-fold dilution at pH 7.0 of the initial 
supernatant. The results of loadings 1 and 2 were samples that did not contain pure 





Figure 3.4 Schematic summarizing the strategy followed for the purification of FH-8-9. 
 
3.1.2.1 Representative results for batch 2, loading 3 
 
The Q-Sepharose column was eluted over a linear gradient from 0 to 1 M 
NaCl (Fig. 3.5 A). Fractions from the elution, as well as samples from the crude 












Figure 3.5 Q-Sepharose for loading 3 of FH-8-9. (A) Chromatogram of the elution. (B) Gradient 
SDS-PAGE of the fractions from the elution of (A) (lanes 1-9).   
 
A single major peak appears in the chromatogram, while the profile of the 
SDS-PAGE gel showed what appeared to be single bands for FH-8-9 under both 
reducing and non-reducing conditions at 15 kDa. Fractions 35-40 were combined, 
EndoHf treated, and loaded on a size-exclusion chromatography column (Fig. 3.6 A). 
Fractions from this step were analyzed by SDS-PAGE (Fig. 3.6 B). 
 
Figure 3.6 Final purification of FH-8-9. (A) Chromatogram of the size-exclusion 
chromatography run (B) Gradient SDS-PAGE of the fractions from the elution in (A) which are 
indicated with a black bar (lanes 1-4).  The lanes between lane 4 and the molecular weight 
markers have been masked with a white box, as they correspond to samples not relevant to this 
section.  
 116 
The peak indicated with a black bar in figure 3.6, that eluted around 75 ml 
corresponds to the expected one for a double CCP module of ~ 15 kDa. Fractions 
from the middle of the peak (that appear as single bands at the expected size of  
15 kDa in SDS-PAGE in 3.6 B) shown in figure 3.6 A were combined to afford a 
final sample at a concentration of 80 μM in 0.5 ml. LC-MS was used for validation 
of the accurate mass (see Fig. 3.7). 
 
 
Figure 3.7 LC-MS spectrum of FH-8-9.  
 
The calculated mass for FH-8-9 of 13465.1 Da indicated on the spectrum 
corresponds to the mass of FH-8-9 which encompasses a GlcNAc attached to the 
glycosylation site. The measured mass of 13863.7, also indicated on the spectrum, 
revealed that the protein also carried two N-terminal EA amino acid repeats that 
remained from the expression system.  
In conclusion, despite major technical issues with the ion-exchange step that 
were not fully understood, work-up of this batch produced pure FH-8-9 according to 




3.1.3 Construct FH-10-11 
 
3.1.3.1 Mini-scale and medium-scale (shaker-flask) protein production 
 
This construct was produced with the objective of determining its 3-D 
solution structure using NMR. Following very promising mini-scale protein 
production trials (Fig. 3.8) shaker-flask expression (volumes of media: 500 ml BMG 
followed by 125 ml BMM for the induction) was performed. After harvesting, the 
supernatant was diluted four-fold with sodium acetate buffer pH 4.5, and the pH was 
adjusted to 4.5. It was then loaded onto a 5-ml self-poured SP-Sepharose 
chromatography column and was eluted by gravity using the same buffer as above 




Figure 3.8 Gradient SDS-PAGE of spin-concentrated samples (initial volume prior to 
concentration was 500 μl) of cell-depleted media from mini-scale protein production trials from 
two colonies of the FH-10-11 construct (lanes 1-4). The two lanes between the molecular weight 
markers and lane 3 have been masked with a white box, as these correspond to samples not 
relevant to this section. 
 
All samples showed bands running at the expected molecular weight for FH-10-11, 
~15 kDa (as expected the protein migrates more slowly under reducing conditions). 





Figure 3.9 Gradient SDS-PAGE of fractions from cation-exchange chromatography performed 
on the supernatant from a shaker-flask FH-10-11 protein production trial. Lanes 1-5 were each 
loaded with 15 microlitres from a fraction of 0.5 ml. The band at lane 6 indicates that only a 
small proportion of the protein was present in the flow-through. 
 
Fractions 1-4 from this elution (shown in figure 3.9) were pooled, buffer-
exchanged into PBS, concentrated to 0.5 ml, and loaded onto the size-exclusion 
column (see also Materials and Methods section 2.2.6). The profile of the elution was 
typical for a double-CCP module. The dominant peak, which presumably 
corresponds to FH-10-11, eluted at ~75 ml PBS (Fig. 3.10 A). Fractions 48-53 from 
this peak were analyzed by SDS-PAGE (Fig. 3.10 B). 
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Figure 3.10 Second step in purification of construct FH-10-11 from shaker-flask protein 
production trial, using a HiLoad 16/60 Superdex 75 column. (A) The higher peak on the 
chromatogram probably corresponds to FH-10-11 based on the expected elution volume of a  
15-kDa protein.  (B) Gradient SDS-PAGE of fractions from the size-exclusion chromatography 
shown in (A): the peak indicated with a black bar, (lanes 1-8).  
 
Fractions 50-53, which yielded single bands at the expected size of 15 kDa in 
SDS-PAGE (Fig. 3.10 B), were chosen, combined, concentrated to a volume of 0.5 
ml and then buffer-exchanged into 20 mM potassium phosphate buffer, pH 6.6. NaN3 
and D2O were added at 0.01 % w/v and 10 % v/v of the final volume (which was  
~ 450 μl), respectively. The final sample which had a concentration of ~80 μM FH-
10-11, was used to record a 1-D 
1







Figure 3.11 1D 
1




Figure 3.12 LC-MS spectrum for FH-10-11.  
 
The NMR spectrum showed well-dispersed peaks, indicative of proper 
folding of the protein (Fig. 3.11). From mass spectrometry it can be clearly seen that 
there are two main species (peaks at charge state 9+). The molecular weight of 
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14160.5 Da corresponds to one EA addition (~200.2 Da) (compared to theoretical, 
14160.2, assuming four disulfide bonds); whereas 13959.4 Da is close to the 
theoretical mass (13960.0, again assuming four disulfide bonds) expected if there are 








N-labeled samples were produced in total in order to ensure an 
adequate supply of protein for all the necessary NMR experiments. The protocol 
used for the fermentation is detailed in the Materials and Methods chapter, section 
2.1.15.7. Data will be presented only for batch 1 (while the corresponding data for 
batch 2 may be found in the supplementary CD section 1.2). 
 
3.1.3.2.1 Representative results for batch 1 
 
After fermentation the cell-depleted growth media (~900 ml) was filtered. It 
was then diluted five-fold with distilled water, and the pH was adjusted to 4.5 prior 
to cation-exchange chromatography (see also Materials and Methods section 2.2.6) 
on a SP-Sepharose column. The protein was eluted by using sodium acetate buffer, 
pH 4.5, with a gradient from 0 M NaCl to 1 M NaCl. A major peak started eluting at 
~45 % of the 1 M NaCl solution (~ 450 mM NaCl, Fig. 3.13 A). Corresponding 
fractions from the elution, as well as sample from the flow-through, were analyzed 
by SDS-PAGE (Fig. 3.13 B and C).  
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Figure 3.13 Chromatography of 
15
N-FH-10-11 on SP-Sepharose. (A) Chromatogram (B) 
Gradient SDS-PAGE of: the sample prior to loading on column (lanes 1 and 2), the flow-
through (lanes 3 and 4), and the collected fractions (lanes 5-10) corresponding to the peak 
indicated with a black bar shown in (A).  
 
The chromatogram showed two main peaks and fractions from the region 
indicated with a black bar were analyzed by SDS-PAGE. In fractions from the crude 
supernatant bands at ~15 kDa presumably correspond to FH-10-11. In the samples 
from the flow-through, it is evident that protein was still present. In the ten-fold 
concentrated aliquots from the indicated fractions bands at ~15 kDa are visible in all 
lanes corresponding to the expected size for FH-10-11.  
Surprisingly most of the protein was in the flow-through while the UV 
absorbance of the dominant peak eluting during the gradient was relatively low. 
Hence, the flow-through (~4800 ml) was further diluted by adding 1.5 L of distilled 
water and the pH was adjusted to 4.0. All subsequent cation-exchange 
chromatography steps on FH-10-11 were conducted at this lower pH using sodium 
acetate buffer. The diluted sample was reloaded onto the SP-Sepharose column and 
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eluted with a NaCl gradient as before. The fractions (Fig. 3.14 A) were analyzed by 




Figure 3.14 Reloading of the flow-through from first SP-Sepharose run. (A) Chromatogram. (B) 
The outcome of gradient SDS-PAGE on a sample from the flow-through (lanes 1 and 2) as well 
as  fractions from the region indicated with a black bar in (A) as denoted below the gel (lanes 3-
13) .  
 
Fractions from the elution (shown above) corresponding to the region on the 
chromatogram indicated with a black bar were analyzed by SDS-PAGE. No bands of 
FH-10-11 are visible for the samples corresponding to the flow-through of the 
elution. Fractions from the elution contain bands at the expected molecular weight 
for the target protein, ~15 kDa.  
Fractions 41-51 from this re-loaded SP-Sepharose run were combined, 
concentrated to a volume of 1 ml, buffer-exchanged into PBS (pH 7.6), filtered and 
applied to the size-exclusion chromatography column for a final polishing step (Fig. 
3.15 A). Fractions from the elution were analyzed by SDS-PAGE (Fig. 3.15 B). 
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Figure 3.15 Size-exclusion chromatography for the FH-10-11 samples from the re-run of the SP-
Sepharose step, using a HiLoad 16/60 Superdex 75 column. (A) Chromatogram. (B) Gradient 
SDS-PAGE of a sample before the gel-filtration (lanes 1 and 2) as well as fractions from the 
peak indicated with a black bar in (A) and as indicated below the gel (lanes 3-10). 
 
The SDS-PAGE indicated that small extra bands appearing, in non-reducing 
conditions, prior to loading on the gel-filtration column had been removed from 
fractions corresponding to the main peak in the chromatogram.  
Fractions 47-52 from the gel-filtration step were concentrated in spin-
concentrators to a volume of ~0.4 ml and buffer-exchanged into 20 mM potassium 






C-enriched expression in a fermentor 
 
Due to unanticipated degradation problems (evidenced by the state of the 
15
N-
labeled sample following the NMR experiments, data not shown) with the double-
labeled FH-10-11 sample the entire expression and purification procedure had to be 
performed three times in order to obtain sufficient material for the NMR experiments 
necessary for the structural studies. The protocol used for fermentations is detailed in 
the Materials and Methods (section 2.1.15.7). The purification procedure for all three 
batches of double-labeled samples was identical to that followed for the 
15
N-labeled 
sample. Representative results will be shown for batch 1 (data on batches 2 and 3 can 
be found in the supplementary CD sections 1.3 and 1.4).Batches 2 and 3 resulted in 
purified final samples at concentrations of 150 and 500 μM respectively (in volumes 
of ~ 450 μl). 
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3.1.3.3.1 Representative results for batch 1 
 
The first purification step was cation-exchange chromatography at pH 4.0, of 
the diluted cell-depleted growth media (volume: ~700 ml), using an SP-Sepharose 
column (Fig. 3.16 A). Fractions from the elution of the column were analyzed by 




Figure 3.16 Purification of the double-labeled FH-10-11 sample, batch 1, on SP-Sepharose (A) 
Chromatogram showing which fractions were pooled for SDS-PAGE (B) Gradient SDS-PAGE 
of: Lanes 1, 2 - sample before loading onto the column; Lanes 3, 4 – ten-fold concentrated 
sample taken from the flow-through of the column; lanes 5-11 - fractions 33-39 corresponding to 
peak 1 as indicated in (A). (C)  In this gel, lanes 1-5 are for fractions 41-44 corresponding to 
peak 2 as indicated in (A). Lanes 6-11 - fractions from the higher peak, peak 3 as shown in (A).    
 
The chromatogram contained at least three overlapped peaks. According to 
SDS-PAGE, fractions from peak 3 (Fig. 3.16 C) contained stronger bands, compared 
to those from other peaks, at the expected size for FH-10-11. Fractions 47-53 from 
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that peak (see Fig. 3.16 A) were concentrated in spin concentrators and buffer-
exchanged into PBS for size-exclusion chromatography (Fig. 3.17 A). The fractions 
from the elution of the size-exclusion column were analyzed by SDS-PAGE (Fig. 




Figure 3.17 Size-exclusion chromatography of fractions 47-53 from the SP-Sepharose run, using 
a HiLoad 16/60 Superdex 75 column. (A) Chromatogram. (B) Gradient SDS-PAGE. Lanes 1-8 
correspond to fractions 48-51 from Peak 2.  Lanes 7 and 8 correspond to fraction 31 from Peak 
1. 
 
Fractions from peak 2 in the chromatogram (Fig. 3.17) produced single strong 
bands of the expected size for FH-10-11 in SDS-PAGE (Fig. 3.17). Fractions 48-53 
from the centre of this peak were concentrated and buffer-exchanged three times into  
20 mM potassium phosphate, pH 6.6. This yielded a 400 μM sample in ~450 μl. 
 




This construct was produced in order to asses its suitability for NMR-based 
structural analysis. A glycerol stock of a P. pastoris KM71H clone expressing FH-
13-14 was re-streaked on a YPD agar plate containing 100 μg/ml zeocin and single 
colonies were used to inoculate BMG media. Unlabeled protein was produced in 
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shaker flask while 
15
N-enriched protein was produced in a fermentor. Identical 
purification procedures were followed in both cases: cation-exchange 
chromatography on a SP-Sepharose column (sodium acetate buffer, pH 5.0 and 
eluted with a gradient from 0 - 1 M NaCl) was followed by size-exclusion 
chromatography on a HiLoad Superdex 75 column.  
 
3.1.4.1 Shaker-flask production of unlabeled protein 
 
The cell-depleted growth medium (375 ml) was diluted six-fold and the pH 
was adjusted to 5.0. It was then applied to the pre-equilibrated SP-Sepharose column 
(Fig. 3.18 A). Fractions were deglycosylated by incubation with EndoHf and 




Figure 3.18 Cation-exchange chromatography of unlabeled FH-13-14. (A) Chromatogram from 
the elution of the SP-Sepharose column. (B), (C) Gradient SDS-PAGE of fractions from the 
elution shown in (A). (B) Lanes 1, 2: samples from crude supernatant immediately after 
harvesting. Lanes 3-6:  samples from fractions as indicated below the gel. (C) Samples from the 
fractions indicated below the gel.  
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The chromatogram contained a small peak on the leading shoulder of a much 
larger main peak. The SDS-PAGE analysis revealed that samples (from fractions 35-
46) prepared under non-reducing conditions contained multiple bands with the 
smallest running as expected for FH-13-14. On the other hand, under reducing 
conditions multiple bands appeared below a band of the expected molecular weight. 
This could be explained by the presence in the samples of proteolytically generated 
polypeptides held together (under non-reducing conditions) by disulfide bonds.  
Fractions 35-46 were combined, Endo Hf-treated, concentrated and buffer-exchanged 
into PBS. The sample was then divided into two equal portions and each was loaded, 
separately, onto a size-exclusion chromatography column (Fig. 3.19 A and C). 
Fractions were analyzed by SDS-PAGE (Fig. 3.19 B and D).  
 
 
Figure 3.19 Size-exclusion chromatography of FH-13-14, using a HiLoad 16/60 Superdex 75 
column. (A) Chromatogram of the first batch of two. (B) Gradient SDS-PAGE of fractions from 
(A). Lanes 1-9:  samples from the fractions indicated below the gel. (C) Chromatogram of the 
second batch of two. (D) Gradient SDS-PAGE of fractions from (C). Lanes 1-8: sampled from 
the fractions indicated below the gel. The peaks that probably correspond to FH-13-14 are 
indicated with a black bar. 
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The two size-exclusion chromatography runs performed showed identical 
elution profiles. The first peak probably contains a dimer (or oligomer(s)) formed by 
FH-13-14 that persist under denaturing conditions according to the corresponding 
SDS-PAGE. The larger peak eluted at the volume expected for a double-CCP 
module. It yields a single band on SDS-PAGE under non-reducing conditions, but 
there is evidence of degradation in SDS-PAGE loaded under reducing conditions. 
Fractions 49-53 were pooled separately for each size-exclusion 
chromatography run. Following spin-concentration the first batch of fractions yielded 
a sample of ~100 μM protein that was stored at -80 
o
C. The second batch produced a 
sample of 150 μM protein in ~450 μl. This was buffer-exchanged in 20 mM 
potassium phosphate, pH 6.6, the pH was adjusted to 6.7, and this sample was used 
to record a 
1
H-NMR spectrum (Fig. 3.20). The spectrum shows neither a very good 
dispersion nor well resolved peaks probably due to the presence of partially unfolded 
material. In addition, it revealed the presence of carbohydrate contaminants (multiple 
sharp peaks at around 4.8 ppm, (147)). These non-N-linked glycans are most likely 
non-specifically associated with the protein as was observed in the case of, for 
example, β-Lactoglobulin produced in P. pastoris (147). The sample was therefore 
applied to a ConA-lectin resin column in order to remove any remaining non-
covalently attached sugar moieties. SDS-PAGE was subsequently performed on a 
sample prior to application on the column as well as fractions from the elution (Fig. 
3.21).   
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Figure 3.20 1D 
1
H-NMR spectrum of FH-13-14. The sample was 150 μM in 20 mM potassium 





Figure 3.21 Gradient SDS-PAGE performed before and after elution from the ConA column. 
Lanes 1 and 2 contain the NMR sample (the sample originating from the second batch of size-
exclusion chromatography, prior to loading on the ConA column). Lanes 3-6 contain sequential 
fractions from the elution of the column.  
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     Fractions from the elution of the ConA column showed bands consistent with 
the profile already observed for FH-13-14. This exercise verified that the 
recombinant protein was not N-glycosylated presumably as a result of EndoHf 
treatment. Hence the polysaccharides evident in the 
1
H-NMR spectrum shown in 
figure 3.20 do not correspond to N-linked glycans. However, whether carbohydrate 




N-enriched expression in a fermentor 
 
The sample described above appeared to be highly susceptible to proteolytic 
degradation according to SDS-PAGE run under reducing conditions as well as 
improperly or incompletely folded according to 
1
H-NMR. Therefore FH-13-14 
behaves differently to the vast majority of CCP module pairs that have been studied 
in this laboratory. Since FH-13 is compactly folded and stable as an individually 
expressed module (30), it was hypothesized that FH-14 must be the source of these 
problems. To test this, production of a 
15
N sample for FH-13-14 was undertaken. 
Fermentation, with 
15
N enrichment, was performed as described (Materials 
and Methods, section 2.1.15.7). The culture was harvested and the supernatant  
(~900 ml) was diluted tenfold (rather than threefold, in an effort to reduce the loss of 
protein in the flow-through from ion-exchange chromatography, as observed for FH-
8-9 and FH-10-11 – see above). The supernatant was applied to a SP-Sepharose 
column equilibrated with 20 mM sodium acetate buffer pH 5.0. The protein was 
eluted over a linear gradient from 0 to 1 M NaCl (Fig. 3.22 A). Fractions from this 




Figure 3.22 Cation exchange chromatography of 
15
N-FH-13-14 on SP-Sepharose column. (A) 
Chromatogram (B) Gradient SDS-PAGE Lanes 1-2; before loading. Lanes 3-8: fractions as 
indicated. 
 
Protein eluted as a single peak early on in the gradient. SDS-PAGE revealed 
a similar pattern of bands to that observed with the non-labeled sample; oligomers 
under non-reducing conditions and degradation products when the disulfide bonds 
had been reduced. There was little variation between fractions (taken from across the 
peak) in terms of the relative quantities of oligomers/degradation products detected 
so it was concluded that these all co-eluted with the target material.  In an attempt to 
enrich for the target protein, fractions 43-62 were combined, EndoHf-treated, 
concentrated and buffer exchanged into PBS for size-exclusion chromatography. The 
pooled sample was then split into two equal portions and loaded separately (Fig. 3.23 





Figure 3.23 Size-exclusion chromatography of 
15
N-FH-13-14 (batches 1 and 2), using a HiLoad 
16/60 Superdex 75 column. (A) Chromatogram for first batch. (B) Gradient SDS-PAGE (for 
first batch). Lanes 1-7: fractions as indicated below gel. (C) Chromatogram for second batch. 
(D) Gradient SDS-PAGE for second batch Lanes 1-6: fractions as indicated below the gel. 
 
For both batches, three main peaks were eluted from the size-exclusion 
chromatography column, with the latest-eluting and highest peak in each case 
corresponding to material of the expected size for FH-13-14. The SDS-PAGE 
analysis revealed that individual peaks corresponded to what appeared to be single 
bands (under both non-reducing and reducing conditions) indicating that oligomers 
had been resolved from the monomer by this method. Unfortunately, closer 
inspection of the actual gels indicated that extra bands were present (not easily 
discernible in the figure above) under reducing conditions corresponding to 
degradation products. This is consistent with cleavage having occurred within the 
FH-13-14 polypeptide – at some stage in protein production, harvesting or 
purification - that is only revealed when the disulfides are reduced. Nonetheless, 
fractions 48-52 of the two runs were combined separately. The sample originating 
from the first size-exclusion chromatography was ~150 μM in 300 μl volume. It was 
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subsequently buffer-exchanged into 20 mM potassium phosphate buffer, pH 6.6, and 




N-HSQC spectrum shown in figure 3.24. The pooled 










N-HSQC spectrum of 
15
N-FH-13-14. The sample was 150 μM in 20 mM 
potassium phosphate buffer, pH 6.6. A black box highlights unidentified cross-peaks that have 
previously been observed in degraded FH fragment preparation, while a red circle highlights 
one of the clusters of overlapped peaks potentially due to the presence of unfolded material.  
 





HSQC spectrum from the non-uniformity of peak intensities and line-widths and the 
heavily overlapped clusters of peaks with random-coil shifts (for example in the 
middle region of the spectrum, also indicated with a circle). In addition there are 
weak but well-dispersed peaks that might correspond to compactly folded protein. It 
is difficult to judge the relative proportions of folded and unfolded/aggregated 








N-HSQC for FH-13 alone (which shows that the protein is properly folded), (Fig. 
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3.25) revealed that a small proportion of the well-dispersed peaks observed in the 
former could possibly arise from FH-13 (highlighted with circles in figure 3.25). 
Although both samples were in the same buffer and conditions it is likely that there 
could be a deviation in the actual pH between the two (e.g. due to experimental error 
when adjusting pH or calibration of the pH meter) which could in turn affect the 
chemical shift positions of the residues. All in all it seems probable that FH-14 as 
well as potentially the linker between the two modules are responsible for the 








N-HSQC spectrum of 
15




N-HSQC spectrum of 
15
N-FH-13 (shown in orange). Circles highlight cross-peaks that may 
possibly belong to FH-13.  Both samples were in 20 mM potassium phosphate buffer pH 6.6.  
 
In conclusion, FH-13-14 does not appear to be a well folded protein. It is 
possible that changes in the conditions of the protein sample, such as pH and salt 
concentration could have an impact to its properties but this investigation was not 
pursued further mainly due to the focus of this work on the remaining aims. 
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However, it can be said that this construct is most likely not suitable for NMR-based 
structure determination.  
 
3.1.5 Construct FH-14-15 
 
3.1.5.1 Mini-scale expression trials 
 
This construct was produced for assessment of its suitability for NMR-based 
structural analysis. Five colonies were selected for mini-scale production trials (Fig. 
3.26). Upon concentration and EndoHf treatment, a dominant band appears in SDS-
PAGE at ~17 kDa under reducing conditions (which might, in fact, be two bands). 
This corresponds approximately to the right size for FH-14-15 (~15 kDa). However, 
under non-reducing conditions there is clearly a second band (Fig. 3.26) at below  
17 kDa, indicating some degradation. As was observed also for FH-13-14 there 
appear to be a ladder of oligomers under non-reducing conditions and a proteolytic 
degradation product emerges when samples are reduced. Despite this unpromising 
mini-scale production trial, a shaker-flask production was undertaken with the 
prospect of recording a 
1
H-NMR experiment in mind.  
 
Figure 3.26 Gradient SDS-PAGE of the resultant spin-concentrated samples under reducing 
and non-reducing conditions.  The lanes prior to lane 1, and the two lanes between the 
molecular weight markers and lane 3 have been masked with a white box, as these correspond 
to samples not relevant to this section. 
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3.1.5.2 Production trials of FH-14-15 in shaker flasks  
 
The supernatant of the culture (~125 ml) was harvested, diluted, and 
subjected to cation-exchange (SP-Sepharose) chromatography at pH 4.0 (see section 
2.2.6).  Fractions from the elution of the column were subjected to EndoHf treatment 
and analyzed by SDS-PAGE (Fig. 3.27 A.). The gel showed bands where expected 
however it is evident that severe degradation has occurred as judged by the 
overloaded bands below 10 kDa. In addition, protein was still present in the flow-
through, although in small quantities. Hence, the flow-through was diluted four-fold 
with sodium acetate buffer, pH 4.0 and re-applied to the same column (Fig. 3.27 B). 
 
 
Figure 3.27 Gradient SDS-PAGE of the fractions from the elution of the SP-Sepharose column. 
(A) Lanes 2-4 correspond to fractions 2-5 that were eluted from the column. Lane 5 corresponds 
to sample from the flow-through (B) Lanes 1-3 and 4-6 correspond to fractions from the elution 
of the column after the flow-through was re-applied.  
 
SDS-PAGE of the fractions from the SP-Sepharose elution revealed a rather 
weak band at the expected size for FH-14-15 (15 kDa) however the gel is dominated 
by very strong (overloaded) bands running ahead of the 10-kDa molecular weight 
marker (lanes 2-5). Fractions 2-5 from (A) and 1-3 from (B) (in Fig. 3.27) were 
combined, concentrated and applied to the size-exclusion chromatography column 
(see section 2.2.6) (Fig. 3.28). Resultant fractions were analyzed by SDS-PAGE 




Figure 3.28 Size-exclusion chromatography of FH-14-15, using a HiLoad 16/60 Superdex 75 
column. 
 
The size-exclusion chromatogram contained multiple peaks indicative of a 
wide range of oligomers and breakdown products. A minor peak occurred at 75 ml, 
corresponding to the expected elution volume of a monomeric, double-CCP module. 
Analysis of fractions by SDS-PAGE, however, revealed that neither this nor any of 
the other peaks corresponded to an intact polypeptide chain of the expected size. It 
was concluded that recombinant P. pastoris-derived FH-14-15 was susceptible to 
misfolding (which could either be a cause of, or an outcome of, inappropriate 
disulfide bond formation), to proteolysis and/or to aggregation.  This was not 
investigated further after considering the time-limitations and main aims of this 
project. It is interesting, however, to note that FH-15 folds compactly, with no 









3.1.6 Construct FH-10-15 
 
Both unlabeled and 
15
N-enriched batches of FH-10-15 were required as they 




N-HSQC and TROSY NMR experiments, respectively.  
 
3.1.6.1 Purification of unlabeled FH-10-15 
 
Crude EndoHf-treated and concentrated cell-depleted (by centrifugation and 
filtering) supernatant was retrieved from storage at -80 
o
C, and samples of 0.5-1.0 ml 
were loaded onto the size-exclusion chromatography column (as described in section 
2.2.6). Fractions corresponding to peaks that eluted where expected were analyzed 
by SDS-PAGE, then subjected to a second size-exclusion chromatography step (on 
the same column).  Data can be found in the supplementary CD section 1.5 while 
figure 3.29 shows the final sample produced as analyzed by SDS-PAGE. 
 
 
Figure 3.29 Gradient SDS-PAGE of the final sample for unlabeled FH-10-15. Under these 
reducing conditions, some minor degradation is visible. 
 
The final sample, 140 μM in 1 ml, was used for subsequent SPR studies. Mass 
spectrometry analysis was not performed in the present work; however it has been 







N-enriched expression in a fermentor 
 
P. pastoris glycerol stocks containing the DNA for FH-10-15 were re-
streaked on a YPD plate containing 100 μg/ml zeocin. Single colonies were used for 
the starter culture in BMG. This was subsequently used to inoculate the fermentor. 
The fermentation procedure was carried out as described in Materials and Methods. 
The culture (~900 ml) was harvested and was then diluted ten-fold. FH-10-15 is 
known (on the basis of prior experience in the lab) to precipitate at low pH, therefore 
cation-exchange chromatography was ruled out as a first capture step. Anion-
exchange chromatography was used, instead, on a Q-Sepharose column equilibrated 
at 20 mM Tris-HCl, pH 8.5. Due to incomplete solubilisation (as judged by the 
blockage of the column) it was subsequently decided to split the tenfold-diluted 
supernatant (10 L) into five 2-L batches, further dilute these threefold and apply one 
batch at a time to the column with the aim to elute one of each of the five 6-L batches 
daily. The elution was achieved using 20 mM Tris-HCl over a linear gradient from  
0 to 1 M NaCl. Each batch-elution was subsequently analyzed by SDS-PAGE then 
fractions containing FH-10-15 were pooled, EndoHf-treated and prepared for two 
consecutive rounds of gel-filtration chromatography. All fractions were analyzed by 
SDS-PAGE. The results for one representative purification are shown (batch 1)
$
 


















This work was performed in conjunction with Vanessa Vongvarotai, an undergraduate student 
working under the supervision of the author. 
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Figure 3.30 Anion-exchange chromatography of batch 1 of 
15
N-labeled FH-10-15. (A) 
Chromatogram of the elution of the Q-Sepharose column. (B) Gradient SDS-PAGE of fractions 
from the elution as indicated, as well as from the “waste”.  
 
The chromatogram contains one main peak (of three) that, according to SDS-
PAGE of the relevant fractions (28-36), contains protein of the expected size  
(42 kDa) (lanes 1-4 in figure 3.30). Fractions 24-34 were combined, EndoHf- treated, 
concentrated, buffer exchanged into 20 mM potassium phosphate buffer, pH 7.4, 
containing 0.5 M NaCl and split into two samples. Each was subjected separately to 





Figure 3.31 Size-exclusion chromatography for batch 1 of 
15
N-FH-10-15, using a HiLoad 16/60 
Superdex 75 column.  (A), (B) Chromatograms (C) Gradient SDS-PAGE of the fractions as 
indicated below the gel from the two gel-filtration runs (from the peaks indicated with a black 
bar). Lanes 1-2: fractions from the middle of the main peak shown in (A). Lanes 3-6: fractions 
from the main peak shown in (B).  
 
Size-exclusion chromatography revealed that near-homogeneous samples of 
15
N-FH-10-15 had been prepared (as judged from the SDS-PAGE gel).  Fractions 
from the main peak of both runs were combined and subjected to a second round of 
size-exclusion chromatography (Fig. 3.32). 
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Figure 3.32 Final purification for batch 1 of 
15
N-FH-10-15, using a HiLoad 16/60 Superdex 75 
column. (A) Chromatogram. (B) Gradient SDS-PAGE of fraction 41. 
 
The size-exclusion chromatography profile featured just one peak that eluted at the 
expected volume for 
15
N-FH-10-15 whilst the SDS-PAGE gel of the fraction from 
the middle of the peak confirmed its purity. 
The NMR sample used to record 1D and 2D experiments was ~100 μM in  
0.5 ml and resulted from the combination of some of the purest fractions shown in 
this section along with fractions for the remaining batches shown in the 
supplementary CD sections 1.6-1.8. An overloaded sample of that was run on a SDS-









FH-10-15. Strong bands at the expected positions appear under reducing and non reducing 
conditions consistent with purified protein. 
 
In addition to the NMR sample, combination of some of the purest fractions resulted 
in the following 0.5 ml samples that were subsequently stored for future usage: a  
15 μM sample, a 30 μM sample and a 20 μM sample.  
 




A purified NMR sample (550 μl) of ~100 μM 
15
N-labeled FH-10-15, which 
ran as a single band on SDS-PAGE, was prepared in 20 mM potassium phosphate  







Figure 3.34 1D 
1
H-NMR spectrum of 
15
N-FH-10-15. Arrows indicate peaks thought to derive 








N-HSQC spectrum for 
15








N-TROSY spectrum for 
15




H-NMR spectrum shows a relatively good dispersion with peaks that are 
well resolved considering the relatively high molecular weight of this protein, along 
with some very broad peaks that could reflect self-association or multiple 
conformations. In addition, there appears to be contamination with carbohydrates. 
This had also been observed in the case of FH-13-14 and could potentially be due to 





spectrum showed significant overlap as well as some well-dispersed and resolved 
cross peaks. Some of the overlap might be ascribed to a combination of line-
broadening and the presence of many cross peaks both of which are a consequence of 
the relatively large size of the protein. On the other hand there are a wide range of 
peakwidths and a large number of cross-peaks at random coil shifts (around  
8.3 ppm) that could reflect conformational mobility on the intermediate timescales.  
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In general, line widths depend on the tumbling of a molecule in solution and 




N-HSQC spectrum with a wide range 
of cross-peak widths could imply self-association and formation of a large complex 





spectrum of an unfolded protein signals appear as clusters of not well-defined peaks 
around 8.3 ppm (random-coil shifts) with little dispersion in either dimension. 




N-TROSY spectrum as 
expected since this pulse sequence promotes mutual cancellation of T2 relaxation 
pathways. Nonetheless there remains a cluster of cross peaks near the centre of the 
spectrum consistent with the presence of disorder and line broadening due to 
interchanging (intermediate timescale) conformations. This sample (stored for future 
use at -80 °C) could be applied to a ConA column to remove the carbohydrate 
contaminants and further work could then be done to optimise conditions such as pH, 




D-labelling conditions to improve the quality of the TROSY spectrum and 
possibly allow some assignments based on the assignments of the component 
modules.  
 
3.1.7 Construct FH-8-15 
 
This construct was prepared for binding studies with PspCN/PspCNR1-
proteins from S. pneumoniae. Cell-depleted growth media was retrieved from storage 
at -80 
o
C and deglycosylated with EndoHf. In a trial, six samples of 0.5-1 ml each 
were flowed, separately, down a size-exclusion chromatography column, then 
appropriate fractions were pooled and re-loaded (in two batches) onto the same 
column for a second size-exclusion chromatography step. Data for this purification 
can be found in the supplementary CD section 1.10. The final resultant sample  





Figure 3.37 Gradient SDS-PAGE of the final sample for FH-8-15. Strong bands appear at the 
expected molecular weight; under reducing conditions some mild degradation is visible while 
under non-reducing conditions a single band appears. 
 
The final sample for FH-8-15 was homogeneous as judged by SDS-PAGE and was 
used for the SPR experiments. 
 
3.2 Production, purification and characterization of the PspC constructs 
 
The first PspCN construct to be produced was His-tag PspCN-GSGC. The 
expression construct for PspCN with a non-native C-terminus GSGC sequence was 
designed for its potential future use as a platform for labeling or thiol chemistry and 
was already available in the lab. The protein was used in initial SPR studies of its 
interaction with FH. The second segment produced was His-tagged PspCN. In this 
case the non-native C-terminal amino acid addition was absent. This protein was 
used for follow-up SPR analysis of PspCN-FH interactions. Finally, the constructs 
SUMO-PspCN and SUMO-PspCNR1 were produced, utilizing the pE-SUMOPro- 
Kan vector. This final approach was adopted because of the increased yields and 
solubility that can be achieved. In addition, cleavage of SUMO (that is fused to the 
protein of interest) results in the native form of the proteins (no N- or C- terminal 
tags and/or non-native residues). These constructs were subjected to the final and 
most extensive SPR experiments with FH and C3. 
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The table below (Table 3.4) summarizes the PspC constructs produced in this 





Table 3.4 Summary of the PspC constructs used in this study.  
 
The cloning, expression, purification and characterization performed for each 
of the PspC constructs employed in this study is summarized in Tables 3.5 (parts 1 




Table 3.5 Overview of the PspC constructs employed in this study (Part 1). 
 




Table 3.6 Summary of the expected and experimentally determined molecular weights for all 
the PspC constructs prepared in this study. 
 
3.2.1 Construct His-tag PspCN-GSGC 
 
Figure 3.38 shows the position of the His-tag PspCN-GSGC construct within 
the native PspC protein as well as the amino acid sequence including the non-native 










Figure 3.38 Schematic representation of the PspC protein. Residues 37-140 correspond to the N-
terminal PspCN construct. The native sequence for this construct is shown in black, the N-
terminal non-native tag in blue and the C-terminal non-native GSGC amino acid sequence in 
red.   
 
In an initial purification step, Co
2+
-affinity chromatography was employed. 
The buffer used was 20 mM potassium phosphate pH 7.0, 500 mM NaCl, 20 mM 
imidazole (buffer A) while the His-tagged protein was eluted using the same buffer 
but with 500 mM imidazole instead of 20 mM (buffer B). Two batches of His-tag 
PspCN-GSGC were produced and the data are presented for just one of these (data 
for the remaining batch can be found in the supplementary CD section 1.11). In both 
cases, the soluble fraction obtained after cell lysis (see Materials and Methods 
section 2.1.16.3 for details) was diluted with an equal volume of buffer A before 
application to the pre-equilibrated IMAC column. Protein was then eluted over a 




3.2.1.1 Representative results for batch 1 
 
Figure 3.39, shows the results of SDS-PAGE performed to assess the 








This work was performed in conjunction with Vanessa Vongvarotai, an undergraduate student 
working under the supervision of the author. 
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Figure 3.39 Gradient SDS-PAGE of samples from a culture of E. coli cells engineered to 
overproduce His-tag PspCN-GSGC, taken before and after induction with IPTG.  
 
According to SDS-PAGE gel, a strong band appears just below the 20 kDa 
size marker after 3 h of induction which becomes more pronounced 19 h after 
induction. The equivalent band is not observed in the absence of IPTG. PspCN has a 
molecular weight of only ~15 kDa (including the His-tag, thrombin site and cloning 
artifacts), however it is strongly positively charged (pI = 9.46) consistent with slower 
migration on SDS-PAGE than the standards and an apparently higher molecular 
weight. 
Eight individual colonies were selected and each grown in 500 ml LB media, 
as described in Materials and Methods, section 2.1.16. Following harvesting, cells 
were weighed and frozen. Four out of the eight were pooled (as an initial batch, 
while the rest were kept for subsequent purification), giving a total wet cell weight of 
7.4 g. Cells were lysed and the lysate was applied on the IMAC column as described 
in Materials and Methods section 2.2.6, (Fig. 3.40 A). Fractions from this step were 





Figure 3.40 First purification step for His-tag PspCN-GSGC; metal-affinity chromatography 
using a HiLoad IMAC column. (A) Chromatogram. (B) and (C) Gradient SDS-PAGE of the 
fractions of the elution as indicated. 
 
No distinct peaks were eluted from the IMAC column, rather a continuous 
increasing trace in the A280 nm UV absorbance was obtained due to the imidazole 
gradient. Despite the lack of a peak of absorbance, from SDS-PAGE it appears that 
fractions between 32 and 70 are potentially enriched with the protein of interest. 
Hence, fractions 32-40 and fractions 44-70 were combined separately. The pool 
corresponding to fractions 44-70 was concentrated and buffer-exchanged into PBS 
containing 5 mM EDTA in preparation for size-exclusion chromatography (Fig. 3.41 





Figure 3.41 Size-exclusion chromatography for His-tag PspCN-GSGC, using a HiLoad 16/60 
Superdex 75 column. (A) Chromatogram of the size-exclusion chromatography run. (B) 
Gradient SDS-PAGE of the most representative fractions corresponding to the peaks visible in 
the chromatogram shown in (A). 
 
The main feature of this size-exclusion chromatography run was the very low 
UV absorbance as seen in the chromatogram indicating that only a very small 
fraction of the original protein had survived the IMAC step. In the SDS-PAGE, faint 
band appears just above 75 kDa for fraction 32 (corresponding to the first peak that 
eluted from the column) which could be an E. coli contaminant. Fraction 41 shows a 
band around 37 kDa and could be potentially arising from the formation of a dimer 
(note the C-terminal Cys residue that could form a disulfide bond). Finally, fraction 
48 exhibits a band at the expected size for monomeric His-tag PspCN-GSGC just 
below 20 kDa. In spite of the low UV absorbance of the eluted peaks, fractions were 
stored.  
 
3.2.2 Construct His-tag PspCN 
 




Figure 3.42 Representation of the amino acid sequence used in this part of the study. The non-
native His-tag followed by the thrombin cleavage site and the cloning artifact are highlighted in 
blue one-letter code. The native PspC sequence of the N-terminus region of PspC, termed 
PspCN is shown in black. 
 
Three batches of cells were cultured, (each corresponding to 3L LB media) 
harvested (wet cell weights  were 8.7 g, 10 g and 6.5 g for the first, second and third 
batches) and lysed as described in Materials and Methods, section 2.1.16.3. Protein 
was eluted from the metal-affinity chromatography capture step using an imidazole 
gradient from 20 to 500 mM imidazole. Size-exclusion chromatography was used as 
a second purification step. Representative data for batch 2 will be presented below 
(results for batches 1 and 3 can be found in the Supplementary CD sections 1.12 and 
1.13).  
 
3.2.2.1 Representative results for batch 2 
 
 
Figure 3.43 First purification/capture step for His-tag PspCN (Batch 2) using immobilized 
metal-affinity chromatography. (A) Chromatogram of the elution of the IMAC column. (B) 
Gradient SDS-PAGE of fractions from the elution as indicated below the gel. Fractions 44-80 
were also run on a separate gel however no bands were visible (data not shown). 
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The lack of distinct peak/peaks following the launch of the gradient has been 
observed and commented on previously (section 3.2.1.1). Fractions 32-41 (lanes 8-
11) showed bands in the SDS-PAGE gel (Fig. 3.49 B) at the expected size for His-
tag PspCN from the elution of the IMAC column (migrating to just below 20 kDa) 
(Fig. 3.43 A). Fractions 44-80 which were included in a separate gel did not show 
any bands (data not shown). Nonetheless fractions 35-75 were pooled, concentrated 
and buffer exchanged in PBS containing 5 mM EDTA in preparation for size-
exclusion chromatography. The resultant sample was split in two and two runs were 
performed for each of the two samples (Fig. 3.44 A and B). Fractions from the main 
peaks of those two runs were combined, further concentrated and subjected to a 
second round of size-exclusion chromatography (Fig. 3.44 C). Fractions from this 
final step were monitored by SDS-PAGE (Fig. 3.44 D). 
 
 
Figure 3.44 Second and final purification for His-tag PspCN, using a HiLoad 16/60 Superdex 75 
column. (A), (B) Chromatograms of the two size-exclusion chromatography runs. The main 
peaks, indicated with a black bar, correspond to PspCN. (C) Chromatogram of the size-
exclusion chromatography run performed on fractions 47-50 of the runs shown in (A) and (B). 
One main peak eluted which corresponds to PspCN. (D) Gradient SDS-PAGE of fractions from 
the main peak indicated with a black bar in (C). 
 159 
Two consecutive rounds of size-exclusion chromatography resulted in protein 
eluting as a single peak. It is evident from the final SDS-PAGE gel performed that 
the majority of the protein was purified while some degradation might have occurred 
as reflected by the bands below the expected size for PspCN (~20 kDa). Fractions 
47, 48, 49 and 50 were frozen and kept separately. From those, samples for fractions 
49; 130 μM in 1 ml, and 50; 95 μM in 1 ml, were submitted for accurate mass 
analysis (Figs. 3.45, 3.46). 
 
 
Figure 3.45 LC-MS spectrum for fraction 49 of purified His-tag PspCN. The highest peak 




Figure 3.46 LC-MS spectrum for fraction 50 of purified His-tag PspCN. The measured mass 
was identical to what was found for fraction 49 shown in figure 3.98.  
 
From the LC-MS analysis it can be concluded that although other species 
were present in the spectrum, the highest peaks for both fractions 49 and 50 
correspond to intact protein. 
 
3.3 Production of PspC constructs in pE-SUMOPro Kan vector 
 
3.3.1 Construct SUMO-PspCN 
 
Following transformation and DNA manipulation (Materials and Methods 
sections 2.1.11-2.1.13), purified plasmid DNA was used to transform two E. coli 
strains in order to decide which was better for expression: BL21 (DE3) and BL21 
(DE3) - pLysS. Colonies were used to inoculate 5 ml of LB media containing  
30 μg/ml kanamycin and both strains were tested at different temperatures and 
concentrations of IPTG (Fig. 3.48).   
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The figure below (Fig. 3.47) shows the amino acid sequence used consisting 
of the SUMO sequence shown in magenta and the native PspCN sequence shown in 
black. 
 
Figure 3.47 Representation of PspC in which the sequence corresponding to the N-terminus 
used in this study, denoted PspCN fused with SUMO is indicated.  
 
 
Figure 3.48 Gradient SDS-PAGE of the trial expressions for SUMO-PspCN. (A) Lanes 1-4 show 
the expression obtained by using the E. coli strain BL21 (DE3), as indicated. The band 
appearing just below 37 kDa probably corresponds to SUMO-PspCN and is visible in lanes 2-4. 
Lanes 5-8 show the expression as indicted on the gel. Bands for the expected protein appear just 
below 37 kDa in lanes 6-8. Lanes 9-12 show the expression for the strain BL21 (DE3)-pLysS, as 
indicated. SUMO-PspCN once again appears just below 37 kDa in lanes 10-12. (B) Lanes 1-4 
show the expression for the strain BL21 (DE3)-pLysS. Bands for SUMO-PspCN are visible just 
below 37 kDa in lanes 2-4. 
 
It is evident from SDS-PAGE (Fig. 3.48) that use of the E. coli strain BL21 
(DE3) and an overnight induction period at 20 
o
C yielded both the highest amount of 
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protein (as reflected by the stronger bands), and the highest ratio of soluble-to-
insoluble protein (note that a very faint band appeared in the actual gel in the lane for 
the insoluble fraction, however this is not visible in the figure). This strain and these 
conditions were used for a larger-scale growth. 
The wet weight of cells following harvesting (of the 2-L LB cultures), after 
combining all four flasks was 7 g. The soluble lysate was applied onto the IMAC 
column and eluted as already described (the buffers were identical to those described 
in the sections 3.3.1 and 3.3.2) (Fig. 3.49 A and B). Fractions from the elution were 
analyzed by SDS-PAGE and are shown in figure 3.50 B & C.  
 
 
Figure 3.49 Gradient SDS-PAGE gel of SUMO-PspCN, prelude to purification attempt on a 
HiTrap chromatography column: (A) Lanes 1 and 2: samples as indicated.  (B) Lanes 1-4: 
samples as indicated. All lanes contain bands at the expected molecular weight for SUMO-
PspCN (indicated with an arrow).  The lanes between lane 2 and the molecular weight markers 
in (A) and between the molecular weight markers and lane 1 in (B) have been masked with 




Figure 3.50 First purification step of SUMO-PspCN. (A) Chromatogram of the elution of the 
IMAC column. (B) Gradient SDS-PAGE of fractions from the elution shown in (A). Lanes 2-9 
contain fractions-every 5
th
 fraction as shown.  (C) Gradient SDS-PAGE gel for the remaining 
fractions shown in (A).  
 
The profile of the IMAC elution, with no distinct peaks, was similar to that 
obtained previously. Fractions were analyzed by SDS-PAGE (Fig. 3.50 B and C). 
(B) shows there is no detectable protein in the flow-through. All fractions from the 
elution show bands that presumably correspond to SUMO-PspCN that migrates to 
just below 37 kDa (despite the protein having a molecular weight of 24 kDa). Lanes 
1-5 in (C) all contain bands for SUMO-PspCN.  
  It appears that fractions 18-78 all contain SUMO-PspCN. Fractions 15-80 
were combined and split into two samples. The first sample (I) (~165 ml) was 
subjected to cleavage of the SUMO protein (as described in Materials and Methods 
section 2.2.5) while the other sample (II) was concentrated and buffer-exchanged in 
PBS containing 5 mM EDTA, in preparation for size-exclusion chromatography. 
Once sample I had been subjected to cleavage, it was subsequently re-passed 
over the IMAC column and the cleaved protein was collected (that should have lost 
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its N-terminal His-tag). The column was then washed and once again the flow-
through was collected. Finally, 20 ml (of 20 mM potassium phosphate buffer, pH 
7.0, 500 mM NaCl, 500 mM imidazole) were applied and the flow-through collected 




Figure 3.51 Gradient SDS-PAGE of samples collected after the re-pass through the IMAC 
column of SUMO-PspCN following cleavage.  
 
From SDS-PAGE gel, it looks as if the majority of SUMO-PspCN was 
cleaved to afford the native PspCN, as reflected by the strong bands at the expected 
positions in lanes 1, 2 and 3 (Fig. 3.51). The fractions containing cleaved protein 
eluted from the second re-pass on the IMAC column were combined and 
concentrated in preparation for size-exclusion chromatography (Fig. 3.52). Samples 




Figure 3.52 Size-exclusion chromatography for cleaved PspCN, using a HiLoad 16/60 Superdex 
75 column. (A) Chromatogram. The main peak is indicated with a black bar. (B) Gradient SDS-
PAGE of samples/fractions of the main peak shown in (A) with the exception of lane 2 which 
contains a sample from the first lower peak in (A) and lane 1 which contains a sample prior to 
application on the column. 
 
The profile of the chromatogram showed a main peak eluting at ~75 ml. 
When fractions from this peak were analyzed by SDS-PAGE (Fig. 3.52 B) they all 
showed single bands appearing just above 15 kDa thus leading to speculation that 
purified cleaved PspCN was contained in those fractions. Fractions 49-51 were 
combined and concentrated affording a 1 ml sample at a concentration of ~580 μM. 
From this, 400 μl were used to record NMR experiments (Figs. 3.53, 3.54), 5 μl in 
order to obtain accurate mass analysis (Fig. 3.55) while the rest (~600 μl) of the 
sample was frozen.  
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Figure 3.53 1D 
1
H-NMR spectrum for PspCN. The sample was 580 μM in 20 mM potassium 








N-HSQC spectrum for PspCN. The sample was 580 μM in 








N-HSQC spectra indicate that there is some folded 
material present. This is reflected by the good dispersion and resolution exhibited by 
some of the peaks, however there is some potentially unfolded material as may be 
judged from clusters of not well-defined peaks appearing in parts of the spectrum. 





Figure 3.55 LC-MS spectrum for PspCN. All peaks correspond to charge state 14+.  
 
According to the accurate mass analysis it can be concluded that the protein 
had the mass expected judging from the comparison between the calculated mass 
(without the N-terminal Met residue) and the measured mass, both of which are 
indicated on the spectrum. 
Following the NMR experiments a SDS-PAGE gel was run to test the state 
and the stability of the protein after four days in the NMR instrument, the 
temperature of which was set at 25 
o




Figure 3.56 Gradient SDS-PAGE of a purified sample of PspCN after the completion of the 
NMR experiments.  
 
In SDS-PAGE gel an overloaded band appears where expected, while negligible 
degradation is visible below the main band. This experiment suggested that the 
protein remained intact. 
The second batch originating from the concentrated IMAC fractions, which 
remained uncleaved, was split in two samples and two size-exclusion 
chromatography runs were performed, one for each. Data for this can be found in the 
Supplementary CD section 1.14. 
 
3.3.2 Construct SUMO-PspCNR1 
 
The same procedure described for PspCN was followed and two E. coli 
strains were used in order to decide which was best for expression: BL21 (DE3) and 
BL21 (DE3) - pLysS. Single colonies were used to inoculate 5 ml of LB media 
containing 30 μg/ml kanamycin and both strains were tested at different temperatures 
and concentration of IPTG (Fig. 3.58). 
The figure below (Fig. 3.57) shows the amino acid sequence used consisting 





Figure 3.57 Representation of PspC where the sequence corresponding to the N-terminus-R1 




Figure 3.58 Gradient SDS-PAGE following the trial expressions of SUMO-PspCNR1. (A) Lanes 
1-4 show the expression obtained by using the E. coli strain BL21 (DE3), as indicated on the gel. 
The band appearing just above 50 kDa corresponds to SUMO-PspCNR1 and is visible in lanes 
2-3. Lanes 5-8 show the expression for the strain BL21 (DE3) as indicated. Bands for the 
expected protein appear just above 50 kDa in lanes 5-8. (B) Lanes 1-4 show the expression for 
the strain BL21 (DE3)-pLysS.  SUMO-PspCNR1 does not appear where expected in any of the 
lanes. Lanes 5-8 show the expression for the strain BL21 (DE3)-pLysS. Bands for SUMO-
PspCNR1 cannot be seen in any of the lanes.  
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Analysis by SDS-PAGE indicates that the strain BL21 (DE3) –pLysS was not 
at all suitable for the expression of SUMO-PspCNR1. The strain that yielded the 
most protein was BL21 (DE3), following overnight induction at 20 
o
C. These 
conditions also yielded the most favorable ratio of soluble to insoluble protein.  
 
For large-scale expression, the procedure followed was identical to that 
already described for SUMO-PspCN in Section 3.4.1. The wet cell weight was 6.5 g. 
The outcome of the first purification step (IMAC) is shown in Figures 3.59 and 3.60. 
. 
 
Figure 3.59 Gradient SDS-PAGE of the following samples: (A) Lanes 1 and 2: samples as 
indicated.  (B) Lanes 1-4: samples as indicated. The lane between lane 2 and the molecular 
weight marker in (A) has been masked with a white box as it contained a sample not relevant to 
this section. All lanes contain bands at the expected molecular weight of around 50 kDa 







Figure 3.60 First purification step for SUMO-PspCNR1. (A) Chromatogram of the elution of the 
IMAC column. (B) Gradient SDS-PAGE of fractions from the elution shown in (A) as indicated 
below the gel. 
 
The profile of the elution following launch of the gradient is similar to what 
has been previously observed. In SDS-PAGE analysis, lanes 1-11 in (B) correspond 
to fractions spanning 22-78 and all contain bands for SUMO-PspCNR1, around  
50 kDa, although in lanes 8-11 they are very faint.  
The expected molecular weight for SUMO-PspCNR1 is 41.173 Da. However, 
it runs more slowly than standard proteins of the same size so the band appearing to 
have a MWt of ~50 kDa could be the target protein. Fractions 15-80 were pooled and 
spilt into batches I and II which were subsequently treated as described for SUMO-
PspCN in section 3.4.1.  
After overnight dialysis/cleavage of Batch I, a sample was kept aside for 
SDS-PAGE and the rest re-applied to the IMAC column that had been pre-
equilibrated with the same buffer. This was eluted and analyzed by SDS-PAGE as in 




Figure 3.61 Re-pass of cleaved SUMO-PspCNR1 on the IMAC column.  
 
As can be observed from SDS-PAGE the majority of the protein batch was 
successfully cleaved. Fractions from the IMAC column containing the cleavage 





Figure 3.62 Size-exclusion chromatography for cleaved PspCNR1, using a HiLoad 16/60 
Superdex 75 column. (A) Chromatogram of the size-exclusion chromatography run. (B) 
Gradient SDS-PAGE of a sample before the size-exclusion chromatography run, in lane 1, and 
fractions from the chromatogram shown in (A) (lanes 3-8).  
 
The highest peak, indicated with a black bar in Fig. 3.62, probably 
corresponds to cleaved PspCNR1. In the SDS-PAGE that followed, lanes 3-5 contain 
fractions from the main peak indicated in the chromatogram and all show single 
bands just below 37 kDa corresponding to pure protein. PspCNR1 is 28.9 kDa 
however it migrates in an SDS-PAGE gel to just below 37 kDa due to its high 
positive charge. More pronounced degradation is visible in lane 6 containing fraction 
42 while in lane 7 which contains a fraction from the following shoulder of the main 
peak degraded protein amounts for half the sample. Lane 8 contains mostly degraded 
material. 
SDS-PAGE revealed that pure cleaved PspCNR1 were eluted in fractions 39 
and 40. In fractions 41 and 42 some slight degradation is visible. Therefore fractions 
39-40 were combined, concentrated and afforded a sample of 1 ml at a concentration 
of 120 μM. Half of that sample was used to record NMR experiments (Fig. 3.63) and 
mass spectrometry data (Fig. 3.64) while the rest was stored in the -80 
o




Figure 3.63 1D 
1
H-NMR spectrum for PspCNR1. The sample was 120 μM in 20 mM potassium 
phosphate buffer, pH 6.4.  
 
SDS-PAGE (Fig. 3.65) confirmed that the sample was stable after several 






Figure 3.64 LC-MS spectrum for PspCNR1. All peaks correspond to charge state 34+.  
 
Accurate mass analysis verified the presence of intact protein as the measured 
and expected mass are in very good agreement. 
 
 
Figure 3.65 Gradient SDS-PAGE on a sample after the NMR experiments for PspCN and 
PspCNR1.The first lane contains the same sample as shown in figure 3.63. PspCNR1 appears as 
a strong in the second lane at the expected molecular weight. Lower faint bands correspond to 
some mild degradation. 
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The SDS-PAGE gel shows an overloaded band at the expected weight 
consistent with intact protein. Despite some very mild degradation compared to the 
intact portion that the protein has undergone, it was considered suitable for further 
experiments at room temperature. 
A similar approach was followed for the purification of SUMO and 
uncleaved SUMO-PspCNR1. The results for both can be found in the Supplementary 
CD sections 1.15 and 1.16. 
 
3.4 Conclusions- Protein production, purification and characterization 
 
In this study three segments of the complement regulator, FH, and two 
segments of PspC, a bacterial protein and important virulence factor expressed by S. 
pneumoniae, were overproduced as recombinantly expressed gene products. The 
remaining FH constructs presented in this chapter were already available either as 
DNA incorporated in the P. pastoris genome, or as expressed and unpurified material 
and were further processed accordingly by the author for use in functional studies. 







C-enriched media for the purpose of three-dimensional structural studies. 
Two 
15




C-labeled were produced in total in order to cover 
all experiments required. The quality of the obtained material was excellent as 
reflected by purity confirmed by SDS-PAGE in conjunction with accurate mass 
analysis and finally by how well the proteins were folded as judged by the NMR 
experiments.  The majority of the remaining FH proteins prepared in the current 
work proved to be pure as judged by SDS-PAGE, folded as judged by NMR 
experiments, and produced in adequate yields for the studies in plan, while in some 
cases accurate mass analysis confirmed the correct primary sequence. The exceptions 
were FH-4-6, FH-13-14 and FH-14-15. In the case of FH-4-6 a relatively pure 
sample was obtained however at a low yield. In the case of FH-13-14 adequate yields 
were achieved, however the protein became degraded almost immediately. In 




N-HSQC spectrum it appears that some part of the 
construct is folded while the remaining is aggregated and/or unfolded. This could 




N-HSQC spectrum of FH-13 alone showed 
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properly folded material (30). One possibility is that in the context of a larger 
construct FH-13-14 is stabilized by its neighboring CCPs. If that were the case, then 
the site(s) in FH-13-14 susceptible to cleavage (when the construct is produced as a 
double CCP module) may no longer be accessible to proteases when in the context of 
FH-10-15 or FH-8-15. In the case of FH-14-15 due to the limited investigation 
performed it can be said that, similarly to FH-13-14, the protein becomes degraded 
immediately, however at which stage takes place is not known. It is interesting 
though that this construct also involves FH-14. The fact that neighboring CCP 
modules of 13, 14 and 15 may be required for the observed shift in the behavior of 
the proteins (when going from double CCP constructs to bigger segments), may be 
evidenced by the fact that larger FH regions, i. e. FH-10-15 and FH-8-15 appear to 
be much more stable, not as susceptible to degradation and to a large extent folded. 
For FH-10-15 this conclusions can be drawn based on the present work while for 
FH-8-15 also based on previous work performed by Dr C. Q. Schmidt. Overall, it 
appears that within the FH-10-15 structure there are compactly folded modules along 
with at least one less well-ordered module (see also section 3.1.6.3 of this chapter). 
Taking into account the observations above for FH-10-11, FH-13-14 and FH-14-15 
together with the excellent quality of NMR spectra obtained for FH-11-12 (discussed 
further in Chapter 4), FH-13 (30) and FH-15 (44), the best candidate for a disordered 
module is FH-14. The presence of disorder in FH-10-15 might explain the difficulty 
that was encountered in crystallizing this construct despite a serious effort (Dr C. Q. 
Schmidt, personal communication).  
The use of E. coli for the expression of the PspC constructs was fast and 
efficient. Three different versions of PspCN were produced and one version of 
PspCNR1. Adequate yields were produced in all cases. In addition, SDS-PAGE 
confirmed their purity while accurate mass analysis confirmed the correct primary 
amino acid sequences. When the “SUMO” approach was followed (utilizing the pE-
SUMOPro Kan vector) higher yields and increased solubility were achieved. In 
addition subsequent cleavage of the SUMO from the expressed fusion products (i. e. 
SUMO-PspCN and SUMO-PspCNR1) resulted in the native sequence for both 




N-HSQC performed on PspCN revealed the 
presence of folded material (supported by the good peak-dispersion observed in parts 
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of the spectrum) however there is also evidence for incomplete folding of the protein. 
A similar however not as conclusive comment can be made for PspCNR1 based on 
the 
1
H-NMR experiment. It is likely that the PspC proteins adopt a folded 





recorded on PspCN in complex with FH-8-9 was consistent with proper folding of 
PspCN (experiments performed by Dr A. Herbert). In conclusion this work 
successfully produced a panel of proteins the majority of which were suitable for 




























































Recent models for the mechanism of action of FH envisage its central region 
as playing a major architectural role that is key to its biological function of 
minimising complement-mediated damage to the host (15), (43). According to this 
model, the C- and N- terminal regions are brought into spatial proximity, thereby 
allowing for cooperation in engaging their binding partners, namely C3b and 
polyanionic carbohydrates.  
As detailed in the Introduction, a binding site for C3b is located within FH-1-
4. Indeed these modules can, alone, carry out the fluid-phase CA and DAA of FH. 
FH-7 contains a polyanion-binding site that probably aids in self-surface recognition. 
At the other end of the molecule, FH-19-20 bind C3b as well as polyanionic self-
surface markers. There is a plethora of high-resolution structural data for these 
regions. Conversely, the lack of binding sites for C3b or polyanions in FH-8-15 has 
resulted in less attention as only limited structural information is available for this 
region. Intriguingly, the data that do exist suggest these modules adopt a unique 
compact conformation (15, 43). Even the incomplete picture currently available is 
suggestive of a mechanism of how the N- and C-terminal binding sites might 
cooperate. There is a clear need to acquire more structural information with the aim 
of further elucidating the spatial organisation of the central modules of FH. 
Within FH, CCPs 10-15 are connected by the longest intermodular linking 
sequences. These allow for bends between modules that can thereby make more 
contacts with one another and form compact and potentially rigid structures as 
indicated by recent biophysical data (43). Previous attempts to crystallise FH-10-15 
(personal communication, Dr C. Q. Schmidt, University of Edinburgh) were 
unsuccessful. The only high-resolution structure available to date is that of CCP-
module pair FH-12-13 solved by NMR (43).  Interestingly, a rigid 80
o
 tilt or bend 
angle is formed between these two modules. This information was helpful, but 
inadequate, for the unambiguous interpretation of SAXS curves generated from 
samples of FH-10-15 and FH-8-15. 
In order to obtain additional high-resolution information on the modules that 
constitute the central region of FH, two module pairs, FH-10-11 and FH-11-12 (Fig. 
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4.1) were selected for solution structural determination using NMR. These 
recombinant protein fragments were judged to be suitable for NMR in terms of their 
yield of production, size (~13 kDa), solubility, homogeneity following purification 
and relative stability of the final samples. The aim was to determine their structures, 
then combine these, and the previously solved FH-12-13 structure, to generate 
models of FH-10-12 and FH-10-13. These could then be compared against SAXS 
data collected both on the module-pairs and on longer fragments (e.g. FH-10-12, 11-
14, 10-15 and 8-15) (SAXS data will be presented in Chapter 5). 
 
Figure 4.1 Representation of the 20 CCP modules that comprise FH.  The CCP modules for 
which high-resolution structures are available are coloured in light blue. The FH pairs 10-11 
and 11-12 of the central region that were subjected to structural studies in the current work are 
shown in pink. The structure of FH-12 was also solved by NMR in the context of FH-12-13 (43) 
(drawn using bolder outlines).   
 
4.1 NMR structures of FH-10-11 and FH-11-12  
 
For 3D structural studies by NMR of the two pairs, FH-10-11 and 11-12, 
triple-resonance techniques were required and hence double-labeled samples were 
produced. Pure samples were prepared as follows: 400, 150 and 500 μM FH-10-11 in 
20 mM potassium phosphate buffer, pH 6.7; and 650 μM FH-11-12 in 20 mM 
potassium phosphate buffer, pH 6.3. These samples were subjected to a standard 
suite of double- and triple- resonance NMR experiments as described in Materials 
and Methods.  







C nuclei.  Specifically, for FH-10-11 94 % of amide,  
97 % of backbone and 97 % of sidechain H nuclei were assigned (by the author). In 
the case of FH-11-12, 94 % of amide, 95 % of backbone and 96 % of sidechain H 
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HSQC spectra of FH-10-11 and FH-11-12. 




N-HSQC spectrum of FH-10-11. The sidechain NH resonances of Gln 
and Asn residues are connected by a horizontal line. Folded (negative or antiphase) cross peaks 
are shown in grey. 
 184 




N-HSQC spectrum for FH-11-12. See legend to Figure 4.2 for 
explanation.  
 
4.1.1 Structure calculations 
 
The figure below (Fig. 4.4) summarizes the basic steps followed en route to 












Figure 4.4 Summary of the most important steps followed in this study for the purpose of 
obtaining the two NMR-derived ensembles of FH-10-11 and FH-11-12.  
 
To determine the 3D structures by NMR, distance constraints are extracted 
from nuclear Overhauser effect spectroscopy (NOESY) spectra. These NOEs may be 
equated to upper-distance bounds for one (or more, if ambiguous) pairs of protons. A 
large number of pairs of interacting hydrogen nuclei must be identified to generate 
adequate sets of distance restraints. 
For the purpose of this study, the program CYANA (126) was utilized (see 
section 2.3.4.9.2 of Materials and Methods). Following the complete structure 
calculation, i.e. after seven CYANA cycles, the 20 lowest-energy structures were 
selected out of the 100 calculated in total, and their reliability was assessed according 
to several quality-control criteria (see Appendix section C1 for details). 
After the structure calculations in CYANA a total of 100 structures were 
calculated within CNS (130) for each of FH-10-11 and FH-11-12, and these were 
ranked according to overall and NOE energies (see Figs. 4.5 and 4.6). 
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Figure 4.5 Energy plots for the 100 structures calculated in the final CNS run for FH-10-11. 
Overall and NOE energy are shown for each structure. 
 
Figure 4.6 Energy plots for the 100 structures calculated in the final CNS run for FH-11-12. 
Overall and NOE energy are shown for each structure. 
 
In these plots, some 30-40 calculated structures lie to the left of the first 
inflection point, suggesting convergence. It was decided, however, that the 20 
lowest-energy structures in each case represented an adequate ensemble and all of 
these structures also met the criterion of having no NOE violations in excess of  
0.5 Å. These ensembles were then subjected to water refinement using the 
appropriate scripts in CNS. The resultant ensembles are presented in figures 4.7 and 
4.8. 
As may be been judged from RMSD values for the two ensembles (when 
superimposed on the backbone atoms), excellent structural convergence was 
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obtained at the level of individual modules. Moreover, the RMSD values of the 
module pairs are also relatively low, consistent with small variations in inter-modular 
orientation within each ensemble.  
 
Figure 4.7 Ensemble of NMR-derived structures for FH-10-11 after water refinement in CNS. 
Backbone overlays (and RMSDs referring to backbone atoms) of the 20 lowest-energy 
structures. A. Overlaid on module 10. B. Overlaid on module 11. C. Overlaid on both modules. 






Figure 4.8 Ensemble of NMR-derived structures for FH-11-12 after water refinement in CNS. 
Backbone overlays (and RMSDs referring to backbone atoms). A. Overlaid on module 11. B. 
Overlaid on module 12. C. Overlaid on both modules. The 0.8 Å RMSD indicates a good 
convergence and a small deviation in intermodular orientation. 
 
4.1.2 Description and characteristics of the structures  
 
The modules 10, 11 and 12, have structures that are typical of CCP modules. 
Each module contains two disulfide bonds that are formed in a Cys (I)-Cys (III), Cys 
(II)-Cys (IV) manner. In FH-11 and 12, the consensus Trp residue located between 
the third and the fourth Cys residue is buried in a small hydrophobic core. However 
in FH-10 this Trp is absent and a Leu residue lies in its place (Fig. 4.9). Like all 
CCPs, modules 10, 11 and 12 of FH have elongated, ovoid structures in which anti-
parallel β-strands are the predominant type of secondary structure (Figs. 4.10 and 
4.11). In addition, in both pairs there is a cis-Pro residue (
618
Pro in FH-10 and 
708
Pro 
in FH-12) (see also Materials and Methods section 2.3.4.7). 
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Figure 4.9 Semi-transparent surface representation of the two closest-to-mean structures in 
which the buried Trp and Leu residues are highlighted. (A) FH-10-11 in which 
616
Leu and the 




Figure 4.10 Representations of the secondary structural elements within the closest-to-mean 
member of the ensemble of NMR-derived FH-10-11 structures. (A) Visual illustration of the 
STRIDE (138) output in which the β-strands are shown labeled. The linker residues are 
underlined by a blue line. (B) Cartoon of the closest-to-mean structure in which the β-strands 
calculated using STRIDE are indicated. The strands are labeled according to the convention 
based on the occurrence of a maximum of eight strands (A-H) (144) in any given CCP. Disulfide 




Figure 4.11 Representations of the secondary structural elements within the closest-to-mean 
member of the ensemble of NMR-derived FH-11-12 structures.  See legend to Figure 4.10 
 
4.1.3 Identification of slowly exchanging amide protons 
 
Samples of both FH-10-11 and FH-11-12 were lyophilized, resuspended in 




N-HSQC experiments. Spectra 
were recorded in 15-min intervals.  
Exchange of N-H for N-D atoms results in a loss of cross-peaks in the HSQC 
spectrum, and occurs rapidly for solvent-exposed protons. On the other hand, N-H 
protons that are buried within the protein – and are therefore normally participants in 




















N-HSQC spectrum for FH-11-12, after 15-min exposure to D2O.   
 
In the case of FH-10-11, 24 cross-peaks persist in the HSQC spectrum, two 
from FH-10, none from the 10-11 linker region, and 22 from FH-11. The relevant 
slowly exchanging protons are highlighted on the structure of FH-10-11 in figure 
4.14. Of these 24 protons, 21 participate in the formation of hydrogen bonds, 18 of 




 (which lies 
immediately after FH-11 β-strand D) hydrogen bonds with the carbonyl of residue 
638




 is hydrogen-bonded to 






(which lies just after FH-11 β-
strand H) hydrogen-bonds with the carbonyl of 
662
Arg (which lies immediately prior 
to FH-11  β-strand E). Of the non-hydrogen bonded protons, the Hε of the consensus 
Trp residue in FH-11, 
678




 exhibits a weak signal that 





that does not appear to be within hydrogen-bonding distance of any acceptor atom 
yet does not exchange even after 60 min. Its amide in all 20 conformers of the 
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ensemble is not exposed, and points towards the interior of the structure, thus being 
rather inaccessible. 
It is interesting that only two residues retain their amide proton in FH-10 
whereas the remaining 22 slowly exchanging amides lie in FH-11. FH-10 appears to 
be more dynamic. This is despite the fact that this module has the most extensive 
formation of β-sheets (as detected by STRIDE). It must be concluded that modules 
10 and 11 have quite distinct dynamic properties even though they form a well-
defined inter-modular interface. The absence of the consensus Trp may contribute to 
the potential lack of rigidity in FH-10.  Note that the presence of FH-9 may enhance 
the stability of FH-10 in the context of full-length FH.  
In the case of FH-11-12, a total of 27 cross-peaks remain detectable after 15 
min of exposure to D2O. The relevant protons are highlighted on the structure of FH-
11-12 in figure 4.15. Of these, 17 belong to FH-11, one to the linker region and 9 to 
FH-12. Two of these correspond to the H
ε





Trp in FH-12) and 24 correspond to H-bonded backbone amide 













 of FH-12 lying just after β-strand G which 
forms a hydrogen bond with the carbonyl of 
732




(lying immediately after CCP 11 β-strand F), which hydrogen bonds with 






, which presumably hydrogen bonds with the 
carbonyl of 
674
Val although in the closest-to-mean structure it appears to not be 
positioned at an optimum geometry for this to take place. However, according to 










 is not within hydrogen bonding distance of any acceptor 
however it exhibits similar characteristics as described in the case of FH-10-11. 
The slowly exchanging protons of FH-11 in the two contexts (i. e. in FH-10-
11 and FH-11-12) largely coincide. A total of 17 amides - out of 22 slowly-
exchanging FH-11 amides in FH-10-11 and 18 slowly-exchanging FH-11 amides in 
FH-11-12- agree. This conservation of dynamics (on the time-scale probed by the 
observation of slowly-exchanging amides) observed between the two constructs is 




Figure 4.14 Representation of the closest-to-mean structure of FH-10-11 in which beta strands 
are shown, and residues that retained their amide H
N
 atom in the hydrogen-deuterium exchange 
experiment are highlighted in red. 
 
Figure 4.15 Representation of the closest-to-mean structure of FH-11-12 in which beta strands 
are shown, and residues that retained their amide H
N
 atom in the hydrogen-deuterium 
experiment are highlighted in green. 
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4.1.4 Assessment of the structures of FH-10-11 and FH-11-12 
 
PROCHECK assesses the stereochemical quality of a protein structure. 
Amongst other things, it allows evaluation of the extent to which the phi and psi 
angles occupy energetically favored regions in the Ramachandran plot (145). After 
refinement using explicit water, PROCHECK was utilized to analyse the 
experimentally derived structures of FH-10-11 and FH-11-12 (Figs 4.16 and 4.17). 
For FH-10-11, 80.5 % of residues are located in the most favored regions and 
16.4 % in the additionally allowed regions. For FH-11-12, 74.6 % lie in the most 
favored region while 22.4 % in the additionally allowed regions. Very few residues 
lie in the disallowed regions (1.8 % for FH-10-11 and 1.3 % for FH-11-12) and 
overall these values are comparable with those obtained for other published NMR-


















4.1.5 FH-10-11 and FH-11-12 form bent structures 
 
In FH-10-11, FH-10 is connected to FH-11 through a six-residue linker, 
where a linker is defined as the sequence of residues lying between Cys IV of the N-
terminal CCP and Cys I of the C-terminal CCP (in fact one of the linker residues lies 
within CCP 10 β-strand H and therefore could be considered part of FH-10). A ~118
o
 
tilt is present between the modules (according to the convention in which zero 
degrees corresponds to a fully extended, linear structure), a ~57
o
 twist and a ~89
o
 
skew. The linker between (the cysteines of) FH-11 and 12 is also six-residues long - 
with two residues actually forming part of FH-11 strand H -  and a ~90
o
 tilt angle 
occurs between these modules. The twist angle is ~72
o
 while the skew angle is ~57
o
 
(see also figure 4.18 and Appendix section C2). 
 
 
Figure 4.18 Schematic explanation of the intermodular angles tilt, twist and skew between CCP 
modules (Figure adapted from (150)). Tilt, twist and skew angles in degrees were determined 
using (for a reference x-axis) a vector between the principal axis of the inertia tensor (the z-axis) 
and the α-carbons of Leu616 in FH-10 and the conserved Trp678 in FH-11 or Trp738 in FH-12, 
respectively. Module boundaries were defined as CysI-CysIV (Cys569-Cys684 in the case of FH-
10-11 and Cys630-Cys744 in the case of FH-11-12). 
 
For calculations of surface areas buried between modules, module boundaries 
were defined as follows: one residue before Cys 
I
 and three residues after Cys 
IV
 for 









FH-11) and three amino acids before Cys 
I 
and one amino acid after Cys 
IV
 for the 








Val for FH-12). This 
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produced values of ~360 Å
2
 for FH-10-11 and ~ ~640 Å
2 
for FH-11-12. Thus (see 
Fig. 4.19) even though FH-10 and FH-11 have a greater tilt angle, significantly less 
surface area is buried compared to the FH-11-FH-12 interface. In the latter case an 
extended loop (between strands D and E) from FH-11 contacts the linker as well as 
residues from FH-12.  
 
Figure 4.19 Surface representations of the structures of FH-10-11 and FH-11-12. (A) Surface 
representation of FH-10-11 in two views rotated by 90
o
 about the x-axis. (B) Surface 
representation of FH-11-12 in two views rotated by 90
o
 about the x -axis.  
 
The table below (Table 4.1) summarizes the statistics for the 20 lowest-









 FH-10-11 FH-11-12 
Number of structures in 
ensemble 
20 20 
Numbers of upper-limit distance constraints 
Intraresidue, |i-j| <=1 
Medium range, 1< |i-j| < 5 
Long range, |i-j|>=5 
Total 
Intermodular 
Module i to linker 
























































Most favoured (%) 
Additionally allowed (%) 























of each CCP module 
b
 Closest-to-mean structures/ Calculated by breaking the bimodules at the midpoint of the linker 




4.1.6 Description of the intermodular interfaces  
 
As already mentioned, the linkers in the central region of FH (six residues 
between both FH-10 and 11, and between FH-11 and 12) are longer than average. 
Before the current study, various hypotheses had been suggested for the structural 
ramifications of these longer linkers. Intuitively it seemed likely, for example, that a 
long linker would allow flexibility or, in contrast, that a long linker would allow 
flanking CCPs to fold back against each other. 
The resulting structures interestingly revealed that both FH-10-11 and FH-11-
12 show defined, strongly bent conformations, as supported by a multitude of NOE 
cross-peaks allowing upper-distance restraints to be applied between modules and 
linkers or directly from one CCP to its neighbour. In the case of FH-10-11 there are 
eight intermodular NOEs, 62 NOEs from FH-10 to the linker and 65 NOEs from the 
linker to FH-11. For FH-11-12 there are 38 intermodular NOEs, 89 NOEs between 
FH-11 and the linker and 39 NOEs between the linker and FH-12. Thus far from 
introducing flexibility the longer linkers appear to rigidly associate the two CCPs 
that they connect. (Inter-modular flexibility will be discussed further in Chapter 5). 









Val from FH-10 (from β-strand E of CCP 10), and residues 
651
His (from the FH-11 B-D loop) and 
675
Asp (from the FH-11 F-G loop) are 
predominantly responsible for interacting with the linking sequence and also interact 
with each other. For example, NOEs were observed between atoms Hg2* of the side 
chain of 
602
Thr of FH-10 and Hb atoms of 
651
His of FH-11, and between 
627
Val Hb 
atom of the linker and 
651
His Hb atoms of FH-11.  The overall result is a defined 







(from the linker and part of strand H), and 
651
His bury their sidechains. The β- and ε-
methylenes of 
624
Lys (linker) also contribute to this core. None of these residues, 
however, exhibit any slowly exchanging amides. This further validates the interface.  








Ser, on the other hand, 
project on the outside of the inter-modular bend (see Figs. 4.21, 4.23) and are 




Lys, which is also the last residue of FH-10 β-strand H) and 
675
Asp of the 
F-G β-turn of FH-11 (Fig. 4.20).  
 
Figure 4.20 Ribbon representation of the lowest energy conformer of FH-10-11; K624 of the 
linker presumably forms a salt bridge with D675 of the F-G β-turn of FH-11 and these residues 
are highlighted.    
 




. The amide of 
685
Ile of β-strand H of the linker also exhibits slowly exchanging properties 
according to the H-D experiment. A notable feature of the FH-11-12 interface is the 
important role played by aromatic sidechains (Fig. 4.22). Side-chains of the D-E loop 






Leu) make extensive van der Waals 




Val, while polar portions 




















Figure 4.21 Stick and surface representation of the linking sequence for FH-10-11. Linker 
residues are labeled (in upper panel), and are shown by partial transparency in the context of 









Figure 4.22 Stick and surface representation of the linking sequence of FH-11-12. The 
corresponding residues are labeled when shown on their own on the stick representation and 















Figure 4.23 Representation of the two structures in which the residues that participate in the 
tight interfaces are represented as spheres and are labeled. (A) FH-10-11. Residues that belong 
to FH-10, the linker and FH-11 are shown in blue, beige and purple respectively. (B) FH-11-12. 
Residues from FH-11, the linker and FH-12 are shown in purple, light blue and grey 
respectively. 
 
Figures 4.24 and 4.25 show examples of 
13
C-NOESY data depicting long-
range intermodular NOEs that define the relative orientations of the modules for FH-




Figure 4.24 Example of intermodular NOEs for FH-10-11. (A) Representation of the structure 
in which three of the residues that participate in the tight interface, their sequence numbers and 
the atoms chosen for this demonstration are labeled. (B) 
13
C-NOESY strips of atoms of the 
interface as indicated on top of each strip. These atoms correspond to the root resonance. 
Horizontal and vertical lines show the connectivities between NOE cross-peaks that arise 






Figure 4.25 Example of intermodular NOEs for FH-11-12.  See legend to figure 4.24 for details. 
 
In conclusion, the smaller number of NOEs observed between FH-10 and 11 
(compared to FH-11 and 12) is entirely consistent with the difference in the number 
of residues participating in the intermodular interfaces (and surface areas buried).  
The nature of the residues involved also contributes to the number of NOEs 
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observed. The NOE-based structure calculations suggest that both module pairs 
converge equally well.  The large number of NOEs between modules and linker (for 
both pairs) is important in this respect. Overall, the network of over 100 NOEs 
contributing to the definition of intermodular orientations (in both pairs) supports the 
contention that these calculated structures are not over-restrained. Nonetheless, a 
reliance on NOEs alone might be unwise and hence further characterisation of these 
module pairs was carried out using SAXS (see Chapter 5) 
 
4.1.7 Description of the FH-10-11 and FH-11-12 electrostatic and 
hydrophilic/hydrophobic surfaces 
 
FH engages more efficiently with C3b bound to a self-surface when 
polyanions, such as GAGs are present, through the use of two binding sites that 
cooperate to recognize specific surface polyanions. The regions of FH primarily 
responsible for binding to polyanions are FH-6-8 and FH-19-20. Interactions with the 
multiple negatively charged groups of GAGs are probably favored by 
complementary electropositive surfaces on domains 6-8/19-20. Indeed, in a recent 
model of the FH:C3b complex, domains 6-8 and 19-20 are proximal to the 
hypothetical GAG-rich surface to which the target C3b would be tethered, and the 
central modules form a compact bent-back structure.  It is however unclear where 
these central modules would reside, relative to other parts of the complex, nor if, or 
how, they might interact with a GAG- or sialic acid -coated surface. Thus it is 
interesting to consider the electrostatic surface of the new bi-module structures. Note, 
however, that although FH-13 in the previously solved NMR structure (43) has a 
striking electropositive patch on one face, it does not appear to interact with heparin.  
Electrostatic analysis of the surfaces of the structures of FH-10-11 and FH-
11-12 suggest it is in fact unlikely that the FH-10-12 region would contribute to 
favorable interactions with a polyanionic surface. One face of FH-10-11 is mainly 
negatively charged while the other face of the molecule exhibits a dispersion of 









Lys) (see Fig. 4.26 B). Both faces of FH-
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11-12 are predominantly negatively charged due mainly to plentiful Glu residues 
(Fig. 4.26 C). 
 
 
Figure 4.26 GRASP (139) electrostatic representations of the two structures (two views rotated 
by 180
o 
about the x-axis). (A) Scale of electrostatic surface potential: Red = negative charge, blue 
= positive charge, range -5/+5 kT. (B) Representation of FH-10-11 in which charged residues are 
indicated on the surface. (C) Representation of FH-11-12 in which the residues responsible for 
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Figure 4.27 MOLCAD (140) lipophilic representation of the two CCP pairs (two views rotated 
by 180
o 
about the x-axis in each case). (A) Hydrophilic to Hydrophobic scale. Blue corresponds 
to the most hydrophilic while brown to the most lipophilic. (B) Hydrophilic-lipophilic surface 
features for FH-10-11. (C) Hydrophilic-lipophilic surface features for FH-11-12. 
 
According to the MOLCAD lipophilic surface representation of FH-10-11 
and FH-11-12 (Fig. 4.27), there appears to be no prominent lipophilic patches on the 
faces of the two module pairs.  
 
4.1.8 Overlay of FH-10-11 and FH-11-12 with other CCPs 
 
The closest-to-mean structures of FH-10, 11 and 12 were compared to a set of 
individual experimentally derived CCP structures from the complement system (see 
Appendix section C3 for summary of the extent of structural similarity of FH-10, 11 
and 12 with one another and with other solved CCP module structures). The 
comparison was based upon alpha-carbon RMSD values using the structural 
alignment program Combinatorial Extension (143). The FH-10 structure does not 
overlay particularly well with structures of other FH CCPs (backbone RMSD > 2 Å 
in all cases), while, amongst known structures it is most similar to CCP 3 of MCP 
with which it shares only 20 % identity (with the exception of an inserted proline-
rich loop following Cys-II in MCP the backbone overlay was 1.4 Å.) FH-11 and 12 
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on the other hand, are quite similar to one another (backbone RMSD ~1.6 Å) and 
overlay well with FH-18 and FH-19 (e.g. backbone RMSD is 1.1 Å for FH-11(-12) 
versus FH-19 which share 33 % sequence identity). FH-12 overlays very well with 
CR2 CCP2 (backbone RMSD is 1.4 Å and sequence identity is 44 %). FH-10, 11 and 
12 all belong to cluster “B” according to Soares et al. (144). Figures 4.28-4.30 shown 
below illustrate the best overlaying partners in each case.  
 
4.1.8.1 Overlay of FH-10 with CCP 3 of MCP 
 
 
Figure 4.28 Upper panel: Sequences of FH-10 and CCP 3 of MCP in which identical residues 
are highlighted and similar residues shaded in grey. Lower panel: structures in cartoon 
representations of the individual CCPs as well as an overlay of the two. Disulfide-bonded Cys 














Figure 4.29 Upper panel: Sequences of FH-11 and FH-19 in which identical residues are 
highlighted and similar residues shaded in grey. Lower panel: structures in cartoon 
representations of the individual CCPs as well as an overlay of the two. Disulfide-bonded Cys 





4.1.8.3 Overlay of FH-12 with CCP 2 of CR2 
 
 
Figure 4.30 Upper panel: Sequences of FH-12 and CCP 2 of CR2 in which identical residues are 
highlighted and similar residues shaded in grey. Lower panel: structures in cartoon 
representations of the individual CCPs as well as an overlay of the two.  Disulfide-bonded Cys 
residues within each CCP are shown with sticks. 
 
4.1.8.4 Overlay of FH-11a of FH-10-11 with FH-11b of FH-11-12 and FH-12a of 
FH-11-12 with FH-12b of FH-12-13 
 
The figures below (Figs. 4.31 and 4.32) show the backbone overlays of the closest-






Figure 4.31 Overlay of the closest-to-mean structures of FH-10-11 and FH-11-12 in ribbon 




Figure 4.32 Overlay of the closest-to-mean structures of FH-11-12 and FH-12-13 in ribbon 
representation. The linkers are shown in beige. 
 
FH-11 of FH-10-11 overlays well with FH-11 of FH-11-12, with an RMSD 
value of 0.8 Å (i.e. when both structures are superimposed on the mutual CCP 
module 11). Similarly, FH-12 of FH-11-12 overlays relatively well with FH-12 of 
FH-12-13 with an RMSD value of 1.1 Å.  
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These models – that assume non-neighbouring CCP modules have no influence on 
remote intermodular junctions - were validated against SAXS data (see below). 
 
4.2 Conclusions  
 
The central region of FH has remained, to date, little-explored territory in 
terms of structural biology, with the exception of a study combining the high-
resolution structure of FH-12-13 and SAXS of FH-11-14 and FH-10-15. This study 
however was unable to distinguish between two compact models of FH-10-15 (43). 
The current work describes new high-resolution structural information 
obtained on the central region of FH. Both module pairs are structurally similar to 
FH-12-13 (which has a tilt of ~80
o
), but different than FH-1-2 (which has a tilt of 
~23
o
 (39) FH-2-3 (tilt of ~15
o
 (39)) and FH-19-20 (~11
o
 (27)). 
Longer linkers were initially considered a likely source of flexibility in full-
length FH (43). With this in mind, it is worth mentioning that the structure of CCPs 
1-2 of complement receptor 2, which are connected through an eight-residue long 
linker, exhibited a side-by-side conformation (intermodular tilt angle ~142
o
) (151). 
Another example of a similar arrangement was observed for CCPs 2-3 of factor B, 
which are joined by a six-residue long linker (tilt ~189
o
) (152). Finally, the six-
residue linker that connects CCP 2 to CCP 3 of C2b (C2b is important for C4b 
binding in C3 convertase formation of the classical pathway) promotes a side-by-side 
arrangement (tilt ~218
o
) (153).  
Thus, based now on three examples, longer linkers can - in addition to 
promoting side-by-side structures and providing the potential for greater flexibility - 
result in specifically oriented structures (like the ones presented in this work). These 
could likely contribute to the biological diversity and specificity.  
The high-resolution structural information for FH-10-11 revealed the 
presence of a His (
651
His in module 11) sidechain in the miniature hydrophobic core 
at the interface between FH-10-11. Interestingly, FH-12-13 also has a His (
773
His in 
module 13) residue at an equivalent position in space, and in the sequence (Figs. 4.33 
and 4.34). In general the pKa for His sidechains is ~6; however in the cases of FH-
10-11 and FH-12-13 this was not measured. Additional similarities in these two 
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interfaces were observed. In particular, the His residues of FH-11 and 13 are closely 




Thr) from FH-10, or FH-12, respectively. 
Moreover 
627
Val from the linker in FH-10-11 and 
747
Ile from the linker in FH-12-13 
make similar contributions to their respective interfaces.  Finally, in the NMR-
derived structure of FH-15-16 a His (
878
His, although in this case it is located on the 
other end of the double-module structure compared to FH-10-11 and FH-12-13) 
residue is also buried in an interface that involves hydrophobic residues (Figs. 4.33 
and 4.34). 
With these interfacial His residues in mind, it may be significant that a low-
resolution structural study, focusing on the conformational and oligomerization 
properties of FH, showed that these are NaCl concentration and pH-dependent. For 
example, it was shown that at low pH, 5.4, FH exists mostly in a compact 
conformation. FH became more elongated at pH 9.4 (52). It is possible, therefore, 
that change in the protonation state of the aforementioned His residues (
651
His in 
module 11 and 
773
His in module 13, located at critical positions between modules) - 
from positively charged, polar and hydrophilic below its pKa to neutral and 
hydrophobic above its pKa - could affect intermodular orientations and hence the 
overall architecture of the whole of the central region. 
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Figure 4.33 Cartoon representation of the structures of (A) FH-10-11, (B) FH-12-13 and (C) FH-
15-16. In (A) and (B) the three residues predominantly responsible for the similarity of the 
interfaces of FH-10-11 and FH-12-13 are shown in sticks and are color-coded. The His residues 
that occupy an equivalent position in their corresponding module pair are highlighted. In (C) 





Figure 4.34 Multiple sequence alignment of the 20 CCPs that compose FH. Red boxes highlight 
the CCP modules and their corresponding His residues that are involved in the interfaces of FH-
10-11, FH-12-13 and FH-15-16 (figure modified from (38)). 
 
The new structures determined in this study allow for reinterpretation of the 
SAXS data for FH-10-15 and help distinguish between the two-currently existing-
models (see also Fig. 4.30). SAXS data as well as the resultant modelling for the 
central region of FH will be presented in the next chapter, Chapter 5, while a 
hypothesis of how this region is important for the biological action of FH will be 















Small-angle X-ray scattering-based studies of the central 






























The central region of FH is emerging as an architecturally critical element of 
the protein that is essential for its full biological activity. A previous study (43) 
which combined the NMR-derived structure of FH-12-13 with interpretation of 
SAXS data collected on longer segments of FH showed that FH-10-15 adopts a 
compact arrangement.  Since there was no evidence for co-existence with the more 
extended conformational possibilities that are typical of other multiple-CCP module 
segments, this compact conformation appears to be stable and could be rigid. It is 
noteworthy that within this region FH-12-13 proved to be inflexible as judged by 
both NMR and SAXS (43).  
This study was, however, unable to distinguish between two different 
compact structural models for FH-10-15 ((43), Fig. 5.1)). In particular it did not 
reveal the tilt angles between other module pairs (besides FH-12-13) and only hinted 
at the existence of pairs with high tilt angles in which modules are folded back 
alongside their neighbours. Were such arrangements to exist they could have 
profound albeit indirect effects on those functions of FH that require collaboration 
between its N- and C-terminal ends. The newly determined solution structures of FH-
10-11 and FH-11-12 provided an opportunity for further efforts to combine NMR 




Figure 5.1 Previous models of FH-10-15 inferred from SAXS and the solution structure of FH-
12-13. (A) Overlay of the two most typical BUNCH-derived models of FH-10-15 with the 
DAMMIF-derived ab initio shape envelopes (I and II). (B) The two most typical BUNCH-
derived models of FH-10-15 (I and II). The cartoons are colour coded as follows: FH-10, green; 
FH-11, cyan; FH-12, red; FH-13, blue; FH-14, yellow and FH-15, pink. Orange spheres 
represent linker residues (Figure and legend adapted from (43)). 
 
          Initially SAXS data were used to validate the NMR-derived structures of FH-
10-11 and FH-11-12 presented in Chapter 4. Subsequently SAXS was used to 
confirm the lack of flexibility within these pairs that had been inferred from the 
relaxation data. Finally the high-resolution structures derived from NMR (along with 
SAXS data collected on FH-8-9) were used to help interpret SAXS data collected on 
FH-10-15 and FH-8-15.  
 Taken together with the difficulties that had been encountered in producing 
samples of FH-13-14 and FH-14-15, these studies were interpreted in terms of a 
highly compacted structure for FH-12-15 and a dependence of FH-14 on its 
neighbours for stability. 
 
5.1 Introduction to SAXS 
 
SAXS is a technique for structural analysis performed in solution. In a typical 
SAXS experiment, the sample is exposed to a collimated monochromatic X-ray 
beam. The scattered intensity I is recorded as a function of the scattering vector 
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s=4πsinθ/λ where 2θ is the angle between the incident and the scattered beam (Fig. 
5.2). The scattering from the solvent is measured separately and then subtracted to 
give the data of interest. This background-corrected intensity I(s) is proportional to 
the scattering of a particle averaged over all orientations. Several 1-D curves can be 
extracted from the I(s) information, from which important parameters can be 
obtained related to the molecule’s size, oligomeric state and overall shape. These 
parameters include the molecular mass (MM), radius of gyration (Rg), hydrated 
particle volume (Vp), and maximum particle diameter (Dmax) (154). 
          From the scattering patterns, ab initio shape reconstruction, validation of high-
resolution structural data, rigid-body modeling of larger complexes using known 




Figure 5.2 Representation of the scattering experiment; k0 corresponds to the incident wave 
vector, k1 to the final wave vector and 2θ to the so-called scattering angle (the angle between the 
incident and the scattered beam) (figure from Dr H. D. T. Mertens). 
 
5.2 SAXS-derived parameters for FH-8-9, 10-11, 11-12, 10-12 and 8-15 
 
Analysis of parameters extracted from scattering profiles and real-space 
distance distribution functions, p(r), revealed monomeric proteins under conditions 
used for data collection (Table 5.1).  
          Bi-modules FH-8-9 and FH-10-11 yielded similar Rg values of ~2.2 nm, and 
Dmax values of ~7.5 nm, while FH-11-12 appears to be, overall, more extended with 
 224 
Rg and Dmax of 2.4 nm and 8.3 nm respectively (Table 5.1). The positively skewed 
p(r) functions of both bi-modules (Fig. 5.3) are characteristic of two-domain 
“dumbbell” shaped structures, with the first maximum representing a common 
average intra-module distance of ~1.7 nm and the second maximum representing an 
approximate average separation of the centers of mass of the modules, ~3.5 nm for 
FH-8-9 and ~3.8 nm for both FH-10-11 and FH-11-12 (Fig. 5.3). Thus intra-modular 






































3.5 ± 0.1 3.7 ± 0.1 12.5 ± 0.5 92 ± 10 62 ± 5 93 ± 10 47 ± 5 
 




 are the radius of gyration estimated from 
the SAXS data using the automated Guinier analysis routine and GNOM, respectively.  Dmax, Vp, 
VDAM, MMSAXS and MMDAM are the maximum particle dimension, hydrated particle volume, 
dummy-atom model total excluded volume, molecular-mass estimated from I(0), and molecular-
mass estimated from the dummy-atom model volume, respectively. Data shown is that averaged, 
or merged and extrapolated to infinite dilution, using the SAXS profiles recorded at several 





Figure 5.3 SAXS data for FH constructs. Pairwise interatomic distance distributions, p(r) for the 
FH constructs; FH-8-9 (red), FH-10-11 (light blue), FH-11-12 (dark blue), FH-10-12 (orange) 
and FH-8-15 (green). 
 
5.3 Validation by SAXS of the NMR-derived structures of FH-10-11, FH-11-
12 and of the NMR-derived, concatenated, FH-10-12 model 
 
The NMR structures calculated were fit to the experimental SAXS data using 
the program CRYSOL (155). All 20 individual NMR conformers of the FH-10-11 
ensemble provide a good fit to the scattering data with χ values between the data and 
the model of 1.3 < χ
 
< 1.6 (Fig. 5.4).  
 
 
Figure 5.4 Fit of the best NMR conformer of FH-10-11 (solid lines) and best DAMMIF model 
(broken lines) to the FH-10-11 data (circles) (circles highlight the slight deviation on the curves 
observed form the fitting to the SAXS data). 
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The individual NMR conformers in the FH-11-12 ensemble, provide a less 
good but still acceptable fit with χ values between the data and the model of 1.6 < χ< 
2.2 (Fig. 5.5).  
 
Figure 5.5 Fit of the best NMR conformer of FH-11-12 (solid lines) and best DAMMIF model 
(broken lines) to the FH-11-12 data (circles) (circles highlight the slight deviation on the curves 
observed form the fitting to the SAXS data). 
 
 In an ab initio approach, the average structures of both FH bi-modules were 
reconstructed from SAXS data using the bead-modeling program DAMMIF (156). 
Ten independent reconstructions were performed for each pair, and within each set 
highly similar shapes were obtained as measured by low (<1.0) normalized spatial 
discrepancies (NSD) (157). The discrepancies between the generated models and the 
experimental data were good (0.9 < χ
 
< 1.2) in both cases (Figs. 5.4 and 5.5). The 
total excluded dummy atom volume of the model was consistent (in each case) with 
what was expected, yielding comparable estimations of MM (Table 5.1). The 
average ab initio shapes were superimposed with the corresponding NMR ensembles 
of FH-10-11 and FH-11-12 using the program SUPCOMB (157), and good spatial 




Figure 5.6 Overlay of the NMR ensembles of (A) FH-10-11 and (B) FH-11-12 with the most 
representative ab initio DAMMIF models, superimposed using the program SUPCOMB. Models 
FH-10-11 and FH-11-12 are colored light blue and dark blue respectively and ab initio shape 
envelopes are shown as mesh surfaces (two views are shown for each following 90
o
 rotation 
about the x axis).  
 
 A model of the FH-10-12 structure was derived by concatenating the average 
structures of FH-10-11 and FH-11-12 thus generating a simple model for the tri-
module FH-10-12, using the very similar independent structures of module 11 as an 
alignment template (in MODELLER). This model was then validated by fitting it to 
the SAXS data for FH-10-12 using CRYSOL (155) and provided an excellent fit  




Figure 5.7 Fit of the concatenated NMR model for FH-10-12 (solid lines) and best DAMMIF 
model (broken lines) to the FH-10-12 data (circles).    
 
 In a separate ab initio approach similar to that described above for the bi-
modules, the average solution structure of FH-10-12 was reconstructed from SAXS 
data using DAMMIF (156). As with the bi-modules, normalized spatial discrepancies 
were low ((NSD) =0.73 ± 0.12) and discrepancies between models and experimental 
data were low (χ =0.88 ± 0.01) (Fig. 5.7), while the total excluded dummy atom 
volume of the model was consistent with the MM (Table 5.1). Moreover the average 
ab initio shape superimposed well with the concatenated NMR model of FH-10-12 
(SUPCOMB, (157)) (Fig. 5.8).  
 229 
 
 Figure 5.8 Overlay of the concatenated NMR model of FH-10-12 with the most representative 
ab initio DAMMIF model, superimposed using the program SUPCOMB. The FH-10-12 model is 
shown in orange while the ab initio shape envelope is shown as mesh surface (two views are 
shown for each following 90
o
 rotation about the x axis).  
  
Studies of tri-molecular FH-10-12 showed that addition to FH-10-11 of 
module 12 or, from another perspective, addition to FH-11-12 of module 10, yielded 
only modest 0.1-0.3 nm increases in Rg and 0.8-1.2 nm increases in Dmax (Table 5.1). 
Thus these three modules must form a non-linear structure.  
 




N spin-lattice (T1), 
15





NOEs were performed on both FH-10-11 and FH-11-12. Briefly, motions in the 
range of μs-ms can be investigated by T1 and T2 values while the latter are sensitive 
to fast motions. Motions in the nanosecond time scale can be probed by the 
heteronuclear NOE. Regions in the protein with flexible properties have small (<0.7) 
NOEs and larger than average T1 and T2 values. A T1/T2 ratio that exceeds the 
average by more than one standard deviation probably reflects a contribution to the 
line width by conformational exchange (158). 
          The corresponding values obtained after processing for each experiment were 
plotted against residue number. Peaks corresponding to prolines, residues that were 
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located in overlapped regions in the spectra and those that exhibited weak signals 
were not included in the analysis. The amide for residue 
675
Asp could not be 
identified in any of the two constructs thus was also excluded from the analysis. The 








Figures 5.9 (A) and (B) 
15
N Relaxation data for FH 10-11 and FH 11-12.  Plots of the measured 
15
N spin-lattice (T1) and 
15





values, plotted versus residue number. In each plot, the mean (shown in blue lines), +/- one 
standard deviation is indicated (shown in red and green lines respectively), calculated on the 
basis of residues with heteronuclear NOEs of 0.6 or above (159). Beta-strands and the position 
of the linker are shown by the labeled, shaded boxes. Inverted triangles on the x-axis indicate 
proline positions, star shapes denote residues that were excluded from the analysis due to 
overlap or low signal while a star shown in cyan marks the amide (
675
Asp) that was not found in 
the HSQC. 
  
For FH-10-11, mean values of T1, T2 and heteronuclear NOEs are similar in 
both modules (mean T1 values of 777 ms and 760 ms for FH-10 and FH-11 
respectively, mean T2 values of 87 ms and 85 ms for FH-10 and FH-11 respectively 
and mean HetNOE values of 0.69 and 0.68 for FH-10 and FH-11 respectively). 
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These equal T1 and T2 averages are consistent with the notion that these modules do 
not move independently of one another but behave as a single fused entity. A similar 
observation was made in the case of FH-11-12 (mean T1 values of 735 ms and 732 
ms for FH-11 and FH-12 respectively, mean T2 values of 74 ms and 77 ms for FH-11 
and FH-12 respectively and a mean HetNOE value of 0.72 for both). 
Notably, the linker regions are not particularly mobile (compared to other 
regions of the module pairs) on the timescales probed by relaxation measurements. 
Although the FH-11-12 linker includes two residues with lower than average NOEs, 
T1 and T2  values are unexceptional and other residues have average NOEs. In the FH-
10-11 linker, one residue (Gln
626
) has a low T2,  but this is in the middle of the six-
residue linking sequence with its backbone in an exposed position (on the convex 
surface of the tilted modules) so it could be in conformational exchange 
independently of the rest of the linker.  




N NOE values reveal ns-timescale mobility in 
the A-B and G-H loops as well as in the region between strands B and D that 
includes the short strand C. T1 and T2 values are unexceptional so there is little 
evidence for conformational exchange in FH-10 (this is despite the earlier 
observation that this module has very few slowly exchanging protons). The B-C loop 
also appears mobile (low HetNOEs) and residues within this loop belong to a small 
electropositive patch on one face of FH-10 (Fig. 5.10). The N-terminal region of FH-
11 is more mobile (low hetNOEs, some high T1 and T2 values) in the FH-11-12 
context (than in FH-10-11) as expected given the absence of module 10.  
          Interestingly, the B-D loop of FH-11 (within FH-10-11, lacking strand C) 
exhibits numerous residues with low T2 values as well as two residues with very low 
heteronuclear NOEs. A similar pattern is observed in FH-11 within the FH-11-12 
context, except that there are a significantly greater number of low heteronuclear 
NOEs. This is a mobile feature of module 11 in both pairs but it is stabilised to some 
extent in FH-10-11, presumably due to its participation in the interface with module 
10. Likewise, in FH-12 there are several consecutive residues just prior to strand D 
with higher than average heteronuclear NOEs, which is again consistent with 
rigidification due to the compact interface with the preceding module. These are in 
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contrast to FH-12 strand B and its following residues that have the highest T2 values 
in the protein and (for a strand) low heteronuclear NOEs.  
          In summary, several strands of evidence – similar average relaxation 
parameters on a per module basis, the rigidifying of loops close to intermodular 
interfaces, and the low levels of overall mobility in the linkers – reinforce inferences 
from structure calculations and from SAXS-based EOM analysis (see below), that 
both module pairs are overall rigid structures with little flexibility between modules.  
 
 
Figure 5.10 Ribbon representation of the closest-to-mean structure of FH-10-11 showing the 
region in module 10 that appears mobile on the timescales probed by NMR and that also forms 
a miniature electropositive patch. The corresponding residues are shown as sticks as indicated.  
 
5.5 Flexibility analysis of FH-10-12 using the SAXS Ensemble Optimization 
Method (EOM) 
 
The flexibility of construct FH-10-12 was studied by the SAXS-based EOM 
method which can assess the degree of compactness or extendedness. This method 
selects an ensemble of possible conformations from a pool of randomly generated 
models (10,000), using CRYSOL to calculate the theoretical scattering profiles and a 
genetic algorithm, GAJOE to select the representative set (160). In this way the 
solution behaviour of the sample relative to the random pool may be described. 
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When a selected ensemble shows a size-distribution profile as broad as that of the 
random pool it may be considered flexible while a narrower profile is indicative of a 
relatively rigid system.  
          For studying the flexibility of FH-10-12 the random pool of conformers was 
initially generated from FH modules 10, 11 and 12 with all linkers defined as 
flexible. The selected ensemble from the resultant size-distribution was less broad 
than that of the random pool and was skewed toward compact structures (Fig. 5.11 
A). This suggests that the tri-module is not significantly flexible or extended in 
solution. In a subsequent calculation the FH-11-12 structure was treated as a rigid 
body while the FH-10-11 linker was allowed to be flexible. The Rg distribution from 
that calculation was narrow suggesting that the FH-10-11 linker is not significantly 
flexible in the FH-10-12 context (Fig. 5.11 C). When the orientations of FH-11-12 
CCP modules are fixed, mainly compact 10-11 linker orientations (as also observed 




Figure 5.11 EOM analysis of FH-10-12. A vertical line indicates the experimentally determined 
Rg. Yellow dashed curves show the pools of randomly generated models, while solid curves the 
selected representative ensembles from within the pools. (A) All linkers were defined as flexible. 
(B) FH-10-11 defined as a rigid body while the FH-11-12 linker as flexible. (C) FH-11-12 defined 
as a rigid body while the FH-10-11 linker as flexible. 
 
5.6 Modelling of FH-11-14 and FH-10-15 based on SAXS and NMR-derived 
structures 
 
SAXS-based rigid body modelling was conducted for the larger FH 
constructs using merged models of the known NMR structures of FH-10-11, 11-12 
and 12-13 (Fig. 5.12) the SAXS-derived data and the programs BUNCH and 
 235 
CORAL (161), (162). This enabled us to optimise the spatial distribution of the CCPs 
in the corresponding SAXS envelopes and was performed specifically for domains 
11-14, 10-15 and 8-15.  
The NMR-derived model of FH-10-13 shown below (Fig. 5.12) demonstrates 
how the curvature of FH-10-11 does not follow the arc described by FH-11-13 
resulting in an out-of-plane zigzag structure.  
 
 
Figure 5.12 Cartoon representation of the NMR-derived concatenated model for FH-10-13. Two 
views are shown following 90
o
 rotation about the x-axis. The linkers are shown in beige.   
 
For the FH-11-14 region, the NMR-derived concatenated model of FH-11-13 
was used in the modelling. The resultant model was in good agreement with previous 
findings (43) (Fig. 5.13). In this model FH-11-13 adopt a C-shaped orientation which 
is followed by an unusual and extreme tilt of the linker between FH-13 and FH-14 
which in turn drives the orientation of FH-14. 
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Figure 5.13 Modelling of the FH-11-14 region. Representation of the FH molecule: each CCP is 
shown as an oval; the FH-1-4 and 19-20 regulatory domains are shown in orange and green 
respectively. The NMR-derived FH-11-13 domain is shown in light blue and was used for the 
SAXS-derived modelling of the FH-11-14 region. FH-14 is shown in yellow (grey corresponds to 
dummy residues at the C-terminus of FH-14). The surface representation of the spatially 
optimized arrangement of FH-11-14 following modelling is shown colour-coded as already 
mentioned followed by a simplified version using oval shapes for each CCP module.  
 
          For SAXS-based modelling of the FH-10-15 region, the NMR-derived model 
of FH-10-13 was utilized. The model providing the best results (Fig. 5.14) was 
consistent with model I of the two possible previously determined, thus enabling 
distinction between the two (Fig. 5.15). In this model FH-10, 11, 12 and 13 follow a 
more open zigzag path with 90
o
 tilts. The extreme tilt between FH-13 and FH-14 
results in a more compact globular “13-15” end as FH-14 and 15 appear to wrap 











Figure 5.14 Modelling of the FH-10-15 region using the NMR-derived FH-10-13 model.  See also 
figure 5.13 for explanation of the (similar) representations viewed. In this case the NMR-derived 





Figure 5.15 Modelling of the FH-10-15 region using the NMR-derived concatenated model for 
FH 10-13. (A) The two possible models of FH-10-15 as previously determined (43). (B) Model I 
from (A) was chosen as the representative based on the NMR structures of FH-10-11, 11-12 and 
12-13.  Representation of the SAXS-derived envelope (from model I) shown in spheres and the 
modelled CCPs within showed as cartoons as indicated on the figure. Note that in the newest 
model the positioning of the CCP modules within the envelope is the other way around 
compared to the initial model. The experimentally determined linkers from the NMR-derived 
FH-10-13 model are shown in beige whereas light-orange spheres represent linker residues 
modelled as a chain of dummy atoms. Two views are shown following 90
o
 rotation about the x-
axis. Finally the FH-10-15 modelled region is shown in cartoon representation without the SAXS 
envelope (CCPs are labeled as indicated).  
 
5.7 SAXS data of FH-8-15 and flexibility analysis using the SAXS Ensemble 
Optimization Method (EOM) 
  
The eight-module FH-8-15 construct yields SAXS parameters that are not 
compatible with a highly extended structure; its Rg and Dmax values of 3.5 and  
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12.5 nm respectively are consistent with previous SAXS-based experiments (15), 
(43) (Table 5.1, Fig. 5.16). This reinforces the conclusion that the FH central 
modules contribute to a relatively compact structure core. 
 
 
Figure 5.16 Fits of the best CORAL rigid body models of FH-8-15 with all linkers between CCP 
modules free (solid line) or with FH-10-13 fixed (dotted line) and the best DAMMIF model 
(broken line) to the FH-8-15 data. 
 
The EOM analysis of FH-8-15 was conducted either with all linkers between 
modules defined as flexible, or with all linkers excluding 10-11, 11-12, 12-13 (43) 
treated as flexible. In the first case the resulting size-distribution of the selected 
ensemble is narrower than the random pool and skewed toward compact structures 
suggesting that this construct has limited flexibility (Fig. 5.17 A).  In the second case 
however, a predominantly two-state system resulted. Significant populations of 
extended and more compact linker conformations are required in order to fit the 




Figure 5.17 EOM analysis of FH-8-15. Green dashed curves show the pools of randomly 
generated models while solid lines the selected representative ensemble from within the pools. 
(A) All linkers defined as flexible. (B) FH-10-13 is defined as a rigid body while the FH-8-9, 13-




Both NMR-derived structures of FH-10-11 and FH-11-12 were validated by 
SAXS, since good fits were observed in both cases. The FH-10-12 model obtained 
by concatenating the closest-to-average structures of the two overlapping bi-modules 
provided an excellent fit to the SAXS data. The two-domain “V-shaped” orientations 
exhibited by both the NMR-derived FH-10-11 and FH-11-12 were further supported 
by the SAXS-derived parameters from real-space distribution functions p(r). All in 
all it appears that FH-10-12 forms a rigid and not highly elongated structure. 
          EOM-based flexibility analysis of FH-10-12, using three approaches whereby 
either one or both linkers were defined as flexible, supported the inference that the 
10-12 region forms a rather rigid system. This is in agreement with NMR-derived 
relaxation analysis conducted on the two pairs; no signs of inter-domain flexibility 
were observed on the time-scales probed by NMR. 
           The combination of the NMR structures of FH-10-11, 11-12 and the 
previously solved and SAXS-validated 12-13 resulted in models which were 
subsequently used for the SAXS rigid-body based modeling of the larger 11-14, 10-
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15 and 8-15 regions. Specifically, modeling of the SAXS data of FH-11-14 using the 
11-13 NMR model was in agreement with previous findings (43).  
          There were two possible models existing to date for the FH-10-15 region, from 
which model I was selected as the more realistic one following modeling using the 
NMR-derived 10-13 model. In this model one end is clearly more compact than the 
other (i.e. 10-11 vs. 14-15, figure 5.15. B), however up to now it was unclear which 
end was which. Since the NMR data for the “10-12” end are not suggestive of such a 
compact arrangement on that part of the molecule this clearly leaves the possibility 
that the “13-15” end is the one in which modules are tightly associated. In this 
optimized conformation of this region FH-10-13 adopts a relatively open 
arrangement followed by a much more compact conformation of FH-14 and 15, 
which actually wrap around FH-13; ultimately the three modules form a highly 
compacted supermodule.  
          Furthermore, EOM analysis of the FH-8-15 region using the “10-13 fixed” 
approach, (i.e. wherein all linkers excluding 10-11, 11-12 and 12-13 are treated as 
flexible), resulted in a predominantly two-state system. Since FH-10-15 appears 
compact and lacks flexibility this result would imply that FH-8-9 acts as a flexible 
end to the 8-15 region. What is more, the SAXS-derived parameters of FH-8-9 
(Table 5.1) (indicative of a standard bi-module dumbbell shaped structure) reinforce 
the resultant unusual orientation of the FH-13-15 end in the central region of FH. For 
















SPR-based functional studies of the interaction of FH with 



























Successful pathogens must possess means of evading attack by the 
complement system (67). Some have evolved strategies to exploit the complement-
regulatory abilities of host proteins (67).  Many of these sequester or capture FH 
(69), that presumably then acts to prevent C3b amplification on the microbial 
surface. One such pathogen is S. pneumoniae (69). One of the ways by which it 
presumably escapes complement-mediated destruction is by expressing the gene for 
PspC, a surface-exposed protein and virulence factor that binds to FH (70), (84), 
(85).  
Previous studies showed that the N-terminal region of PspC denoted PspCN 
is required for FH binding (88). In addition, an ITC measurement of the binding of 
full-length human FH (purified from plasma) to a 104-residues polypeptide 
representing the PspCN region yielded a KD < 1 nM (88). Inconsistent data have been 
reported in the literature regarding which regions of the large (20-CCP) FH molecule 
are responsible for binding to PspC. In various studies, binding to one or more of 
several regions, including 6-10, 13-15, 8-11 & 19-20, have been reported (87), (90), 
(91). 
It may be that microorganisms simply capture FH via its central or C-terminal 
modules such that FH modules 1-4 are able to engage with C3b and prevent it 
reaching the surface. Alternatively, or additionally, it could be that FH is held in such 
a way as to emulate its presumed conformation on a self-surface that – according to 
some hypotheses – renders it tenfold more potent. To investigate this issue, and 
thereby also potentially shed light on the mechanism of this key complement 
regulator, it was decided in the current work to pinpoint the regions of FH 
responsible for binding to the recombinant proteins PspCN (and also of PspCNR1-
the N-terminal region of PspC, i. e. PspCN, but extended to the first of the two R 
repeats, see also figure 6.1-C). A further aim was to investigate the potential 
interaction of the complexes – both FH-PspCN and FH-PspCNR1 - with various 
(activated and inactivated) fragments of C3.   
For these purposes, it was decided to perform surface plasmon resonance 
(SPR). The proteins used in the current work, were either recombinantly produced, or 
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Figure 6.1 Summary of proteins employed in the current study of interactions between 
(fragments of): PspC, FH and C3. (A) Representation of full-length FH and the constructs used. 
Each oval represents a CCP module. Full-length FH is shown in blue and the FH segments 8-15, 
10-15, 6-8Y, 10-11, 8-9 and 19-20 are shown in various colours. (B), (C) Representations of PspC 
in which the N-terminal region, the R1 and R2 repeats, the Proline-rich region (P) and the 
Choline-binding domain (CBD) are highlighted, and the various tagged and fusion versions 
listed (see text); (B) The fragments of the N-terminal region, designated PspCN, (C) The 
fragments designated PspCNR1. (D) Representation of the C3 fragments used for the current 
study; C3b, C3c and C3d. 
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For the binding studies of complement proteins with PspC fragments, three 
sets of SPR experiments were performed. In each experiment different versions of 
PspCN/PspCNR1 were used (see Fig. 6.1-B, -C), these being: His-tagged  PspCN-
GSGC (i.e. with the His tag at the N-terminus and a C-terminal artefact, GSGC, that 
was present for reasons described in Chapter 3 section 3.3), His-tagged PspCN (with 
no C-terminal artefact), a fusion of PspCN with N-terminal His-tagged SUMO (i.e. 
His-tag SUMO-PspCN), native PspCN obtained after cleavage of the N-terminal 
SUMO fusion partner, His-tag SUMO-PspCNR1, and finally native PspCNR1 
obtained from cleavage of SUMO-PspCNR1. SUMO fusion proteins were  produced 
by utilizing the pE-SUMOPro Kan vector (which is associated with higher yields and 
solubility) (107). 
 
6.1 Binding of FH and FH fragments to His-tag PspCN-GSGC 
 
This experiment was performed primarily to further map the FH regions 
responsible for binding to PspCN. In addition, it served to demonstrate data quality 
and reproducibility when the nitrilotriacetic acid (NTA) sensor chip was employed 
i.e. when immobilisation depended on the binding of the His sequence at the N-
terminus of the PspCN –GSGC- fragment to an NTA-chelated Ni
2+
 atom on the chip. 
The affinity of the His-tag:Ni
2+
 interaction, i.e. KD = 1 μM, was deemed adequate for 
most studies while this approach has the advantage over amine coupling that the His-
protein molecules are immobilised in a uniform way (163).  Values of KD between 
FH constructs and immobilised PspCN-GSGC were not determined in this 
exploratory experiment, but the levels of response obtained (which correlate with the 
mass of analyte bound to the sensor chip surface) allowed a semi-quantitative 
comparison. 
Thus, the NTA chip was charged with Ni
2+ 
(see Section 2.5.1), then  
~400 RUs of His-tagged PspCN-GSGC were immobilized, and the analytes (FH 
fragments) were flowed over the loaded chip surface. It should be noted that no 
successful regeneration conditions could be identified, therefore, after each cycle of 
charging - immobilizing – and analyte injection, the chip surface was stripped with 
sequential washes of EDTA, NaOH and SDS (see section 2.5.2). 
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In an initial experiment, all FH samples were injected in duplicate at 
concentrations of 0.5 μM. A good negative control would probably have been a 
recombinant version of FH-1-4 since there are no reports that this region interacts 
with PspC. The version however of FH-1-4 available in the lab had a C-terminal His-
tag and was thus unsuitable. Figure 6.2 shows the sensorgram obtained for this 
experiment. 
 
Figure 6.2 Surface plasmon resonance experiments to identify the PspCN binding regions of FH. 
Colour-coded background-subtracted duplicate traces are shown, see text for details. The parts 
of each trace corresponding to the charging of the NTA chip with Ni
2+
 as well as the 
immobilization levels of PspCN are also indicated on the figure. 
 
The sensorgrams (Fig. 6.2) show that despite the need to strip the chip after 
each cycle of charging, immobilization and injection, reproducibility is excellent. 
Full-length FH shows a rapid association rate (kon) followed by an extremely slow, 
practically undetectable, dissociation rate (koff); this is indicative of a strong 
interaction with the PspCN. A similar observation was made for FH-8-15 although in 
this case dissociation appears slightly faster. On the other hand, FH-10-15 and FH-
10-11 had much lower affinity (no detectable response at 0.5 μM) while FH-19-20 
appeared to bind with low affinity (low response, fast off-rate). In summary, both 
full-length FH and FH-8-15 bind strongly to PspCN while, interestingly, negligible 
affinity exists for FH-10-15 and 10-11. These results clearly imply that FH-8-9 (i.e. 
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the difference between 10-15 and 8-15) is critical for binding to the bacterial protein 
fragment. As far as the weak interaction observed for FH-19-20 is concerned, this 
required further investigation. 
 
6.2 Binding of FH fragments to His-tag PspCN 
  
The previous experiment suggested that modules 8-9 of FH are critical in 
mediating the interaction with PspCN. In order to test this hypothesis further, the 
construct His-tagged PspCN, lacking the non-native C-terminal “GSGC” artefact, 
was used. In this experiment, FH-8-9 and FH-6-8Y were added to the list of FH 
segments to be tested while full-length FH and FH-8-15 were omitted. PspCN was 
once again immobilized through its N-terminal His-tag on the NTA sensor chip and 
the chip stripped between cycles as before. Once again, FH samples were injected in 
duplicate at 0.5 μM. The NTA chip was coated with ~90 RUs of His-tagged PspCN 
during each cycle. Figure 6.3 shows the results obtained. 
 
 
Figure 6.3 Surface plasmon resonance experiments to further investigate PspCN binding by 
various segments of FH. Background-subtracted duplicate traces (colour-coded) for FH are 
shown. 
 
 Reproducibility was, once again, very good. As before FH-10-15 exhibited 
negligible affinity and FH-19-20 exhibited a weak, fast on/fast off, interaction. 
Importantly, FH-8-9 showed a very much slower off-rate than FH-19-20. This is 
indicative of a strong interaction with PspCN while the lower response (compared to 
full-length FH or FH-8-15) is a consequence of its smaller size. FH-6-8Y exhibited a 
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superficially promising looking binding curve but the large response elicited 
suspicion. The size of a response is proportional to the number of bound molecules 
times their molecular mass, i.e. the total mass of protein on the chip surface. The 
theoretical analyte-binding capacity of the surface in RU is given by: RUmax = ligand 
level x MW analyte/ MW ligand x binding stoichiometry. Assuming a 1:1 binding 
stoichiometry and based on the corresponding MW of the ligand and the analyte and 
the 90 RU of ligand immobilized, the expected Rmax for FH-6-8Y would be  
~140 RU. This is clearly not the case as can be observed in the sensogram (a 
response of >400 RUs was obtained). This could be attributed to FH-6-8Y 
interacting non-specifically with the chip surface, and since background-subtracted 
data are shown (where the blank or background surface was not charged with Ni
2+
), 
this interaction is likely to be with the Ni
2+
. This was tested in the experiments 
described below (Section 6.3). 
 
6.3 Binding of various fragments to His-tag SUMO-PspCN, His-tag SUMO-
PspCNR1 and His-tag SUMO 
 
The SUMO-fusion versions of PspC had not yet been tested for how they 
would interact with the FH fragments as well as with full length FH and C3b. As 
they would ultimately be used for the kinetic studies (in order to determine the 
affinity constants) with FH-8-9, FH-8-15 and full length FH (see sections 6.4-6.6) 
and because it was not known how these complement proteins would interact with 
SUMO alone, a preliminary experiment was performed in order to analyse binding 
profiles. His-tag SUMO-PspCN was immobilized on flow cell 2 of the NTA chip, 
His-tag SUMO-PspCNR1 on flow cell 3 and His-tag SUMO alone - as a control - on 
flow cell 4; flow cell 1 was the reference surface (and was not charged with Ni
2+
). 
Full-length FH and the FH fragments 8-15, 10-15, 6-8Y, 8-9 and 19-20, as well as 
C3b, were then flowed over the chip. All samples were injected sequentially at 50 
nM and then 500 nM (the chip was stripped in between injections) except for full-
length FH, which was injected at 50 nM only. The results of this investigation are 





Figure 6.4 Surface plasmon resonance experiments to measure binding of various fragments to 
His-tag SUMO-PspCN. Duplicate traces were recorded (during a single experiment) at 50 nM 
and (except for FH) also at 500 nM. (A) Background-subtracted sensorgrams; traces are 
labeled. (B) Zoomed-in representation of selected background-subtracted sensorgrams not 
clearly distinguishable in (A). 
 
In summary: (i) Full-length FH, FH-8-15 and FH-8-9 show binding profiles 
consistent - in terms of the strength of each interaction - with those obtained from 
previous experiments; thus affinity increases (i.e. KD decreases) in the following 
order: FH-8-9, FH-8-15, FH. (ii) FH-10-15 showed no detectable interaction (as seen 
in previous assays); this FH segment could henceforth serve as a negative control. 
(iii) As before, a small but significant response was obtained with FH-19-20; (iv) a 
large response was observed in the case of FH-6-8Y; whether this could be attributed 
to binding to Ni
2+






Figure 6.5 Surface-plasmon resonance experiments to measure binding to His-tag SUMO-
PspCNR1. Duplicate traces were recorded - during a single-cycle experiment at 50 and 500 nM 
(full-length FH at 50 nM only). (A) Background-subtracted sensogram for the fragments; each 
curve corresponds to a sample as indicated on the figure. (B) Zoomed-in representation of 
selected background-subtracted sensogram not clearly distinguishable in (A).  
 
The results from this assay were similar whether obtained with His-tag 
SUMO-PspCN or His-tag SUMO-PspCNR1. This implies that the R1 region does 




Figure 6.6 Surface plasmon resonance experiments to measure binding of various fragments to 
His-tag SUMO. Duplicate traces were recorded (during a single experiment) at 50 nM and 
(except for FH) also at 500 nM.  Background-subtracted sensorgrams are shown.  
 
It was observed that the following samples interacted with His-tag SUMO 
alone: FH, FH-6-8Y, FH-19-20 and C3b. In the case of FH however the profile 
differed significantly from that obtained when His-tag SUMO-PspCN/NR1 were 
immobilized as a fast off-rate and a smaller response were observed. For remaining 
samples, the profiles of their interaction with His-tag SUMO resemble those obtained 
when His-tag SUMO-PspCN/NR1 were used as ligands. This implies that either 
these samples interact with His-tag SUMO or with Ni
2+
 or both, rather than with 
PspCN/NR1. 
To investigate further, the affinity of FH segments for the NTA chip charged 
with Ni
2+
, in the absence of any immobilised His-tagged protein, was measured 
directly. For this purpose, approximately 55 RUs of Ni
2+
 were immobilized on flow 
cell 2 of the NTA chip and the analytes were injected at 500 nM with the exception 





Figure 6.7 Use of SPR to investigate the binding of FH fragments to Ni
2+
. All fragments, as 
indicated on sensogram, were injected at 0.5 μM concentrations over flow cell 2 of the NTA 
chip, which contained ~55  RUs Ni
2+
with the exception of FH, which was injected at 0.05 μM. 
 
This experiment demonstrated that FH-19-20, 6-8Y, and C3b interacted with 
immobilized Ni
2+
. There is therefore no evidence that these proteins interact with 
His-tag SUMO or PspC. On the other hand, full-length FH, FH-8-15 and FH-8-9 
showed very small, negligible or no detectable interactions with Ni
2+
, confirming 
their chief interaction is with the PspC fragments. In total, these experiments 
established that the NTA sensor chip could be used for further kinetic and steady-
state experiments, with immobilized SUMO serving as a control protein. 
 
6.4 SPR-based studies of FH-8-9 binding to His-tag SUMO-PspCN and His-
tag SUMO-PspCNR1  
 
Based on the finding that FH-8-9 displayed strong affinity for PspCN (shown 
in section 6.3), further SPR was performed in order to obtain the dissociation 
constant. The His-tagged versions of SUMO-PspCN (125 RUs), SUMO-PspCNR1 
(150 RUs) and SUMO (control) (60 RUs) were immobilised on flow cells 2, 3, and 4 
respectively (flow cell 1 = reference). FH-8-9 was injected over all flow cells in a 
concentration series of: 0, 5 nM, 10 nM, 25 nM, 50 nM, 100 nM, 250 and 500 nM. 
After each injection the chip was stripped (see section 2.5.3) due to the slow off-rate 
of FH-8-9 (Figs 6.8-6.11). 
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 6.4.1 Interaction of FH-8-9 with His-tag SUMO-PspCN 
 
Figure 6.8 Use of SPR to measure the dissociation constant for the binding of FH-8-9 to SUMO-
PspCN. Sensogram in which the background-subtracted traces are shown colour-coded for each 
of the concentrations flowed over flow cell 2 of the NTA chip as indicated on the figure. 
 
The KD obtained from this kinetic experiment (by fitting kinetic parameters 
from background-subtracted traces to a one-to-one Langmuir model) was 0.031 μM. 
The unusual shape of the curves may be explained by the possibility that the specific 
interactions of FH-8-9 with PspCN may be de-stabilising the interaction of the His-
tag with the NTA chip, increasing the dissociation rate of PspCN from Ni
2+
 chip. 
This would then suggest an accelerated loss or leaching of the His-tagged PspCN 
from the NTA-Ni
2+
 chip surface when it is in complex with FH-8-9 resulting in the 
traces for the response to become negative instead of returning to baseline, and a 
maximal response that does not coincide with the end of the injection period (for 
higher concentrations of FH-8-9) as is normally observed. A steady-state affinity 
analysis was performed in addition to the kinetic experiments the result of which is 




Figure 6.9 Plot of the SPR response obtained vs. analyte concentration after steady-state affinity 
analysis for FH-8-9 binding to His-tag SUMO-PspCN.  
 
The measured KD value from the steady-state affinity analysis was 0.03 +/- 
0.0015 μM which is in excellent agreement with the value obtained from the kinetic 
experiments. Thus despite the atypical shapes of the profiles these measurements 
appeared to yield a useful and reproducible estimate of the dissociation constant. 
 
6.4.2 Interaction of FH-8-9 with His-tag SUMO-PspCNR1 
 
Figure 6.10 Use of SPR to measure the dissociation constant for the binding of FH-8-9 to His-tag 
SUMO-PspCNR1 by kinetic experiments. Sensogram in which the background-subtracted 
traces are shown colour coded for each of the concentrations flowed over flow cell 3 of the NTA 
chip as indicated on the figure. 
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The measured KD value for the interaction of FH-8-9 with His-tag SUMO-
PspCNR1 was 0.032 μM (obtained by fitting steady-state binding levels derived 
from background-subtracted traces to a one-to-one binding model). This result 
confirms that the R1 region of PspC does not contribute to the binding of PspCNR1 
to FH-8-9. The failure of maximal response to coincide with the end of the injection 
time, and below-zero readings on return to baseline, are more pronounced versions of 
those observed in the previous experiment when SUMO-PspCN was immobilized. In 
addition to the kinetic experiments, steady-state affinity analysis was also performed 
(see Fig 6.11). 
 
 
Figure 6.11 Plot of the response obtained vs. analyte concentration after steady-state affinity 
analysis for FH-8-9 binding to His-tag SUMO-PspCNR1 by SPR.  
 
The obtained KD value following this analysis was 0.026 +/- 0.0025 μM and is in 
very good agreement with the KD value resulting from the kinetic analysis.  
 
6.5 Kinetic studies of FH-8-15 with His-tag SUMO-PspCN and His-tag 
SUMO-PspCNR1 
 
For determination of dissociation constants and kinetic parameters, a similar 
experimental setup to that described for FH-8-9 was employed. FH-8-15 was injected 
at concentrations of: 0, 0.25 nM, 0.5 nM, 1 nM, 5 nM, 10 nM, 25 nM, 50 nM, 75 nM 
and 100 nM (the chip was stripped after each injection) (see Figs. 6.12-6.13). 
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Figure 6.12 Use of SPR to measure dissociation constants for binding of FH-8-15 to His-tag 
SUMO-PspCN by kinetic experiments. Background-subtracted traces are shown colour coded 
for each of the concentrations flowed over flow cell 2 of the NTA chip as indicated on the figure.  
 
The KD value obtained (by fitting kinetic parameters from background-
subtracted traces to a one-to-one Langmuir model)  was 1.7 nM suggesting that FH-
8-15 binds strongly to PspCN. Note that a disproportionate increase in RUs - 
compared to the remaining concentrations - is observed between 10 and 25 nM 
injections. The most likely explanation for this is error during the preparation of the 
dilutions of the samples and requires repetition of the experiment.  The fitting of the 
parameters to a 1:1 binding model was performed by using just the five lowest 
concentrations (0.25, 0.5, 1, 5 and 10 nM) (data not shown), in addition to the full 






Figure 6.13 Use of SPR to measure the dissociation constant for the binding of FH-8-15 to His-
tag SUMO-PspCNR1 by kinetic experiments. Sensogram in which the background-subtracted 
traces are shown colour coded for each of the concentrations flowed over flow cell 3 of the NTA 
chip as indicated on the figure.  
 
The KD value acquired for the interaction of FH-8-15 with His-tag SUMO-
PspCNR1 was 2.3 nM. As in the case of His-tag SUMO-PspCN the fitting to a 1:1 
binding model was also carried out by using the five lowest concentrations. This 
gave a KD value of 1.2 nM (data not shown).   
The tight interactions of FH-8-15 with PspCN/NR1 did not allow for a 
steady-state analysis to be performed in order to obtain KD values (as was done in the 
case of FH-8-9) as in order for equilibrium to be reached a long experimental time 
and significant amounts of material would be required.  
 
 6.6 Kinetic studies of full length FH with His-tag SUMO-PspCN and His-tag 
SUMO-PspCNR1 
 
Full-length FH has been reported to bind to PspCN with a sub-nM affinity 
based on ITC. To obtain an SPR-derived KD estimate, the experimental approach 
previously described for FH-8-9 and FH-8-15 was followed. Samples were injected 
at concentrations of: 0, 0.25, 0.5, 1, 5, 10, 25, 50 and 75 nM (see Figs. 6.14-6.15). 
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Figure 6.14 Use of SPR to measure the dissociation constant for the binding of FH to His-tag 
SUMO-PspCN by kinetic experiments. Sensogram, in which the background-subtracted traces 
are shown, colour coded for each of the concentrations flowed over flow cell 2 of the NTA chip. 
The “glitches” evident in traces for the two highest concentrations, 50 and 75 nM, are boxed. 
 
The KD value obtained (by fitting kinetic parameters from background-
subtracted traces to a one-to-one Langmuir model) from this kinetic experiment was 
a very tight 0.15 nM. At the two highest concentrations, 50 and 75 nM, a “glitch” 
(highlighted with a box in figure 6.14) becomes evident corresponding to a low-
affinity and transient interaction between FH and molecules or ions on the chip 





Figure 6.15 Use of SPR to measure the dissociation constant for the binding of FH to His-tag 
SUMO-PspCNR1 by kinetic experiments. Sensogram in which the background-subtracted 
traces are shown colour coded for each of the concentrations flowed over flow cell 3 of the NTA 
chip as indicated on the figure. For significance of the boxed region see legend to Fig 6.14. 
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The KD value, according to kinetic analysis, of FH for PspCNR1 was  
0.19 nM. This indicates that the R1 region of PspC essentially does not contribute to 
binding to FH, and is consistent with the non-participation of this region of the 
bacterial protein that was observed in binding FH-8-15. As in the previous 
experiment a putative transient and weak interaction with Ni
2+
 is manifested at the 
two highest concentrations (50 and 75 nM). As in the case of FH-8-15, a steady-state 
experiment could not be performed in order to obtain a KD value (for reasons already 
mentioned, see section 6.5).   
In summary, it may be concluded that FH associates very tightly with PspCN 
as demonstrated by a series of experiments, and the KD of 0.15 nM. On the other 
hand, the importance of the interaction of FH with Ni
2+
 can be considered secondary 
in the context of the present work, but is of interest from the viewpoint of previously 
published work on the interaction of FH with bivalent ions (53), (164). 
Table 6.1 summarizes the immobilization levels and KD values obtained for 
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Table 6.1 Summary of immobilization levels and KD values obtained through kinetic and steady-




The figure below (Fig. 6.16) shows a plot of the 1/KD values obtained for the three 
FH segments vs. the two PspC constructs in a comparative manner.  
 
 
Figure 6.16 Bar-chart diagram summarizing KD values determined for binding of full-length FH 
(shown in blue), FH-8-15 (shown in pink) and FH-8-9 (shown in red) to SUMO-PspCN and 
SUMO-PspCNR1.  
 
6.7 Binding of FH, PspCN, PspCNR1, the FH-PspCN complex and the FH-
PspCNR1 complex to C3 fragments: C3b, C3c and C3d 
   
FH binds to C3b and this interaction is key to the protection of host cells 
against unwanted complement activation. It was interesting to investigate whether a 
complex consisting of FH-PspCN or FH-PspCNR1 retains affinity for C3b. Indeed, if 
PspC binds to the central region of FH, as suggested by the SPR studies, this would 
leave FH-1-4 and 19-20 free to interact with C3b thus helping S. pneumoniae to 
avoid being the target of C3b amplification and subsequent complement-mediated 
destruction. This work sets out to measure the affinity of FH-PspCN and FH-
PspCNR1 complexes for C3b and for the smaller fragments generated by FI, namely 
iC3b, C3c and C3dg/C3d. 
An experimental approach was designed on the basis of the previous 
observation that a 1:1 stable complex is formed between FH and PspCN/PspCNR1. 
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Thus C3b, C3c and C3d (all purchased by CompTech) were immobilized, via 
standard amine coupling (see Materials and Methods section 2.5.3), on a C1 sensor 
chip and dissociation constants of the interactions of FH alone, the FH-PspCN 
complex and the FH-PspCNR1 complex were determined by steady-state affinity 
experiments. The two PspC fragments used were devoid of tags or fusion partners. 
The immobilization levels achieved for each of the ligands (in RUs) on the 
carboxymethylated matrix-free C1 chip were as follows: 250 for C3b (in flow cell 2), 
181 for C3c (in flow cell 3) and 37 for C3d (in flow cell 4) while flow cell 1 was the 
reference.  
 
6.7.1 Binding of PspCN and PspCNR1 to C3b, C3c and C3d 
 
In a control set of experiments PspCN and PspCNR1 were tested, on their 
own, for binding to C3, C3c and C3d (immobilized on flow cells 2, 3 and 4 
respectvely). Figure 6.17 confirms a lack of any measurable interactions between 
PspCN and PspCNR1 with the C3 fragments. 
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Figure 6.17 Use of SPR to confirm no appreciable binding of PspCN and PspCNR1 to the C3 
fragments C3b, C3c and C3d. Background-subtracted sensorgrams are shown for PspCN and 
PspCNR1, colour-coded, as they were flowed at a range of concentrations over flow cells 2, 3, 4 
which contained immobilized C3b, C3c and C3d respectively. (A) PspCN is flowed over C3b. (B) 
PspCN is flowed over C3c. (C) PspCN is flowed over C3d. (E) PspCNR1 is flowed over C3b. (F) 
PspCNR1 is flowed over C3c. (F) PspCN is flowed over C3d.  
 
6.7.2 Binding of FH and the complexes FH-PspCN, FH-PspCNR1 to C3b 
 
C3b was immobilized on flow cell 2 of the C1 sensor chip as previously 
described. An initial experiment with non-complexed FH is shown in figure 6.18. 
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Figure 6.18 Use of SPR to confirm the dissociation constant for the binding of FH to C3b. (A) 
Background-subtracted sensogram is shown colour-coded for FH at a range of concentrations 
(0-2 μM). (B) Plot of the response obtained vs. analyte concentration fitted as described in 
Materials and Methods. The resultant KD value is indicated on the plot. 
 
The KD value of 0.6 +/- 0.09 μM obtained is similar to that measured previously 
(0.59 +/- 0.04) μM when a C1 chip was used (30).  
Subsequently a mixture containing a 1:1.1 ratio of FH to PspCN was 
prepared. A series of concentrations were flowed over the immobilised C3b yielding 






Figure 6.19 Use of SPR to measure the dissociation constant for the binding of the FH-PspCN 
complex to C3b by steady-state affinity. (A) Background-subtracted sensogram is shown colour-
coded for the complex at a range of concentrations (all containing a 1:1.1 ratio of FH to PspCN). 
(B) Plot of the response obtained vs. analyte concentration. The resultant KD value is indicated 
on the plot.  
 
The KD value for this interaction was determined to be 0.29 +/- 0.07 μM and 
is about two times stronger than the one observed for FH alone with C3b. 





Figure 6.20 Use of SPR to measure the dissociation constant for the binding of the FH-PspCNR1 
complex to C3b by steady-state affinity. (A) Background-subtracted sensogram is shown colour-
coded for the complex at a range of concentrations (all containing a 1:1.1 ratio of FH to 
PspCNR1). (B) Plot of the response obtained vs. analyte concentration. The resultant KD value is 
indicated on the plot.  
 
6.7.3 Binding of FH and the complexes FH-PspCN, FH-PspCNR1 to C3c 
 
The concerted action of FI and FH results in the cleavage of C3b to form 
inactive iC3b. This becomes further cleaved (by FI and CR1) into C3c and C3dg – 
the latter is cleaved, by one of several proteases, to give C3d. C3d remains tethered 
by to the surface while C3c is released. All previous studies have reported no 
appreciable binding of FH to C3c but there are mixed reports on the affinity of FH 
for C3d. The most recent results from this lab (C. Q. Schmidt, personal 
communication) indicate that FH does not bind to C3d (unlike the fragment FH-19-
20).  
In the first experiments, the affinity for C3c of the FH-PspCN and FH-




Figure 6.21 Use of SPR to compare the binding of FH, FH-PspCN and FH-PspCNR1 to 
immobilised C3c. (A) Background-subtracted sensogram (colour-coded) for FH over the 
concentration range 0-2 μM.  (B) Background-subtracted sensogram is shown colour-coded for 
the complex FH-PspCN at a range of concentrations as indicated (with a 1.1:1 ratio of PspC to 
FH as before).  (C) colour-coded for the complex FH-PspCNR1 at a range of concentrations as 
indicated (with a 1.1:1 ratio of PspC to FH as before). No appreciable binding to C3c was 
observed for FH alone or any of the complexes. 
 
Consistent with previous findings FH does not seem to interact with C3c, and 
the same applies to the complexes FH-PspCN and FH-PspCNR1.  
 
6.7.4 Binding of FH and the complexes FH-PspCN and FH-PspCNR1 to C3d 
 
As alluded to above, only a weak interaction had been previously observed 
for FH binding to the C3d fragment in this lab. This is despite the fact that FH-19-20 
alone can bind well to C3d and indeed has been crystallised in complex with both 
wild-type and a mutant version of FH-19-20. C3d corresponds almost exclusively to 
the thioester-containing domain (TED) and thus remains attached to a target surface, 
probably for days after the initial complement-activating event. Since the complexes 
FH-PspCN and FH-PspCNR1 bound with a higher affinity than does FH to C3b, as 
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shown in section 6.7.2 (above), the possibility of FH within the complex also 




Figure 6.22 Use of SPR to study the binding of FH to C3d. Background-subtracted sensogram is 
shown colour-coded for FH at a range of concentrations (0-2 μM).  C3d was immobilized on 
flow cell 4 of the C1 sensor chip.   
 
In agreement with the aforementioned previous findings of our lab, no 








Figure 6.23 Use of SPR to measure the dissociation constant for the binding of the FH-PspCN 
complex to C3d by steady-state affinity.  A 1:1.1 stoichiometry was used in preparing the 
samples of FH-PspCN. (A) Background-subtracted sensorgrams are shown (colour-coded 
according to concentration of complex) as shown. (B) Plot of the response obtained vs. analyte 




Figure 6.24 Figure 6.27 Use of SPR to measure the dissociation constant for the binding of the 
FH-PspCNR1 complex to C3d by steady-state affinity.  A 1:1.1 stoichiometry was used in 
preparing the samples of FH-PspCNR1. (A) Background-subtracted sensorgrams are shown 
(colour-coded according to concentration of complex) as shown. (B) Plot of the response 
obtained vs. analyte concentration. The resultant KD value is indicated on the plot. 
 
The results clearly demonstrate the ability of both complexes, i.e.  FH- 
PspCN and FH-PspCNR1 to bind C3d with KD values of approximately 2.2 +/- 0.37 - 
2.5 +/- 0.32 μM respectively. Since FH or PspC alone do not display such behavior, 
this result implies that binding to PspCN or PspCNR1 (presumably via its central 
modules) exerts an allosteric effect that alters the binding properties of the N- and/or 
C-terminal ends of FH. 
These results together suggest that free, soluble, human FH has negligible 
affinity for the C3c and C3d parts of C3b although the FH involved in the original 
cleavage could presumably remain bound to iC3b (which corresponds to C3b, C3d 
and C3f) for some time via its C-terminus (only).  In contrast, the FH-PspCN/NR1 
complexes (presumably sequestered on the bacterial surface) can bind (presumably 
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via C-terminal modules) to the C3d portion of iC3b. Moreover, these complexes bind 
slightly more tightly (KDs of ~0.3 μM), compared to free FH (KD of ~0.6 μM), to 
intact C3b prior to cleavage. This difference in affinity might be considered 
significant since measurements of the KD for the FH-C3b interaction have been 
consistently in the region of 0.6-2.2 μM depending on the sensor chip used and the 
different C3b loading on the chip (30). The abovementioned observations are 
consistent with each other if one assumes that the bacterial protein alters the 
architecture of FH to reveal additional binding sites that are normally inaccessible. 
 





                                    C3b                         C3c                       C3d 
FH 0.6 (0.09) - - 
FH-PspCN complex 0.29 (0.07) - 2.25 (0.37) 
FH-PspCNR1 
complex 
0.27 (0.07) - 2.5 (0.32) 
PspCN - - - 




Table 6.2 Summary of the KD values obtained for the interaction of FH, PspC and the FH-PspC 




The protein PspC confers on S. pneumoniae the ability to evade complement-
mediated destruction by promoting sequestration of the complement regulator, FH 
(70). The principal binding sites on FH for its major ligands – C3b, the C3b.Bb 
complex, FI and glycosaminoglycans – all lie within the N-terminal seven CCPs, and 
the C-terminal four CCPs, out of the 20 CCPs that comprise FH (24), (26), (27), (29), 
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(30), (31), (32), (33), (40). The remaining modules of FH – i.e. 8-18 - appear to be 
devoid of any recognition sites for complement proteins although these modules may 
participate in binding to C-reactive (165), (166) and they contain eight N-
glycosylation sites. In previous chapters and in published work (43) it was 
demonstrated that the central modules i.e. 10-13 feature strongly tilted modules and 
could form a hinge or strong bend in the structure of FH.  
In vivo, cleavage of C3b by FI in the presence of FH and other cofactors 
results in the formation of first iC3b and, ultimately, the C3dg and C3d fragments. 
All these fragments contain the thioester domain (TED) and can remain covalently 
attached to the host surface, while the larger C3c fragment is released upon cleavage 
of iC3b to C3dg. Successive cleavages create or expose nascent protein-protein 
interaction sites. Previous studies (15), (57) suggested that FH binds to a C3b 
molecule (or possibly two C3b molecules) via simultaneous engagement of FH-1-4 
with the MG domains (and the CUB and TED domains) of C3b, and of FH-19-20 
with the TED only. The CUB domain is cleaved by FI, which is consistent with loss 
of binding of FH-1-4 to iC3b (31). The TED remains intact in all fragments, 
implying that FH could (after cleavage) remain bound transiently via its 19-20 
domains that also have selective affinity for surrounding GAGs. But dissociation of 
FH from C3d (or iC3b), may normally be a virtually irreversible process since results 
presented here, and previous unpublished observations, suggest no or miniscule re-
binding by intact FH to C3d. Thus the affinity for C3d resident in FH-19 and 20 must 
be masked or hidden in some way within intact FH. This could be important in 
regulating FH action and so warrants further study. 
The work described in this chapter led to the following conclusions: FH and 
some of the FH fragments appear to interact with Ni
2+
, complicating the exploitation 
of the metal affinity of His tags for immobilisation on SPR chips. The most 
pronounced effect was exchibited by FH-6-8. This is interesting from the point of 
view that a study showed that certain transition metals cause FH to aggregate and 
that this was attributed mainly to the FH-6-8 region. Specifically, the most important 
effect was observed with zinc and copper, followed by nickel, cadmium and iron 
(magnesium and calcium had little or no no effect). In addition, the aggregation 
caused was accompanied by loss of FH activity (53), (164). 
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Importantly, the present results clearly showed that full-length FH can bind to 
the N-terminal domain of PspC in an effectively irreversible manner. Notably, both 
FH-8-15 and FH-8-9 exhibit high affinity for PspCN and PspCNR1 while FH-6-8Y, 
FH-10-11 and FH-10-15 do not. The binding of FH-8-15 is – like FH – characterised 
by an extremely slow off-rate. The C-terminal CCP-module pair, FH-19-20, binds 
only weakly to PspCN. However it also appears to interact significantly with 
immobilized Ni
2+
 which makes it difficult for a clear conclusion to be drawn 
regarding the possibility that it could contribute to binding via an avidity effect in the 
context of full length FH. 
The strength of the interaction between full length FH and the N-terminal 
region of PspC determined in this study is of comparable magnitude to the ITC-based 
study (KD values for both are in the low-nM range) (88).  
The results presented in this study may be further compared to the literature 
(however taking into account that the FH fragments used in most cases differed). In 
previous reports, ELISAs indicated that the FH-8-15 region was solely responsible 
for mediating interaction (91) which supports the tight interaction of FH-8-15 for 
PspCN/NR1 observed in this report. Ligand dot blotting localized the PspC on FH 
inclusively between modules 6-10 (90) while SPR suggested FH-8-11 (87) as the 
main site. Both of these studies support the strong interaction measured for FH-8-9 
and PspCN/NR1 in the present study. This is in contrast to another study that 
concluded that fragments FH-8-10 and FH-8-12 lacked the ability to mediate binding 
(91). Finally, in a separate study it was shown that FH-11-15 did not show binding 
(87). This backs-up the lack of affinity of the FH-10-15 region in the present 
investigation.  
  In the next sets of experiments the interactions of the FH-PspCN/NR1 
complexes with the C3 fragments resulting from the action of cofactors and FI were 
studied. Native FH showed affinity for C3b described by a KD of 0.6 (+/- 0.09) μΜ 
on a C1 chip, but only minor interactions with C3c and C3d. Importantly, the FH-
PspCN/NR1 complexes bound more tightly than free FH to C3b, with KDs of about 
0.28 μM (+/- approximately 0.07) - as opposed to the 0.6 μM affinity exhibited by 
free FH (see above). While, as expected, the complexes did not bind to C3c, they did 
bind to C3d with KD values in the region of 2.4 μM. This intriguing observation - 
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taken together with the previous work showing FH-19-20, but not full-length FH, 
binds to C3d - implies that the bacterial protein is able to bind in such a way as to 















































7.1 The central modules of FH are arranged in a unique way that is important 
for biological activity 
 
A range of evidence (15), (43), (49), (50) suggests that FH adopts a bent-back 
conformation such that binding sites on its N and C termini can engage cooperatively 
with the same molecular target(s). Such a bent-back conformation would be 
facilitated via the flexibility afforded by the 19 inter-modular linkers and would be 
stabilized by the extent and the nature of contacts between the 20 modules.  While 
long-range contacts between distant CCPs may be important for FH architecture, the 
current work focuses on more local interactions amongst the central modules that 
lack binding sites for other complement proteins. This focus was dictated by the 
technical difficulties associated with working with full-length FH, which has never 
been crystallized, is probably flexible and dynamic, and is too large and complex to 
yield easily interpretable scattering patterns. We hypothesized that the central 
modules represented a little-explored region of the molecule that is probably critical 
for the dynamic architecture of FH. We further speculated that they may have a 
specific hinge-like role, allowing interchange between distinct conformations of FH 
in which a part-time cryptic binding site is either hidden or exposed. The ability to 
switch between such conformations could be important for the role played by FH as 
a self-surface selective regulator of complement.  
The NMR-derived solution structures of CCP modules 10, 11 and 12 of FH 
exhibit typical CCP characteristics. They approximate to beta strand-rich prolate 
spheroids that have N- and C-terminal residues lying at opposite poles of the long 
axes. The pairs FH-10-11 and FH-11-12 are connected through six-residue long 
linkers. These, far from introducing flexibility as was originally thought likely, act as 
rather rigid spatial organizers. In both cases, the module-pairs adopt a fixed “V-like” 
conformation. Thus both pairs have defined tilts, of about 90-100
o
, stabilized by a 
mini-hydrophobic core that is buried at the intermodular interface. Data collected 
using SAXS independently validated the two NMR-derived structures. Of note, a 
neighboring (overlapping) pair, FH-12-13, adopts a broadly similar conformational 
arrangement (43). FH has been reported to be pH- and salt concentration-sensitive 
(52). In this respect it is noteworthy that His sidechains occupying equivalent 
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Asp occurs in FH-10-11 which may stabilize the 
corresponding interface. 
The multitude of NOEs that support the abovementioned “V-like” structures 
of recombinant FH-10-11 and FH-11-12 tally with the lack of flexibility inferred 
from the NMR-relaxation studies at the particular timescales probed (ps, ns and 
microsecond). The resultant assumption that these bimodules would adopt the same 
compact and rigid bent structures in the FH-10-12 context was validated by SAXS 
analysis. The studies of FH-10-11, 11-12 and 12-13 culminated in the reconstruction 
of the FH-10-13 structure. When the three pairs are superimposed on their mutual 
modules (i.e. 10-11 and 11-12 on FH-11 and 11-12 and 12-13 on FH-12) they adopt 
an out-of-plane “S-like” conformation of length approximately 53 Å, and represent 
the most strongly tilted succession of four CCPs described to date. Its overall 
arrangement, with limited flexibility, supports the concept that its middle region will 
keep FH oriented in one or more preferred conformations so as to allow for the N- 
and C-terminal ends to be appropriately positioned in order to perform their 
regulatory functions.  
In the light of these new data and through revisiting previous data that had 
originally been interpreted in terms of two possible arrangements of modules 10-15 
(43), one model emerged as being more plausible. In this model (Fig. 7.1), modules 





tilts. Despite these large tilt angles, these modules 
nonetheless form the more extended end of the FH-10-15 unit. At the other end, 
SAXS suggests that an 180
o
-bend is imposed between modules 13 and 14 while 
modules 14 and 15 appear to wrap around module 13 and the 12-13 linker. Thus 
modules 12, 13, 14 and 15 together form the more globular end of the FH-10-15 unit. 
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Figure 7.1 Upper panel: the most plausible model for the FH-10-15 region as emerged from 
SAXS and the NMR structures of FH-10-11, 11-12 and 12-13. Representation of the SAXS-
derived envelope is shown in spheres and the modelled CCPs within showed as cartoons. The 
experimentally determined linkers from the NMR-derived FH-10-13 model are shown in beige 
whereas light-orange spheres represent linker residues modelled as a chain of dummy atoms. 
Two views are shown following 90
o
 rotation about the x-axis. Lower panel: the FH-10-15 
modelled region is shown in cartoon representation without the SAXS envelope. 
 
Overall the FH-10-15 appears to lack much intermodular flexibility. The 
unusual positioning of module 14 (and also 15) with respect to the other modules 
may reflect the possibility that its stability depends upon one or more neighboring 
modules and/or linkers. In this respect it is noteworthy that previous attempts to 
produce folded and intact FH-13-14 and FH-14-15 samples proved unsuccessful. In 
addition, the FH-13-14 linker is the most variable amongst orthologues while FH-13 
lacks the D-E loop and β-strand H whish are normally crucial for a stable interface to 
be formed with the subsequent CCP. These are in contrast to, for example, the 
structurally independent FH-8-9 pair that is easy to produce and in which both 
modules is properly folded under a range of conditions. An EOM analysis of FH-8-
15 suggests these modules 8 and 9 correspond to a semi-flexible protrusion of FH-
10-13, in stark contrast with FH-14-15. There is an example in the literature of a 
CCP module that is intrinsically disordered when produced as part of a recombinant 
bimodule (167).  Finally, there are two examples in the literature of strand-swapping 
between adjacent CCPs creating fused modules (168), (169). In summary there is 
 278 
literature precedence for CCP modules that are not autonomously folded and it is 
possible that FH-14 fits into this category. What is more, the existence of some 
higher order structure in the FH-13-15 region was inferred from a functional study 
aiming to locate the FH binding domains for PspC of S. pneumoniae. In this study 
FH-8-15 bound significantly followed, in magnitude, by FH-8-13. Interestingly FH-
8-14 appeared to show decreased binding compared to FH-8-13 which would imply 
that module 14 was obstructing the binding site. This was no longer the case once 
FH-15 was present- in the FH-8-15 context (91).  
Taking everything together a more sophisticated scenario can be envisaged 
regarding how FH may operate in a biologically relevant context. Assuming that the 
compact arrangement observed in P. pastoris-produced FH-8-15 and FH-10-15 is 
retained in the context of the full-length glycoprotein present in human plasma, then 
we may conclude that the central region of FH forms a unique structural unit. 
Moreover, assuming that our “S-shaped” model of FH-10-13 (built from 
concatenating module pairs and SAXS data for FH-10-12) is present in FH-10-15, 
then FH-13, 14 and 15 must be very compact indeed and it is reasonable to speculate 
that module 14 needs its neighbours for stability. The physiological role of this 
arrangement is perplexing. One possible scenario is that under certain conditions 
module 14 becomes dissociated from its neighbours and thereupon behaves like an 
intrinsically disordered domain (held together, presumably, by its disulfides) creating 
a flexible segment and thus allowing the central region to act as a hinge and FH to 
switch between closed and open conformations. In the former case (closed) FH 
would bind with relatively low affinity to C3b and C3d while in the latter (open) it 
could bind bivalently and with high affinity to a C3b molecule (shown in figure 7.2). 
The present study is likely to reflect the closed case (i.e. FH has weak affinity for 
C3b). More investigation is required to test whether flexional stress, or exposure to 
the electronegative environment found on a self-surface bearing the appropriate 
polyanionic markers, disrupts the 13-14 interface. Under these circumstances, 
module 14 would be likely to become intrinsically disordered, creating a very 
flexible segment within the FH molecule and allowing terminal regions to cooperate 




Figure 7.2 Representation of the FH molecule free in the closed conformation (A) and  binding 
to surface-tethered C3b (anchored via its TED domain) in the context of self-surface bearing 
polyanionic markers (B), in the open conformation. In (B) FH-1-4 associate with the C3c-like 
part of C3b and the CUB domain while FH-19-20 bind to the C3d part of C3b (which equates to 
the TED domain). FH-7 and 20 associate with polyanionic markers (indicated with red 
diamonds). This mode of binding is facilitated by the FH-10-15 region in which all CCPs are 
shown in the optimal spatial organization-as determined through NMR and SAXS. A star 
highlights FH-14 that is putatively disordered and confers on the central region of FH the hinge-
like ability thus allowing FH to adopt preferred and stabilised orientation(s) on a surface for 
optimal biological function.   
 
7.2 The binding of PspC of S. pneumoniae to the central region of FH affects 
its interaction with C3b 
 
The surface protein PspC of S. pneumoniae sequesters FH as a means to 
avoid immune killing. A proposed mechanism of action for FH of a separate study 
(92) was that FH binds to pneumococci through domains 8-11 and 19-20. The 
regulatory FH-1-4 region is then free to perform cofactor activity and thus evasion of 
complement by pneumococci takes place. The C-terminal region of FH can interact 
with polyanionic host-surface markers which promotes adhesion following which 
pneumococci exploit a FH-integrin complex for evasion into epithelial cells. Another 
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study using fragments corresponding to the 8-10, 8-12, 8-13, 8-14 and 8-15 FH 
regions concluded in the importance of both FH-13 and 15 in mediating the 
interaction with PspCN (91). 
In the present study it was found that full length FH bound to PspCN and 
PspCNR1 of S. pneumoniae in a virtually irreversible manner. The possibility of 
there being more than a single binding site emerged from the fact that the full-length 
protein bound better than FH-8-15 (which still binds very tightly); however this 
requires further investigation. The FH-8-9 fragment also had a high affinity for the 
bacterial protein (although still lower than that of either FH or FH-8-15). 
Significantly, FH-10-15 did not show any discernible binding. The R1 domain of 
PspC appeared not to contribute to the interactions. This is all in agreement with two 
other separate studies (87), (88). 
Thus the following can be concluded: PspC binds strongly through its N-
terminus, primarily to domains 8-9 of FH. In the FH-8-15 context it may be that 
binding to FH-8-9 induces the exposure of a second binding site only available in the 
FH-8-15 context (given that FH-10-15 showed no binding). Alternatively, binding 
may be enhanced by the presence of the 9-10 linker or interface. Therefore, full-
length FH binds in a practically irreversible manner mainly through modules 8-15. 
          The remarkably strong and largely irreversible interaction of full length FH 
with PspCN/NR1 meant that it was possible to study the behavior of a complex 
consisting of either FH-PspCN or FH-PspCNR1 together with C3b, C3c and C3d. A 
1:1 stoichiometry of the FH-PspC complex had been observed in a separate study 
(88).  
          FH-PspCN and FH-PspCNR1 bound C3b about two times stronger compared 
to free FH (KD values of 0.29 and 0.27 μM as opposed to 0.6 μM correspondingly). It 
is possible that the binding events stabilize a preferred, presumably functionally 
more active (as inferred from the higher affinity observed for the binding of the 
complex to C3b) conformation of FH, that may resemble the one adopted on a 
polyanionic marker-rich host surface. This possibility fits very well with the notion 
that FH has a closed conformation in which access to a cryptic C3b or C3d-binding 
site is occluded, in addition to an open conformation, stabilized by PspC, in which 
this binding site is accessible. 
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Neither the complexes, nor free FH, bound C3c (in which the CUB domain is 
cleaved while the TED domain is missing altogether). The former was an expected 
result, while the latter has already been demonstrated. Strikingly, the complexes 
showed significant binding to C3d with a KD in the range of ~ 2 μM, while native FH 
interacts with C3d very weakly compared to FH-19-20. This observation implies that 
it is the C3b-binding site located in FH-19-20 that is cryptic and that PspC is able to 
bind in such a way as to reveal this cryptic binding site that is directed to the TED 
portion of C3b, or C3d. It is easy to envisage how this could be achieved given that 
PspC appears to bind to more than one discontinuous region of FH and so FH could 
effectively wrap around PspC. 
          The figure below (Fig. 7.3) shows a hypothetical model of PspCN-bound to 
FH engaging with C3b as resulted from the structural and functional assays. The FH-
1-4 regulatory region remains free to operate in the complex. It is possible that 
PspCN mimics the effect that polyanionic markers found on self-surfaces have in 
terms of  orienting FH in a preferred stabilized conformation (see also figure 7.2).  
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Figure 7.3 Hypothetical models of the FH and PspC molecules free and in complex. (A) FH and 
PspC are shown free and FH is in the closed conformation. (B) FH is shown binding to the N-
terminus of PspC-following its sequestering by S. pneumoniae and is in a presumably preferred 
and open orientation, possibly the one adopted on a self-surface. Each oval represents a CCP 
module as indicated-FH-19-20 is shown in green. The FH-10-15 region is shown as modeled 
from the combination of NMR and SAXS. The regulatory FH-1-4 region is shown in complex 
with C3b while FH-19-20 interacts with the C3d part of C3b (i.e. the TED). A star highlights the 
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Media and buffers 
MEDIA COMPOSITION (w/v unless stated otherwise) 
BMG (Buffered minimal glycerol) 100 mM potassium phosphate pH 6 
1.34 % YNB 
4x10
-5
 % biotin 
1 % glycerol 
BMM (Buffered minimal methanol) 100 mM potassium phosphate pH 6 
1.34 % YNB 
4x10
-5
 % biotin 
0.5 % methanol 
 
Low-salt LB (Luria-Bertani) 
(low salt is needed for use with zeocin antibiotic) 
0.5 % yeast extract 
1 % tryptone 
0.5 % sodium chloride 
+/- 1.5 % agar 
LB (Luria-Bertani) 0.5 % yeast extract 
1 % tryptone 
1 % sodium chloride 
+/- 1.5 % agar 
SOC (Super Optimal broth with Catabolite 
repression) 
0.5 % yeast extract 
2 % tryptone 
10 mM sodium chloride 
2.5 mM potassium chloride 
10 mM magnesium chloride 
10 mM magnesium sulfate 
20 mM D-glucose 
YNB (Yeast Nitrogen Base) 10x YNB stock (Sigma) with ammunium sulfate 
without amino acid 
YPD (Yeast extract, Peptone, Dextrose) 1 % yeast extract 
2 % peptone 
2 % dextrose (D-glucose) 
+/- 1.5 % agar 
EDTA stock solution (ethylenediaminetetraacetic 0.5 M stock adjusted to pH with sodium 
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acid) hydroxide 
SDS-PAGE sample loading buffer 50 mM Tris-HCl 
100 mM %-mercaptoethanol 
2 % sodium-dodecyl-sulfate 
0.1 % bromophenol blue 
10 % glycerol 
TCA (trichloroacetic acid) 30 % stock (Sigma) made up in H2O 
TAE buffer 50x in distilled H2O Tris-acetate (2 M) 
EDTA (100 mM) 





























































 1) CYANA quality control criteria for the NMR structures of FH-10-11 and FH-11-
12 
 
Quality control criteria based on the output form the CYANA calculations 
1. The average target function value of cycle should be below 250 Å2 
2. The average target function value of the final cycle should be below 10 Å2 
3. There should be less than 20 % unassigned NOEs 
4. There should be less than 20 % discarded long-range NOEs 
5. The RMSD value in cycle 1 should be below 3 Å 
6. The RMSD between the mean structures of the first and the last cycle should be 
below 3 Å. 























































with off-diagonal assignment 
with unique assignment 
with short-range assignment    |i-j|<=1 
with medium-range assignment 1<|i-j|<5 




















































































Average target function 
value 162.46 85.7 160.81 30.73 15.41 9.46 12.32 4.38 
 
RMSD (residues 566..687) 
Average backbone RMSD 
to mean 6.18 334 1.92 1.15 0.99 1.05 1.13 0.87 
Average heavy atom 
RMSD to mean 6.8 3.7 2.22 1.51 1.37 1.44 1.47 1.26 















































with off-diagonal assignment 
with unique assignment 
with short-range assignment    |i-j|<=1 
with medium-range assignment 1<|i-j|<5 





















































































Average target function value 385.54 187.1 288.64 41.9 19.19 10.6 6.88 3.09 
 
RMSD (residues 630..744) 
Average backbone RMSD to 
mean 5.67 3.22 1.23 0.64 0.54 0.56 0.65 0.46 
Average heavy atom RMSD to 
mean 6.11 3.5 1.45 0.95 0.89 0.9 0.96 0.77 













































































































































































































Table C5 Tilt, twist and skew angles for FH-11-12. 
 
Tables C4 and C5: Inter-modular angles (
o
) for FH-10-11 and FH-11-12. The values for the 



















































































































3) Overlay of FH-10-11 and FH-11-12 with known CCP structures 
 
 
Protein; module; PDB ID 
Reference 
 






C1r; CCP 1; (1GPZ) (1) 
C1r; CCP 2; (1GPZ) (1) 
C1s; CCP 2; (1ELV) (2) 
C2; CCP1; (3ERB) (3) 
C2; CCP2; (3ERB) (3) 
C2; CCP3; (3ERB) (3) 
C4BPα; CCP 1; (2A55) (4) 

































C7; CCP 1; (Clark et al., 
unpublished)  
1.95 (58) 1.97 (58) 1.94 (57) 2.10 (58) 
C7; CCP2; (Clark et al., 
unpublished)  
1.77 (59) 2.47 (57) 2.44 (57) 2.86 (57) 
CR1; CCP 15; (1GKN) (5) 
CR1; CCP 16; (1GKN) (5) 
CR1; CCP 17; (1GKG) (5) 
CR2; CCP 1; (1LY2) (6) 
CR2; CCP 2; (1LY2) (6) 
CRRY; CCP 1; (2XRB) (7) 
CRRY; CCP 2; (2XRB) (7) 
CRRY; CCP 3; (2XRB) (7) 
CRRY; CCP 4; (2XRB) (7) 
DAF; CCP 1; (1OK3) (8) 
DAF; CCP 2 (1OK3) (8) 
DAF; CCP 3; (1H03) (9) 
DAF; CCP4; (1H03) (9) 
FB; CCP 1; (2OK5) (10) 
FB; CCP 2; (2OK5) (10) 
FB; CCP 3; (2OK5) (10) 
FH; CCP 1; (2RLP) (11) 
FH; CCP 2; (2RLQ) (11) 
FH; CCP 3; (2RLQ) (11) 

















































































FH; CCP 5; (not deposited) 
(13) 
2.24 (56) 2.42 (53) 2.45 (53) 2.37 (52) 
FH; CCP 6; (2UWN) (14) 
FH; CCP 7; (2UWN) (14) 













FH; CCP 10; (this study) - 2.04 (57) 2.15 (58) 2.37 (58) 
FH; CCP 11
a
; (this study) 2.04 (57) - 0.87 (59) 1.61 (58) 
FH; CCP 11
b
; (this study) 2.15 (58) 0.87 (59) - 1.57 (58) 
FH; CCP 12; (this study) 2.37 (58) 1.61 (58) 1.57 (58) - 
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FH; CCP 12; (2KMS) (15) 
FH; CCP 13; (2KMS) (15) 
FH; CCP 15; (1HFH) (16) 
FH; CCP 16; (1HFH) (16) 
FH; CCP 18; (3SW0) (17) 
FH; CCP 19; (2G7I) (18) 
FH; CCP 20; (2G7I) (18) 
MASP1; CCP 1; (3GOV) (19) 
MASP1; CCP 2; (3GOV) (19) 
MASP2; CCP 1; (1ZJK) (20) 
MASP2; CCP 2; (1ZJK) (20) 
MCP; CCP 1; (1CKL) (21) 





















































MCP; CCP 3; (3O8E) (22) 
MCP; CCP 4; (3O8E) (22) 
VCP; CCP 1; (1G40) (23) 
VCP; CCP 2; (1G40) (23) 
VCP; CCP 3; (1G40) (23) 






























= from FH 




= from FH 11-12 bi-module pair) and FH 12. Colour key 
used in table: Blue: 0 - 1.99 Å; Green: 2.00 – 2.99 Å; Red: 3.00 – 3.99 Å; Brown: Alignment 
lengths < 40 amino acids. Abbreviations used in Table: C4BPα = C4b-binding protein α-chain; 
CR = complement receptor; CRRY = rat CR1-related protein Y; DAF = decay-accelerating 
factor; FB = factor B; FH = factor H; MASP1 / 2 = mannan-binding lectin-associated serine 
proteases 1 / 2; MCP = membrane cofactor protein; VCP = Vaccinia virus complement control 
protein. Some residues were not present (solved) in the electron density map for the C1r CCP 2 
module crystal structure, and this explains the short structural alignment length (shown in 
brown). The best overlaying structures in each case are indicated by ‘*’ (149). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
